

December 21, 2009

The Honorable Congressman Charles E. Grassley
Ranking Member
United States Senate
Committee on Finance
Washington, DC 20510-6200

Via Electronic Transmission

Dear Senator Grassley:

The American Academy of Dermatology and the American Academy of Dermatology Association are pleased to respond to your letter of December 7 requesting information regarding relationships between commercial interests and our organization.

The American Academy of Dermatology (AAD) is a 501(c)(3) organization and the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 16,000 physicians worldwide, the Academy is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails. The American Academy of Dermatology Association (AADA), the 501(c)(6) sister organization to the Academy, serves as a resource for government affairs and practice information for dermatologists, and works with policymakers to formulate policies that enhance the delivery of quality dermatologic care. AAD and AADA are separate legal entities, managed and operated as separate organizations, that work together to accomplish common objectives. We refer to them collectively as AAD/A or the "Academy" throughout this letter for convenience purposes only.

The Academy is committed to transparency with respect to both individual and organizational relationships with industry and to addressing and resolving potential conflicts of interest. The Academy takes its responsibility to the physician community and the public at large very seriously. We continuously evaluate and strengthen our internal policies and procedures to ensure all activities and relationships are appropriately structured to ensure objectivity and transparency at all times.

Included with this letter are charts listing the funding we have received for the requested time period of 2006-2009, information regarding our current policies and procedures, as well as plans for updating portions of these in light of recent discussions taking place both within and external to our



American Academy of Dermatology
Excellence in Dermatology™

Correspondence
PO Box 4014
Schaumburg, Illinois 60168-4014

Location
930 East Woodfield Road
Schaumburg, Illinois 60173-4729

Main: 847.330.0230
Fax: 847.330.0050
Web site: www.aad.org

David M. Pariser, M.D., F.A.A.D.
President

William D. James, M.D., F.A.A.D.
President-Elect

Evan R. Farmer, M.D., F.A.A.D.
Vice President

Andrew Paul Lazar, M.D., M.P.H., F.A.A.D.
Vice President-Elect

Mary E. Maloney, M.D., F.A.A.D.
Secretary-Treasurer

Robert D. Greenberg, M.D., F.A.A.D.
Assistant Secretary-Treasurer

Ronald A. Henrichs, C.A.E.
Executive Director & CEO

organization. First attached are charts listing industry funding of various Academy activities by year, category of activity, name of company, amount of funding, and reason for the funding. **Attachment A** lists the funding by year and company. **Attachment B** lists the funding by year and category of activity, and provides a more detailed explanation of each of the activities. We have broken down the activities into the following categories:

- Medical Education (accredited continuing medical education (CME))
- Medical Education (non-CME)
- Journal of the American Academy of Dermatology (JAAD)/Academy Support
- Public Education
- Humanitarian
- Specialty Support
- Industry Supported Symposia
- Annual Meeting Activities
- Summer Academy Meeting Activities
- JAAD/Funding provided through Elsevier (publisher)

Attachment C is a listing of AAD programs that received in-kind contributions and the companies that provided the in-kind contributions. The companies have historically not provided the dollar amount associated with these in-kind contributions.

In addition to grants and sponsorships, the Academy conducts traditional business transactions with commercial companies in which a company pays the Academy a fee in exchange for an item, service, or product. This includes the sale of separate technical exhibit space in conjunction with our educational meetings and of advertisements in our peer-reviewed journal (JAAD) and other publications (e.g., organizational magazine, *Dermatology World*). The annual amounts received for these activities are also provided in **Attachment C**. We interpreted your request for information concerning industry funding through “transfers of value” to exclude such business transactions, but if you wish to see more detail for those categories, we would be happy to supply it as well.

The following enumerates our responses to your specific requests. Please note that we have answered Questions 3 and 4 in reverse order to present our information in a more logical flow.

- 1) *Please describe the policies for accepting industry funding and whether or not AAD allows companies to place restrictions or provide guidance on how funding will be spent.*

As noted above, the Academy seeks industry support for a variety of activities that further its mission. The attached “Principles of Corporate Relationships” governs

the acceptance of such funding (**Attachment D**). These funds come primarily in the form of grants and sponsorships.

Those activities certified for AMA PRA Category 1 CME credit must abide by ACCME's accreditation requirements including the ACCME Standards for Commercial Support. The Academy was just recently reaccredited and has met all required criteria of the Standards. We have attached the relevant excerpt from our ACCME application along with relevant guidelines in **Attachment E: Policies and Procedures related to CME**. ACCME accreditation assures the medical community and the public that such activities provide physicians with information that can assist them in maintaining or improving their practice of medicine and are free of commercial bias and based on valid content.

- 2) *If AAD allows companies to place restrictions on industry funding, then please explain all restrictions and/or guidance for each transfer of value from industry. For every transfer of value with a restriction, please provide the following information: year of transfer, name of company and restriction placed on funding.*

The Academy does not permit companies to place restrictions on industry funding. The Academy offers opportunities for support of specific activities, products or sponsorships and in this respect the organization itself is restricting where the industry funding will be used within the budget; however, this is never dictated by the funding organization. These areas are indicated under the program support detail in **Attachments A, B and C**.

- 3) *(your #4) Please explain your policies on disclosure of outside income by your top executives and board members.*

Last year, the Academy's Board of Directors approved a statement for inclusion in our journal (the December 2008 issue of the Journal of the American Academy of Dermatology) that discussed issues surrounding the potential for conflicts of interest with both individuals and organizations, cited the organization's relevant policies, and affirmed its commitment to transparency.

The article outlines the fact that the Academy first developed an "administrative regulation" (AR) on the topic of disclosure over 20 years ago. It also is an example of the organization's commitment to communicating its position regarding clarity and transparency with its members. The article discussed the Academy's conflict of interest policies, particularly in the areas of governance, education and scientific publication. All individuals in the Academy's governance and educational structure are required to disclose their—and their first degree relatives'—relationships with industry, employers, other associations or any other organization that could create a private interest in conflict with the Academy's interest and mission. The opportunity to review or update individual disclosures is

provided at the beginning of any educational activity, council, committee, task force or other meeting associated with the Academy.

The following attachments provide detail on the Academy's current policies regarding conflict of interest and transparency as it relates to individuals affiliated with the Academy:

Attachment F: Administration Regulation (AR) Policy and Procedures Regarding Actual or Potential Conflict of Interest

Please note that we employ an online disclosure process. To review, please go to www.aad.org and log into the members-only section (case sensitive user id: ACCME; password: AADWEB). Go to the Member Resources/My Account and click on Disclosure Form under Academy Member Tools.

Attachment G: "Position Statement on Contemporary Issues: Conflict of Interest," December 2008, JAAD.

- 4) *(your #3) Please explain what policies, if any that AAD plans to adopt to ensure transparency of funding in order to provide a greater public trust in the independence of your organization.*

While the Academy has policies in place reflecting its serious commitment to transparency, it recognizes the need for constant and continuous evaluation and improvement. Accordingly, we have initiated a process of comprehensive assessment for potential strengthening of our current policies. The Academy's Board of Directors discussed this topic at its November 2009 meeting and appointed a task force to reevaluate all disclosure policies and procedures to see how they might be strengthened, particularly in light of changing best practices and the Institute of Medicine (IOM) report released earlier this year. In my role as Executive Director and CEO, I personally served on a task force from the Council of Medical Specialty Societies (CMSS) charged with developing consistent policy and disclosure templates for professional medical associations, a recommendation of the IOM's report. A draft policy was distributed last month and is currently being reviewed by CMSS member organizations for reaction and input. The Executive Director of the CMSS presented and participated in our Board discussion last month.

The AAD/A supports the spirit of the CMSS efforts and expects that the ultimate policy will include a section advocating for transparency as part of the broader document. Once the final version is complete (expected in April), our organization will evaluate the policy for potential formal endorsement.

In addition, the Academy has recently added a detailed listing of corporate support by company with total dollars and name of supported activity for 2009 (as

The Honorable Congressman Charles E. Grassley

December 21, 2009

Page 5 of 5

of November 2009). This is currently posted on our Web site at www.AADdevelopment.org.

- 5) *Please provide the disclosures of outside income filed with your organizations by your top executives and board members.*

Attachment H: Disclosure forms for Board of Directors and senior staff.

I hope this information is helpful. Please do not hesitate to contact me or Karen Collishaw at 202-712-2600 if you would like further information from the Academy or need clarification of anything that is contained in this letter.

Sincerely,

A handwritten signature in black ink, appearing to read "Ronald A. Henrichs". The signature is fluid and cursive, with the first name "Ronald" being the most prominent part.

Ronald A. Henrichs, CAE
Executive Director & CEO

Attachments

American Academy of Dermatology 2009 Corporate Support				
		Attachment A		
Following is the overview of 2009 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
Abbott Laboratories	09 Annual Meeting News Post Edition	\$45,000.00		
	09 Summer Academy Meeting Program-at-a-Glance Map and Floor Plan Divider	\$6,000.00		
	09 "Stop Hiding" Psoriasis Public Awareness Program	\$150,000.00		
	09 "Stop Hiding" Tee Shirts	\$20,000.00		
	09 Psoriasis Net Web site	\$50,000.00		
	09 Print and Electronic Membership Directory	\$25,000.00		
	JAAD Series of Critically Challenging Case Scenarios in Moderate to Severe Psoriasis		\$16,727.00	
	Sub-total	\$296,000.00	\$16,727.00	\$312,727.00
Allergan, Inc.	2010 Practice Management Symposium for Residents	\$100,000.00		
	09 Soft Tissue Fillers Conference: Assessing the State of the Science	\$50,000.00		
	Sub-total	\$150,000.00	\$0.00	\$150,000.00
Amgen Pfizer	2010 Annual Meeting Cyber Center	\$75,000.00		
	09 Addressing Psoriasis Public Awareness Program	\$105,000.00		
	2010 Dermatologic Calendar of Events	\$70,000.00		
	2010 Derm Coding Consult Newsletter	\$45,000.00		
	2010 Print and Electronic Membership Directory	\$25,000.00		
	Sub-total	\$320,000.00	\$0.00	\$320,000.00
Astellas Pharma US, Inc.	09 Camp Discovery	\$50,000.00		
	2009 Astellas Awards	\$100,000.00		
	JAAD Series of Critically Challenging Case Scenarios in Moderate to Severe Psoriasis		\$16,727.00	
	Sub-total	\$150,000.00	\$16,727.00	\$166,727.00
Beiersdorf, Inc.	09 SKINnovations	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
BioForm Medical, Inc.	09 Soft Tissue Fillers Conference: Assessing the State of the Science	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
Pen State (funding provided by Centocor Ortho Biotech Inc.)	09 Industry Supported Symposia	\$65,000.00		
	Sub-total	\$65,000.00	\$0.00	\$65,000.00
Centecor, Inc.	JAAD Poster Abstracts		\$100,000.00	
	Sub-total	\$0.00	\$100,000.00	\$100,000.00
Coria Laboratories, Ltd.	09 Annual Meeting AAD News Network	\$30,000.00		
	Sub-total	\$30,000.00	\$0.00	\$30,000.00
Dermik Laboratories, a business of sanofi-aventis U.S. LLC	09 Camp Discovery	\$50,000.00		
	09 Soft Tissue Fillers Conference: Assessing the State of the Science	\$50,000.00		
	Sub-total	\$100,000.00	\$0.00	\$100,000.00

American Academy of Dermatology 2009 Corporate Support				
		Attachment A		
Following is the overview of 2009 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
Eclipsys Corporation	09 Annual Meeting Pocket Guide (partial support)	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
Galderma Laboratories, L.P.	JAAD New Insights into the Management of Acne		\$102,000.00	
	JAAD Resident Subscription Program		\$136,770.00	
	Sub-total	\$0.00	\$238,770.00	\$238,770.00
Genentech, Inc.	JAAD Series of Critically Challenging Case Scenarios in Moderate to Severe Psoriasis		\$16,727.00	
	Sub-total	\$0.00	\$16,727.00	\$16,727.00
Graceway Pharmaceuticals, LLC	09 Actinic Kerasotes Pamphlet 3/1/09-2/28/10	\$30,000.00		
	09 Camp Discovery	\$12,280.00		
	Sub-total	\$42,280.00	\$0.00	\$42,280.00
Intendis, Inc.	09 Annual Meeting Advance Registration Materials Folder	\$25,000.00		
	09 Annual Meeting News Preview Edition	\$45,000.00		
	09 Annual Meeting Program-at-a-Glance Personal Planner Section	\$45,000.00		
	09 Summer Academy Meeting Program-at-a-Glance Personal Planner Section	\$12,000.00		
	09 Summer Academy Meeting Advance Registration Materials Folder	\$10,000.00		
	09 Summer Academy Meeting Educational Session Handouts and Poster Abstracts on CD	\$25,000.00		
	09 Summer Academy Meeting Lead Retrieval Cards	\$10,000.00		
	2009 Recertification Exam Prep Course	\$125,000.00		
	Rosacea Pamphlets (two years)	\$60,000.00		
	09 Camp Discovery	\$20,000.00		
	09 Print and Electronic Membership Directory	\$25,000.00		
	Sub-total	\$402,000.00	\$0.00	\$402,000.00
Johnson & Johnson Consumer Products Company	09 Shade Structure Program	\$200,000.00		
	2010 Shade Structure Program	\$200,000.00		
	Sub-total	\$400,000.00	\$0.00	\$400,000.00
La Roche-Posay Laboratoire Pharmaceutique	2010 Annual Meeting Residents Reception	\$15,000.00		
	Sub-total	\$15,000.00	\$0.00	\$15,000.00
MDLand International	2010 dEHRm CD	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
Medicis Pharmaceutical Corporation	09 Soft Tissue Fillers Conference: Assessing the State of the Science	\$25,000.00		
	09 Soft Tissue Fillers Conference: Assessing the State of the Science	\$25,000.00		
	Sub-total	\$50,000.00	\$0.00	\$50,000.00
Merz Pharmaceuticals, LLC	2010 Annual Meeting Program-at-a-Glance Program Section	\$25,000.00		
	09 SKiNnovations	\$10,000.00		

American Academy of Dermatology 2009 Corporate Support					
			Attachment A		
Following is the overview of 2009 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.					
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total	
	09 Camp Discovery	\$5,000.00			
	2010 Annual Meeting Young Physician and New Member Reception	\$15,000.00			
	09 Soft-Tissue Fillers Conference: Assessing the State of the Science	\$25,000.00			
	2009 Directions in Residency Newsletter (fall and winter)	\$25,000.00			
	2010 Directions in Residency Newsletter	\$45,000.00			
	Sub-total	\$150,000.00	\$0.00	\$150,000.00	
Neutrogena Corporation	09 Annual Meeting Resident Housing Program	\$500,000.00			
	2010 Annual Meeting Resident Housing Program	\$500,000.00			
	09 Neutrogena Public Awareness Program	\$50,000.00			
	Neutrogena Public Awareness	\$50,000.00			
	Sub-total	\$1,100,000.00	\$0.00	\$1,100,000.00	
NexTech	2010 Annual Meeting Registration Bags	\$90,000.00			
	Sub-total	\$90,000.00	\$0.00	\$90,000.00	
Ortho Dermatologics	09 Annual Meeting Resident Air Travel Assistance Program	\$340,000.00			
	Sub-total	\$340,000.00	\$0.00	\$340,000.00	
Pharm Adura, LLC (funding provided by Medicis Pharmaceutical Corporation)	09 Industry Supported Symposia, Advance Cosmetic Therapy	\$65,000.00			
	Sub-total	\$65,000.00	\$0.00	\$65,000.00	
Procter & Gamble Company	09 SKINnovations	\$50,000.00			
	Sub-total	\$50,000.00	\$0.00	\$50,000.00	
ProPath	2010 Annual Meeting Take Five Express Spa	\$25,000.00			
	Sub-total	\$25,000.00	\$0.00	\$25,000.00	
sanofi-aventis	JAAD Canadian Resident Subscription Program		\$11,520.00		
	Sub-total	\$0.00	\$11,520.00	\$11,520.00	
Stiefel a GSK company	2010 Annual Meeting AAD e-Posters Exhibit Area	\$100,000.00			
	2010 Annual Meeting Hotel Key Cards	\$25,000.00			
	2010 Annual Meeting Program-at-a-Glance Map and Floor Plan Divider	\$15,000.00			
	09 SKINnovations	\$10,000.00			
	09 Soft Tissue Fillers Conference: Assessing the State of the Science	\$10,000.00			
	JAAD Series of Critically Challenging Case Scenarios in Moderate to Severe Psoriasis		\$16,727.00		
	Sub-total	\$160,000.00	\$16,727.00	\$176,727.00	
Total @ Nov '09:		\$4,100,280.00	\$417,198.00	\$4,517,478.00	

American Academy of Dermatology 2008 Corporate Support				
		Attachment A		
Following is the overview of 2008 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
Abbott Laboratories	08 Stop Hiding Psoriasis Public Awareness Campaign	\$150,000.00		
	Camp Discovery	\$10,000.00		
	08 Diamond Level Industry Supported Symposia	\$75,000.00		
	08 Annual Meeting News Post Edition	\$5,000.00		
	08 Program-at-a-Glance Map and Floor Plan Divider	\$7,000.00		
	JAAD Poster Abstracts		\$172,000.00	
	Sub-total	\$247,000.00	\$172,000.00	\$419,000.00
Allergan, Inc.	08-09 Aging SkinNet Web site	\$50,000.00		
	08 Diamond Level Industry Supported Symposia	\$75,000.00		
	09 Annual Meeting Resident Reception	\$15,000.00		
	Sub-total	\$140,000.00	\$0.00	\$140,000.00
Amgen Wyeth	09 Dialogues in Dermatology	\$75,000.00		
	09 Dermatologic Calendar of Events	\$70,000.00		
	09 Annual Meeting Bus Shuttle Service	\$200,000.00		
	08 Summer Academy Meeting Hotel Key Cards	\$10,000.00		
	09 Summer Academy Meeting Cyber Center	\$25,000.00		
	09 Summer Academy Meeting Hotel Cards	\$10,000.00		
	09 Electronic Membership Directory	\$25,000.00		
	09 Derm Coding Consult Newsletter	\$45,000.00		
	09 Sharing Mentoring Breakfast	\$25,000.00		
	Sub-total	\$485,000.00	\$0.00	\$485,000.00
Arcutis Pharmaceuticals, Inc.	08 Leadership Forum	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
Astellas Pharma US, Inc.	09 Derm Clips	\$40,000.00		
	Camp Discovery	\$50,000.00		
	08 Astellas Award	\$10,000.00		
	09 Annual Meeting City Guide	\$45,000.00		
	08 Summer Academy Meeting AAD E-posters CD	\$40,000.00		
	09 Summer Academy Meeting AAD e- Posters Exhibit Area	\$40,000.00		
	Sub-total	\$225,000.00	\$0.00	\$225,000.00
Beiersdorf, Inc.	08 SKINnovations	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
Centocor, Inc.	08 Diamond Level Industry Supported Symposia	\$75,000.00		
	Sub-total	\$75,000.00	\$0.00	\$75,000.00
Coria Laboratories, Ltd.	Camp Discovery	\$5,000.00		
	09 Derm Workforce Initiative	\$25,000.00		
	Sub-total	\$30,000.00	\$0.00	\$30,000.00
Dermik Laboratories, a business of sanofi-aventis U.S. LLC	Camp Discovery	\$50,000.00		
	08 Diamond Level Industry Supported Symposia	\$75,000.00		
	09 Annual Meeting AAD News Network	\$55,000.00		
	09 Annual Meeting Session Handouts on CD	\$75,000.00		
	09 Annual Meeting Lanyards	\$75,000.00		
	09 Annual Meeting Registration Bag	\$90,000.00		
	08 Summer Academy Meeting Program-at-a-Glance Program Section	\$8,000.00		

American Academy of Dermatology 2008 Corporate Support				
		Attachment A		
Following is the overview of 2008 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
	Sub-total	\$428,000.00	\$0.00	\$428,000.00
Galderma Laboratories, L.P.	08 Diamond Level Industry Supported Symposia	\$75,000.00		
	JAAD Resident Subscription Program		\$134,715.00	
	Sub-total	\$75,000.00	\$134,715.00	\$209,715.00
Genentech, Inc.	09 Annual Meeting Lead Retrieval Cards	\$75,000.00		
	09 Annual Meeting Program-at-a-Glance Program Section	\$25,000.00		
	08 Summer Academy Meeting News Preview Edition	\$45,000.00		
	08 Summer Academy Meeting WiFi Internet Lounges	\$30,000.00		
	09 Summer Academy Meeting WiFi Internet Lounges	\$30,000.00		
	09 Annual Meeting New Member Reception	\$15,000.00		
	09 Summer Academy Meeting Mentoring Reception	\$25,000.00		
	Sub-total	\$245,000.00	\$0.00	\$245,000.00
GlaxoSmithKline	08 Audience Response System	\$15,000.00		
	Sub-total	\$15,000.00	\$0.00	\$15,000.00
Graceway Pharmaceuticals, LLC	09 Dermatology World to Residents	\$75,000.00		
	08 Young Physician Focus Newsletter	\$35,000.00		
	09 Young Physician Focus Newsletter	\$45,000.00		
	08 Young Physician Reception	\$15,000.00		
	Sub-total	\$170,000.00	\$0.00	\$170,000.00
Intendis, Inc.	Camp Discovery	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
L'Oreal	JAAD Recent Advances in Photoprotection		\$66,000.00	
	Sub-total	\$0.00	\$66,000.00	\$66,000.00
Mary Kay Inc.	2008 Pamphlets (TBA)	\$35,000.00		
	Sub-total	\$35,000.00	\$0.00	\$35,000.00
Medicis Pharmaceutical Corporation	08 Leadership Forum	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
Merz Pharmaceuticals, LLC	09 SKINnovations	\$10,000.00		
	Camp Discovery	\$25,000.00		
	09 Summer Academy Meeting Pocket Guide	\$10,000.00		
	09 Leadership Forum	\$25,000.00		
	Sub-total	\$70,000.00	\$0.00	\$70,000.00
Neutrogena Corporation	08 Annual Meeting Resident Housing Program	\$500,000.00		
	Sub-total	\$500,000.00	\$0.00	\$500,000.00
PharmaDerm, a division of Nycomed US, Inc.	09 Industry Supported Symposia	\$130,000.00		
	Sub-total	\$130,000.00	\$0.00	\$130,000.00
Phillip Frost	Phillip Frost Grant	\$45,000.00		
	Sub-total	\$45,000.00	\$0.00	\$45,000.00

American Academy of Dermatology 2008 Corporate Support				
			Attachment A	
Following is the overview of 2008 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				

American Academy of Dermatology 2007 Corporate Support				
		Attachment A		
Following is the overview of 2007 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
Abbott Laboratories	07 Diamond Level Industry Supported Symposium	\$75,000.00		
	07 Annual Meeting News Post Edition	\$45,000.00		
	08 Annual Meeting News Post Edition	\$45,000.00		
	07 Summer Academy Meeting News Post Edition (DIF)	\$45,000.00		
	07 Summer Academy Meeting News On-Site Edition	\$35,000.00		
	JAAD Poster Abstracts		\$164,000.00	
	JAAD Abbott Field Force Subscriptions		\$30,800.00	
	Sub-total	\$245,000.00	\$194,800.00	\$439,800.00
Allergan, Inc.	2007 Dialogues in Dermatology	\$20,000.00		
	Educational Grant	\$5,000.00		
	07 Diamond Level Industry Supported Symposium	\$75,000.00		
	Sub-total	\$100,000.00	\$0.00	\$100,000.00
Amgen Wyeth	08 PsoriasisNet Web site	\$70,000.00		
	Psoriasis Pamphlets 6/4/07-6/3/09	\$60,000.00		
	Camp Discovery	\$50,000.00		
	07 Issues in Derm (President's Initiative)	\$25,000.00		
	08 Dermatologic Calendar of Events	\$70,000.00		
	08 Mentoring Forum	\$25,000.00		
	07 Diamond Level Industry Supported Symposium	\$75,000.00		
	08 Annual Meeting E-News	\$45,000.00		
	08 Annual Meeting Shuttle Bus Service	\$183,000.00		
	07 Summer Academy Meeting Hotel Room Key	\$10,000.00		
	07 Forum Relative to FDAAA	\$10,000.00		
	08 Derm Coding Consult Newsletter	\$45,000.00		
	08 Print and Electronic Membership Directory	\$25,000.00		
	Derm Coding Consult Newsletter	\$45,000.00		
	07 Young Physicians Forum	\$25,000.00		
	Sub-total	\$763,000.00	\$0.00	\$763,000.00
Astellas Pharma US, Inc.	Camp Discovery	\$50,000.00		
	Astellas Award	\$100,000.00		
	07 Diamond Level Industry Supported Symposium	\$75,000.00		
	08 Annual Meeting City Guide	\$45,000.00		
	07 AC Posters2View	\$40,000.00		
	07 Summer Academy Meeting Program-Glance	\$6,000.00		
	Sub-total	\$316,000.00	\$0.00	\$316,000.00
Beiersdorf, Inc.	SKINnovations	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
Caruthers	JAAD Canadian Resident Subscription Program		\$6,580.00	
	Sub-total	\$0.00	\$6,580.00	\$6,580.00
Centocor, Inc.	07 Diamond Level Industry Supported Symposium	\$75,000.00		
	Sub-total	\$75,000.00	\$0.00	\$75,000.00
CollaGenex Pharmaceuticals, Inc.	07 Summer Academy Meeting Gold Level Symposium	\$50,000.00		
	Sub-total	\$50,000.00	\$0.00	\$50,000.00
Coria Laboratories, Ltd.	Camp Discovery	\$25,000.00		
	Camp Discovery	\$25,000.00		
	Dermatology Workforce Initiative	\$25,000.00		
	Sub-total	\$75,000.00	\$0.00	\$75,000.00
Cutera	07 Annual Meeting Scrolling Monitors	\$15,000.00		
	Sub-total	\$15,000.00	\$0.00	\$15,000.00

American Academy of Dermatology 2007 Corporate Support				
		Attachment A		
Following is the overview of 2007 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
Dermik Laboratories, a business of sanofi-aventis U.S. LLC	JAAD Physician Assistant Subscription code to 49020	\$89,000.00		
	07 Diamond Level Industry Supported Symposium	\$73,200.00		
	07 Annual Meeting Pocket Guide	\$40,000.00		
	08 Annual Meeting Lanyards	\$75,000.00		
	08 Annual Meeting Pocket Guides	\$40,000.00		
	08 Annual Meeting Scrolling Monitors	\$15,000.00		
	08 Annual Meeting Session Handouts on CD	\$75,000.00		
	07 Summer Academy Meeting Program-at-a-Glance	\$8,000.00		
	Sub-total	\$415,200.00	\$0.00	\$415,200.00
Galderma Laboratories, L.P.	JAAD Resident Subscription Program		\$140,061.00	
	Sub-total	\$0.00	\$140,061.00	\$140,061.00
Genentech, Inc.	Camp Discovery	\$20,000.00		
	08 Annual Meeting Lead Retrieval Cards	\$75,000.00		
	08 Annual Meeting Program-at-a-Glance Program Section	\$25,000.00		
	08 Annual Meeting Program-at-a-Glance Program Section (one additional page)	\$10,000.00		
	Sub-total	\$130,000.00	\$0.00	\$130,000.00
Graceway Pharmaceuticals, LLC	Actinic Keratoses Pamphlets 9/1/07-8/31/09	\$60,000.00		
	SKINnovations	\$25,000.00		
	Camp Discovery	\$10,000.00		
	Derm World to Residents 11/1/07-10/31/08	\$75,000.00		
	Sub-total	\$170,000.00	\$0.00	\$170,000.00
Intendis GmbH	07 Diamond Level Industry Supported Symposium	\$75,000.00		
	Sub-total	\$75,000.00	\$0.00	\$75,000.00
Intendis, Inc.	Camp Discovery	\$25,000.00		
	08 Annual Meeting Advance Registration Materials Folders	\$25,000.00		
	08 Annual Meeting News Preview Edition	\$45,000.00		
	08 Annual Meeting Program-at-a-Glance Planner Section	\$45,000.00		
	08 Annual Meeting Registration Bags	\$90,000.00		
	07 Summer Academy Meeting Lead Retrieval Cards	\$10,000.00		
	07 Summer Academy Meeting Program-Glance Planner Section	\$12,000.00		
	07 Summer Academy Meeting Registration Bags	\$25,000.00		
	08 Summer Academy Meeting Lead Retrieval Cards	\$10,000.00		
	08 Summer Academy Meeting Program-at-a-Glance Planner Section	\$12,000.00		
	08 Summer Academy Meeting Registration Bags	\$25,000.00		
	Print and Electronic Membership Directory	\$25,000.00		
	Print Membership Directory	\$25,000.00		
	Sub-total	\$374,000.00	\$0.00	\$374,000.00
Johnson & Johnson Consumer Products Company	Shade Structure Program 2008	\$250,000.00		
	08 Diamond Level Industry Supported Symposium	\$75,000.00		
	Sub-total	\$325,000.00	\$0.00	\$325,000.00
Mary Kay Inc.	2007 Pamphlets	\$35,000.00		
	Sub-total	\$35,000.00	\$0.00	\$35,000.00

American Academy of Dermatology 2007 Corporate Support				
		Attachment A		
Following is the overview of 2007 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
Merck & Co., Inc.	JAAD Allieviating the burden of herpes zoster through vaccination		\$84,099.00	
	Sub-total	\$0.00	\$84,099.00	\$84,099.00
Merz Pharmaceuticals, LLC	08 Annual Meeting Wireless Internet (WiFi) Lounges	\$50,000.00		
	Sub-total	\$50,000.00	\$0.00	\$50,000.00
Neutrogena Corporation	07 Annual Meeting Resident Housing	\$500,000.00		
	Sub-total	\$500,000.00	\$0.00	\$500,000.00
Obagi Medical Products	07 Diamond Level Industry Supported Symposium	\$75,000.00		
	Sub-total	\$75,000.00	\$0.00	\$75,000.00
Ortho Neutrogena	08 Annual Meeting Air Travel Assistance Program	\$300,000.00		
	Focus Newsletter	\$30,000.00		
	Resident's Newsletter	\$30,000.00		
	Sub-total	\$360,000.00	\$0.00	\$360,000.00
PharmaDerm, a division of Nycomed US, Inc.	07 AAD Regional Practice Management Course	\$100,000.00		
	08 Dermatology Review Course	\$100,000.00		
	08 Practice Management Course	\$100,000.00		
	08 Directions in Residency Newsletter	\$35,000.00		
	08 Annual Meeting Program-at-a-Glance Map and Floor Plan Divider	\$19,000.00		
	Sub-total	\$354,000.00	\$0.00	\$354,000.00
Philip Frost	Philip Frost	\$45,000.00		
	Sub-total	\$45,000.00	\$0.00	\$45,000.00
Procter & Gamble Company	07 Educational Grant	\$50,000.00		
	Sub-total	\$50,000.00	\$0.00	\$50,000.00
ProPath	08 Annual Meeting Take Five Express Spa	\$20,000.00		
	Sub-total	\$20,000.00	\$0.00	\$20,000.00
sanofi-aventis	07 Annual Meeting Lanyards	\$75,000.00		
	Sub-total	\$75,000.00	\$0.00	\$75,000.00
SkinMedica, Inc.	07 Summer Academy Meeting Pocket Guides	\$10,000.00		
	Sub-total	\$10,000.00	\$0.00	\$10,000.00
Stiefel Laboratories, Inc.	Dermatology Review Course	\$50,000.00		
	Practical Approach to Patient Problems	\$100,000.00		
	08 Practice Management Symposium for Residents	\$200,000.00		
	Resident Practice Management	\$200,000.00		
	SKINnovations	\$25,000.00		
	SKINnovations	\$25,000.00		
	Camp Discovery	\$25,000.00		
	Autobiography "The Skin Around Me"	\$30,700.00		
	08 Diamond Level Industry Supported Symposium	\$75,000.00		
	08 Annual Meeting Hotel Key Cards	\$25,000.00		
	Sub-total	\$755,700.00	\$0.00	\$755,700.00
Upsher-Smith Laboratories, Inc.	08 Annual Meeting Press Office	\$10,000.00		
	Sub-total	\$10,000.00	\$0.00	\$10,000.00

American Academy of Dermatology 2007 Corporate Support				
			Attachment A	
Following is the overview of 2007 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
<i>Company Name</i>	<i>Year/Reason</i>	<i>Amount</i>	<i>Amount - JAAD Thru Elsevier Publisher</i>	<i>Combined Total</i>
Total :		\$5,492,900.00	\$425,540.00	\$5,918,440.00

American Academy of Dermatology 2006 Corporate Support				
			Attachment A	
Following is the overview of 2006 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
3M Foundation	Restricted Grant in support of Dermatology Workforce Initiative	\$67,000.00		
	Sub-total	\$67,000.00	\$0.00	\$67,000.00
3M Pharmaceuticals	2006 ActinicKeratosisNet Website	\$80,000.00		
	SKINnovations	\$25,000.00		
	2006 Gold Triangle Awards Benefactor Table	\$5,000.00		
	Sub-total	\$110,000.00	\$0.00	\$110,000.00
Abbott Laboratories	07 Annual Meeting AAD News Network	\$55,000.00		
	06 Summer Academy Meeting News On-Site Edition	\$35,000.00		
	06 Summer Academy Meeting News Post Edition	\$45,000.00		
	2007 AAD Print and Electronic Membership Directory	\$25,000.00		
	JAAD Poster Abstracts		\$159,000.00	
	JAAD Abbott Field Force Subscriptions		\$30,800.00	
	Sub-total	\$160,000.00	\$189,800.00	\$349,800.00
Allergan, Inc.	2006 Maintenance of Certification Manual for Dermatology MOCmd	\$90,000.00		
	Camp Discovery Endowment	\$10,000.00		
	Sub-total	\$100,000.00	\$0.00	\$100,000.00
Amgen Wyeth	2006 Dialogues in Dermatology	\$75,000.00		
	2007 Dialogues in Dermatology	\$75,000.00		
	2007 PsoriasisNet Website	\$70,000.00		
	Educational Grant for General Support	\$175,000.00		
	Camp Discovery Endowment	\$34,000.00		
	2006 Issues in Dermatology (Continuity Summit December 2006)	\$25,000.00		
	2007 Dermatologic Calendar of Events	\$61,000.00		
	07 Annual Meeting Shuttle Bus Service	\$175,000.00		
	06 Summer Academy Meeting Afternoon Break	\$15,000.00		
	06 Summer Academy Meeting Program-at-a-Glance Map and Floor Plan Divider	\$6,000.00		
	07 Summer Academy Meeting Cyber Center	\$25,000.00		
	2006 Derm Coding Consult Newsletter	\$45,000.00		
	2006 Medical Director's Summit and Webinar on Psoriasis	\$34,500.00		
	2007 AAD Print and Electronic Membership Directory	\$25,000.00		
	2006 Young Physician Forum	\$25,000.00		
	JAAD Current uses of Etanercept in Psoriasis and other Dermatoses		\$138,750.00	
	Sub-total	\$865,500.00	\$138,750.00	\$1,004,250.00
Astellas Pharma US, Inc.	Camp Discovery Endowment	\$50,000.00		
	2006 Astellas Award	\$100,000.00		
	Sub-total	\$150,000.00	\$0.00	\$150,000.00
Barrier Therapeutics, Inc.	2006 Gold Triangle Awards Seating	\$900.00		
	Sub-total	\$900.00	\$0.00	\$900.00
Caruthers	JAAD Canadian Resident Subscription Program		\$6,519.00	
	Sub-total	\$0.00	\$6,519.00	\$6,519.00
Centocor, Inc.	06 Summer Academy Meeting News Preview Edition	\$45,000.00		

American Academy of Dermatology 2006 Corporate Support				
		Attachment A		
Following is the overview of 2006 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
	06 Summer Academy Meeting Program-at-a-Glance Program Section	\$8,000.00		
	06 Summer Academy Meeting Program-at-a-Glance Program Section	\$10,000.00		
	Sub-total	\$63,000.00	\$0.00	\$63,000.00
Coria Laboratories, Ltd.	Dermatology Workforce Initiative	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
Del-Ray Dermatologicals, a Division of Crown Laboratories	2006 Gold Triangle Awards Seating (two seats)	\$600.00		
	Sub-total	\$600.00	\$0.00	\$600.00
Dermik Laboratories, a business of sanofi-aventis U.S. LLC	2006 Abstract and Commentary Publications	\$40,000.00		
	SKINnovations	\$26,000.00		
	Camp Discovery Endowment	\$50,000.00		
	2006 Gold Triangle Awards Patron Table (2)	\$20,000.00		
	2006 Issues in Dermatology	\$25,000.00		
	Sub-total	\$161,000.00	\$0.00	\$161,000.00
Doak Dermatologics	2007 Educational Grant	\$25,000.00		
	Sub-total	\$25,000.00	\$0.00	\$25,000.00
Galderma Laboratories, L.P.	SKINnovations	\$20,000.00		
	2006 Gold Triangle Awards Benefactor Table	\$5,000.00		
	2006 Gold Triangle Awards Benefactor Table	\$5,000.00		
	2006 Issues in Dermatology (President's Initiative)	\$25,000.00		
	06 Summer Academy Meeting Advance Registration Materials Folders	\$10,000.00		
	JAAD Management of Pigmentary Disorders		\$81,000.00	
	JAAD Resident Subscription Program		\$130,173.00	
	Sub-total	\$65,000.00	\$211,173.00	\$276,173.00
Genentech, Inc.	Camp Discovery Endowment	\$20,000.00		
	2006 Continuity Summit (December 2006)	\$25,000.00		
	2006 Gold Triangle Awards Sponsor Table	\$5,000.00		
	2006 Synergy Summit (February 2006)	\$25,000.00		
	06 Diamond Level Industry Supported Symposium	\$75,000.00		
	07 Diamond Level Industry Supported Symposium	\$75,000.00		
	06 Annual Meeting City Guide	\$45,000.00		
	06 Annual Meeting Lead Retrieval Cards	\$75,000.00		
	06 Annual Meeting Program-at-a-Glance Program Section	\$25,000.00		
	07 Annual Meeting Lead Retrieval Cards	\$75,000.00		
	07 Annual Meeting Program-at-a-Glance Program Section	\$25,000.00		
	06 Summer Academy Meeting City Guide	\$20,000.00		
	JAAD Practical Guidelines for the Long-term Treatment of Psoriasis		\$94,308.00	
	Sub-total	\$490,000.00	\$94,308.00	\$584,308.00
HMP Communications	2006 Gold Triangle Awards Seating (eight seats)	\$2,400.00		
	Sub-total	\$2,400.00	\$0.00	\$2,400.00
Intendis, Inc.	Rosacea Pamphlet (two years 11/1/06 to 10/31/08)	\$75,000.00		
	Camp Discovery Endowment	\$25,000.00		
	2006 Issues in Dermatology (President's Initiative)	\$25,000.00		

American Academy of Dermatology 2006 Corporate Support				
			Attachment A	
Following is the overview of 2006 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
Company Name	Year/Reason	Amount	Amount - JAAD Thru Elsevier Publisher	Combined Total
	2006 Gold Triangle Awards Benefactor Table	\$5,000.00		
	2006 Gold Triangle Awards Travel Stipend	\$15,000.00		
	06 Annual Meeting News Preview Edition	\$45,000.00		
	07 Annual Meeting Registration Bags	\$90,000.00		
	07 Annual Meeting Advance Registration Materials Folders	\$25,000.00		
	07 Annual Meeting News Preview Edition	\$45,000.00		
	2007 Annual Meeting Program-at-a-Glance Personal Planner Section	\$45,000.00		
	06 Summer Academy Meeting Lead Retrieval Card	\$10,000.00		
	06 Summer Academy Meeting Program-at-a-Glance Personal Planner Section	\$12,000.00		
	Sub-total	\$417,000.00	\$0.00	\$417,000.00
Johnson & Johnson Consumer Products Company				
	2006 Shade Structure Grant Program	\$250,000.00		
	2006 Shade Structure Grant Program	\$8,000.00		
	2007 AAD Shade Structure Program	\$250,000.00		
	06 Diamond Level Industry Supported Symposium	\$75,000.00		
	07 Diamond Level Industry Supported Symposium	\$75,000.00		
	06 Summer Academy Meeting Session Handouts on CD	\$30,000.00		
	2006 Medical Director's Summit and Webinar on Psoriasis	\$34,500.00		
	Sub-total	\$722,500.00	\$0.00	\$722,500.00
La Roche-Posay Laboratoire Pharmaceutique				
	06 Diamond Level Industry Supported Symposium	\$75,000.00		
	Sub-total	\$75,000.00	\$0.00	\$75,000.00
Merz Pharmaceuticals, LLC				
	06 Annual Meeting Wireless (WiFi) Lounges	\$50,000.00		
	07 Annual Meeting Wireless Internet (WiFi) Lounges	\$50,000.00		
	Sub-total	\$100,000.00	\$0.00	\$100,000.00
Niadyne, Inc./ NIA24				
	2006 Gold Triangle Awards Seating	\$600.00		
	Sub-total	\$600.00	\$0.00	\$600.00
Novartis Pharmaceuticals Corp.				
	SKINnovations	\$35,000.00		
	2006 Issues in Dermatology (President's Initiative)	\$25,000.00		
	JAAD Bound Volume CD-rom Sponsorship		\$95,000.00	
	Sub-total	\$60,000.00	\$95,000.00	\$155,000.00
Ortho Neutrogena				
	SKINnovations	\$15,000.00		
	07 Annual Meeting Resident Air Travel Assistance Program	\$300,000.00		
	2006 Issues in Dermatology (Continuity Summit)	\$25,000.00		
	Sub-total	\$340,000.00	\$0.00	\$340,000.00
PharmaDerm, a division of Nycomed US, Inc.				
	2006 Practice Management Courses in Boston and Tucson	\$150,000.00		
	07 Annual Meeting Program-at-a-Glance Map and Floor Plan	\$19,000.00		
	Sub-total	\$169,000.00	\$0.00	\$169,000.00
Procter & Gamble Company				
	SKINnovations	\$50,000.00		
	Sub-total	\$50,000.00	\$0.00	\$50,000.00
ProPath				
	07 Annual Meeting Take Five...Express Spa	\$15,000.00		

American Academy of Dermatology 2006 Corporate Support				
		Attachment A		
Following is the overview of 2006 revenue from industry listed by company name, year, reason for funding and amount. Please see Attachment B for detail.				
<i>Company Name</i>	<i>Year/Reason</i>	<i>Amount</i>	<i>Amount - JAAD Thru Elsevier Publisher</i>	<i>Combined Total</i>
	Sub-total	\$15,000.00	\$0.00	\$15,000.00
Stiefel Laboratories, Inc.	2006 JAAD Case Report Supplements (First Quarter)	\$50,000.00		
	2006 JAAD Case Report Supplements (Fourth Quarter)	\$50,000.00		
	2006 JAAD Case Report Supplements (Second Quarter)	\$50,000.00		
	2006 JAAD Case Report Supplements (Third Quarter)	\$50,000.00		
	Sub-total	\$200,000.00	\$0.00	\$200,000.00
Supergoop! Corporate	2006 Gold Triangle Awards Seating	\$1,500.00		
	Sub-total	\$1,500.00	\$0.00	\$1,500.00
Triax Pharmaceuticals, L.L.C.	06 Summer Academy Meeting Portfolio and Pen	\$30,000.00		
	Sub-total	\$30,000.00	\$0.00	\$30,000.00
Upsher-Smith Laboratories, Inc.	06 Annual Meeting Press Office	\$10,000.00		
	07 Annual Meeting Press Office	\$10,000.00		
	06 Summer Academy Meeting Lanyards	\$25,000.00		
	07 Summer Academy Meeting Lanyards	\$25,000.00		
	Sub-total	\$70,000.00	\$0.00	\$70,000.00
Total :		\$4,536,000.00	\$735,550.00	\$5,271,550.00

American Academy of Dermatology 2009 Corporate Supporters					Attachment B
American Academy of Dermatology (AAD) Funds					
Program	Company	Description		Amount	Amount through Elsevier Publishers
Medical Education (CME)	Intendis, Inc.	2009 Recertification Exam Prep Course	Designed for dermatologists either preparing for the recertification examination or those dermatologists wishing to benchmark their competence against the standard established by the American Board of Dermatology.	125,000.00	
Medical Education (non-CME)	Allergan, Inc.	2010 Practice Management Symposium for Residents	Educational program offered to first, second and third year residents. It provides an opportunity to expand residents' knowledge about the "business side of dermatology" through a variety of topics.	100,000.00	
Public Education	Abbott Laboratories	09 "Stop Hiding" Psoriasis Public Awareness Program	Public awareness program on psoriasis.	150,000.00	
	Abbott Laboratories	09 "Stop Hiding" Tee Shirts	An element of the public awareness program on psoriasis.	20,000.00	
	Graceway Pharmaceuticals, LLC	09 Actinic Kerasotes Pamphlet 3/1/09-2/28/10	Pamphlets address the symptoms, diagnosis, and treatment options for various dermatologic conditions. While specific products are not mentioned, the latest treatments and therapies are discussed.	30,000.00	
	Amgen Pfizer	09 Addressing Psoriasis Public Awareness Program	Public awareness program on psoriasis.	105,000.00	
	Neutrogena Corporation	09 Neutrogena Public Awareness Program	Public awareness program on psoriasis.	50,000.00	
	Abbott Laboratories	09 Psoriasis Net Web site	The Web sites are devoted to providing patient education for common dermatologic conditions. Patients and healthcare professionals use the Web sites as a resource for educational literature and health guideline descriptions.	50,000.00	
	Beiersdorf, Inc.	09 SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	25,000.00	
	Merz Pharmaceuticals, LLC	09 SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	10,000.00	

American Academy of Dermatology 2009 Corporate Supporters					Attachment B
	Procter & Gamble Company	09 SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	50,000.00	
	Stiefel a GSK company	09 SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	10,000.00	
	Neutrogena Corporation	Neutrogena Public Awareness	Public awareness program on psoriasis.	50,000.00	
	Intendis, Inc.	Rosacea Pamphlets (two years)	Pamphlets address the symptoms, diagnosis, and treatment options for various dermatologic conditions. While specific products are not mentioned, the latest treatments and therapies are discussed.	60,000.00	
Humanitarian	Astellas Pharma US, Inc.	09 Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	50,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	09 Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	50,000.00	
	Graceway Pharmaceuticals, LLC	09 Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	12,280.00	
	Intendis, Inc.	09 Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	20,000.00	

American Academy of Dermatology 2009 Corporate Supporters					Attachment B
	Johnson & Johnson Consumer Products Company	09 Shade Structure Program	The AAD Shade Structure Program awards \$8,000 to each recipient for the purchase of permanent shade structures that are designed to provide shade and ultraviolet (UV) ray protection for outdoor areas. This program is offered to non-profit organizations that serve children and teens and that are seeking permanent shade structures for outdoor locations that are not protected from the sun, such as playgrounds, pools, or recreation spaces.	200,000.00	
	Johnson & Johnson Consumer Products Company	2010 Shade Structure Program	The AAD Shade Structure Program awards \$8,000 to each recipient for the purchase of permanent shade structures that are designed to provide shade and ultraviolet (UV) ray protection for outdoor areas. This program is offered to non-profit organizations that serve children and teens and that are seeking permanent shade structures for outdoor locations that are not protected from the sun, such as playgrounds, pools, or recreation spaces.	200,000.00	
	Merz Pharmaceuticals, LLC	09 Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	5,000.00	
Specialty Support	Astellas Pharma US, Inc.	2009 Astellas Awards	The Astellas Awards Program recognizes the achievements of three individuals and/or institutions that have made a significant contribution to scientific research that improved public health. Three awards of \$30,000 each are given to the winners and the remaining \$10,000 is to be used at the discretion of the Academy.	100,000.00	
	Amgen Pfizer	2010 Dermatologic Calendar of Events	Calendar of dermatology/dermatology-related meetings organized chronologically and indexed by event host. The Calendar is sent to all Academy members and is distributed at the Annual and Summer Academy Meetings.	70,000.00	

American Academy of Dermatology 2009 Corporate Supporters					Attachment B
Industry Supported Symposia	Penn State (thru grant from Centocor Ortho Biotech Inc.)	09 Industry Supported Symposia	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	65,000.00	
	Pharm Adura, LLC (thru grant from Medicis Pharmaceutical Corporation)	09 Industry Supported Symposia, Advance Cosmetic Therapy	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	65,000.00	
Annual Meeting Supported Activities Largest dermatologic scientific meeting in the world providing quality education for dermatologists.	Coria Laboratories, Ltd.	09 Annual Meeting AAD News Network	There are four 30-minute programs to be shown a total of 192 times throughout the meeting. Up to six minutes of each program are available for supporter ads.	30,000.00	
	Intendis, Inc.	09 Annual Meeting Advance Registration Materials Folder	Pre-registered US and Canadian attendees have their name badge, tickets and expo card mailed to them in advance of the meeting and use the folder to carry their tickets and expo card throughout the week.	25,000.00	
	Abbott Laboratories	09 Annual Meeting News Post Edition	Mailed one month following the Annual Meeting. Its editorial mission is to highlight educational sessions, plenary speakers and award winners and presidential speeches. It serves as a recap of all educational and social activities.	45,000.00	
	Intendis, Inc.	09 Annual Meeting News Preview Edition	Provides news and information about upcoming meeting, including interviews with speakers, session highlights, details of registration and information on the host city. Has a circulation of approximately 16,000.	45,000.00	

American Academy of Dermatology 2009 Corporate Supporters					Attachment B
	Eclipsys Corporation	09 Annual Meeting Pocket Guide (partial support)	A condensed schedule of events and a quick reference tool that includes an overview of the educational program and technical exhibits.	25,000.00	
	Ortho Dermatologics	09 Annual Meeting Resident Air Travel Assistance Program	This program provides funding for air travel for first, second and third-year residents in dermatology who participate in the program.	340,000.00	
	Neutrogena Corporation	09 Annual Meeting Resident Housing Program	This program provides funding for four night's hotel accommodations (double occupancy) for first, second and third-year dermatology residents that participate in the program.	500,000.00	
	Stiefel a GSK company	2010 Annual Meeting AAD e-Posters Exhibit Area	Fully-searchable, web based Electronic Poster Exhibits which are displayed on monitors for viewing by registrants of the meeting.	100,000.00	
	Amgen Pfizer	2010 Annual Meeting Cyber Center	An area in the meeting facility is setup with multiple computer terminals where registrants have the opportunity to retrieve and leave messages for other meeting attendees along with ability to access e-mail while attending the Annual Meeting.	75,000.00	
	Stiefel a GSK company	2010 Annual Meeting Hotel Key Cards	Hotel Key Cards are distributed to registrants for entry into their hotel room upon check-in at the Annual Meeting headquarter hotel (s).	25,000.00	
	Stiefel a GSK company	2010 Annual Meeting Program-at-a-Glance Map and Floor Plan Divider	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	15,000.00	
	Merz Pharmaceuticals, LLC	2010 Annual Meeting Program-at-a-Glance Program Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	25,000.00	
	NexTech	2010 Annual Meeting Registration Bags	All medical personnel receive a bag to carry their meeting information.	90,000.00	

American Academy of Dermatology 2009 Corporate Supporters					Attachment B
	Neutrogena Corporation	2010 Annual Meeting Resident Housing Program	This program provides funding for four night's hotel accommodations (double occupancy) for first, second and third-year dermatology residents that participate in the program.	500,000.00	
	ProPath	2010 Annual Meeting Take Five Express Spa	Meeting attendees use this lounge to relax and refresh while receiving seated upper body massages and foot massages.	25,000.00	
	Intendis, Inc.	09 Annual Meeting Program-at-a-Glance Personal Planner Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	45,000.00	
Summer Academy Meeting Supported Activities Second largest Academy dermatologic scientific meeting during the year providing quality education for dermatologists.	Abbott Laboratories	09 Summer Academy Meeting Program-at-a-Glance Map and Floor Plan Divider	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	6,000.00	
	Intendis, Inc.	09 Summer Academy Meeting Program-at-a-Glance Personal Planner Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	12,000.00	
	Intendis, Inc.	09 Summer Academy Meeting Advance Registration Materials Folder	Pre-registered US and Canadian attendees have their name badge, tickets and expo card mailed to them in advance of the meeting and use the folder to carry their tickets and expo card throughout the week.	10,000.00	
	Intendis, Inc.	09 Summer Academy Meeting Educational Session Handouts and Poster Abstracts on CD	Handouts for all education sessions are provided on CD to all professional meeting attendees.	25,000.00	
	Intendis, Inc.	09 Summer Academy Meeting Lead Retrieval Cards	All medical personnel receive this card and use it throughout the exhibit hall. Provides exhibitors the ability to capture leads, qualify prospects and plan follow-up contact with physicians who visit their booth.	10,000.00	

American Academy of Dermatology 2009 Corporate Supporters					Attachment B
JAAD through Elsevier Publishers	Abbott Laboratories	2009 JAAD Supplement: A series of critically challenging case scenarios in moderate to severe psoriasis A Delphi consensus approach	Peer reviewed article on selected topic		16,727.00
	Astellas	2009 JAAD Supplement: A series of critically challenging case scenarios in moderate to severe psoriasis A Delphi consensus approach	Peer reviewed article on selected topic		16,727.00
	Genentech	2009 JAAD Supplement: A series of critically challenging case scenarios in moderate to severe psoriasis A Delphi consensus approach	Peer reviewed article on selected topic		16,727.00
	Stiefel Laboratories	2009 JAAD Supplement: A series of critically challenging case scenarios in moderate to severe psoriasis A Delphi consensus approach	Peer reviewed article on selected topic		16,727.00
	Centocor Ortho Biotech, Inc.	2009 JAAD Poster Abstracts	Supplement with Poster Abstracts as presented at the 2009 Annual Meeting.		100,000.00
	Galderma Laboratories, L.P.	2009 JAAD Supplement: New Insights into the Management of Acne An Update from the Global Alliance to Improve Outcomes in Acne Group	Peer reviewed article on selected topic		102,000.00
	Galderma Laboratories, L.P.	2009 JAAD Resident subscription program			136,770.00
	Sanofi Aventis	2009 JAAD Canadian resident subscription program			11,520.00
American Academy of Dermatology Association (AADA)					
Program	Company	Description		Amount	
Specialty Support	Abbott Laboratories	09 Print and Electronic Membership Directory	This is a reference tool and one of the most widely utilized Academy publications.	25,000.00	
	Intendis, Inc.	09 Print and Electronic Membership Directory	This is a reference tool and one of the most widely utilized Academy publications.	25,000.00	
	Allergan, Inc.	09 Soft Tissue Fillers Conference: Assessing the State of the Science	Collaborative effort with medical societies and expert panelists in soft tissue fillers to assess the state of the science with focus on patient efficacy.	50,000.00	
	BioForm Medical, Inc.	09 Soft Tissue Fillers Conference: Assessing the State of the Science	Collaborative effort with medical societies and expert panelists in soft tissue fillers to assess the state of the science with focus on patient efficacy.	25,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	09 Soft Tissue Fillers Conference: Assessing the State of the Science	Collaborative effort with medical societies and expert panelists in soft tissue fillers to assess the state of the science with focus on patient efficacy.	50,000.00	

American Academy of Dermatology 2009 Corporate Supporters					Attachment B
	Medicis Pharmaceutical Corporation	09 Soft Tissue Fillers Conference: Assessing the State of the Science	Collaborative effort with medical societies and expert panelists in soft tissue fillers to assess the state of the science with focus on patient efficacy.	25,000.00	
	Medicis Pharmaceutical Corporation	09 Soft Tissue Fillers Conference: Assessing the State of the Science	Collaborative effort with medical societies and expert panelists in soft tissue fillers to assess the state of the science with focus on patient efficacy.	25,000.00	
	Stiefel a GSK company	09 Soft Tissue Fillers Conference: Assessing the State of the Science	Collaborative effort with medical societies and expert panelists in soft tissue fillers to assess the state of the science with focus on patient efficacy.	10,000.00	
	Merz Pharmaceuticals, LLC	09 Soft-Tissue Fillers Conference: Assessing the State of the Science	Collaborative effort with medical societies and expert panelists in soft tissue fillers to assess the state of the science with focus on patient efficacy.	25,000.00	
	Merz Pharmaceuticals, LLC	2009 Directions in Residency Newsletter (fall and winter)	This newsletter is a resource for dermatology residents providing news, information and analysis to help them prepare for their careers.	25,000.00	
	MDLand International	2010 dEHRm CD	A comprehensive tool kit, that provides dermatologists and their office staff with practical guidance and handy tools to use when considering the adoption of an EHR system.	25,000.00	
	Amgen Pfizer	2010 Derm Coding Consult Newsletter	Quarterly medical coding and Medicare reimbursement newsletter.	45,000.00	
	Merz Pharmaceuticals, LLC	2010 Directions in Residency Newsletter	This newsletter is a resource for dermatology residents providing news, information and analysis to help them prepare for their careers.	45,000.00	
	Amgen Pfizer	2010 Print and Electronic Membership Directory	This is a reference tool and one of the most widely utilized Academy publications.	25,000.00	
Annual Meeting Supported Activities	La Roche-Posay Laboratoire Pharmaceutique	2010 Annual Meeting Residents Reception	Provides an informal environment that promotes networking opportunities and socializing for dermatology residents with colleagues and AAD leadership.	15,000.00	
	Merz Pharmaceuticals, LLC	2010 Annual Meeting Young Physician and New Member Reception	This event welcomes young and new dermatologist members to the Academy and provides an evening of food, fun and networking with colleagues and AAD leadership.	15,000.00	

American Academy of Dermatology 2009 Corporate Supporters						Attachment B
				Total @ Nov '09:		\$4,100,280.00
						\$417,198.00
				Combined Total @ Nov '09:		\$4,517,478.00

American Academy of Dermatology 2008 Corporate Supporters					Attachment B
American Academy of Dermatology (AAD) Funds					
Program	Company	Description		Amount	Amount through Elsevier Publishers
Medical Education (CME)	Amgen Wyeth	09 Dialogues in Dermatology	This audio subscription program, provides dermatologists with quality, cutting edge dermatologic information. This is the Academy's monthly audio journal providing current information on clinical subject matter in a practical and efficient format. This product offers up to 24 AMA PRA Category 1 Credits™ per year.	75,000.00	
	Astellas Pharma US, Inc.	09 Derm Clips	A bi-monthly subscription product that keeps resident dermatologists up to date by scanning recent dermatologic research, summarizing the research in a concise format, and providing expert commentary indicating what is relevant to the practicing dermatologist.	40,000.00	
Public Education	Abbott Laboratories	08 Stop Hiding Psoriasis Public Awareness Campaign	Public awareness program on psoriasis.	150,000.00	
	Allergan, Inc.	08-09 Aging SkinNet Web site	The Web sites are devoted to providing patient education for common dermatologic conditions. Patients and healthcare professionals use the Web sites as a resource for educational literature and health guideline descriptions.	50,000.00	
	Mary Kay Inc.	2008 Pamphlets (TBA)	Pamphlets address the symptoms, diagnosis, and treatment options for various dermatologic conditions. While specific products are not mentioned, the latest treatments and therapies are discussed.	35,000.00	
	Beiersdorf, Inc.	08 SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	25,000.00	
	Merz Pharmaceuticals, LLC	09 SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	10,000.00	

American Academy of Dermatology 2008 Corporate Supporters					Attachment B
	Procter & Gamble Company	08 Educational Grant (SKINnovations)	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	50,000.00	
	Stiefel Laboratories, Inc.	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	10,000.00	
Humanitarian	Abbott Laboratories	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	10,000.00	
	Astellas Pharma US, Inc.	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	50,000.00	
	Coria Laboratories, Ltd.	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	5,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	50,000.00	
	Intendis, Inc.	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	25,000.00	
	Merz Pharmaceuticals, LLC	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	25,000.00	

American Academy of Dermatology 2008 Corporate Supporters					Attachment B
Specialty Support	Amgen Wyeth	09 Dermatologic Calendar of Events	Calendar of dermatology/dermatology-related meetings organized chronologically and indexed by event host. The Calendar is sent to all Academy members and is distributed at the Annual and Summer Academy Meetings.	70,000.00	
	Astellas Pharma US, Inc.	08 Astellas Award	The Astellas Awards Program recognizes the achievements of three individuals and/or institutions that have made a significant contribution to scientific research that improved public health. Three awards of \$30,000 each are given to the winners and the remaining \$10,000 is to be used at the discretion of the Academy.	10,000.00	
	Graceway Pharmaceuticals, LLC	09 Dermatology World to Residents	An important source of socioeconomic and practice news available to dermatology residents.	75,000.00	
	Phillip Frost	Phillip Frost Grant	Funding of named lectureship recognizing innovative therapies of the skin.	45,000.00	
Industry Supported Symposia	Abbott Laboratories	08 Diamond Level Industry Supported Symposia	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Allergan, Inc.	08 Diamond Level Industry Supported Symposia	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	

American Academy of Dermatology 2008 Corporate Supporters					Attachment B
	Centocor, Inc.	08 Diamond Level Industry Supported Symposia	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	08 Diamond Level Industry Supported Symposia	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Galderma Laboratories, L.P.	08 Diamond Level Industry Supported Symposia	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	PharmaDerm, a division of Nycomed US, Inc.	09 Industry Supported Symposia	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	130,000.00	
Annual Meeting Supported Activities Largest dermatologic scientific meeting in the world providing quality education for dermatologists.	Abbott Laboratories	08 Annual Meeting News Post Edition	Mailed one month following the Annual Meeting. Its editorial mission is to highlight educational sessions, plenary speakers and award winners and presidential speeches. It serves as a recap of all educational and social activities.	5,000.00	

American Academy of Dermatology 2008 Corporate Supporters					Attachment B
	Amgen Wyeth	09 Annual Meeting Bus Shuttle Service	Meeting attendees utilize an extensive shuttle bus service which operates approximately 25 motor coaches for six days between 20+ Academy official meeting hotels and the convention center.	200,000.00	
	Astellas Pharma US, Inc.	09 Annual Meeting City Guide	Informative guide that features comprehensive information about the city, including attractions, restaurants, public transportation, airline information, shuttle bus schedule, etc.	45,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	09 Annual Meeting AAD News Network	There are four 30-minute programs to be shown a total of 192 times throughout the meeting. Up to six minutes of each program are available for supporter ads.	55,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	09 Annual Meeting Session Handouts on CD	Handouts for all education sessions are provided on CD to all professional meeting attendees.	75,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	09 Annual Meeting Lanyards	Necklace-type nylon cords that hold the attendee's name badge.	75,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	09 Annual Meeting Registration Bag	All medical personnel receive a bag to carry their meeting information.	90,000.00	
	Genentech, Inc.	09 Annual Meeting Lead Retrieval Cards	All medical personnel receive this card and use it throughout the exhibit hall. Provides exhibitors the ability to capture leads, qualify prospects and plan follow-up contact with physicians who visit their booth.	75,000.00	
	Genentech, Inc.	09 Annual Meeting Program-at-a-Glance Program Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	25,000.00	
	GlaxoSmithKline	08 Audience Response System	Computer automated response system is used to measure the learning ability of attendees.	15,000.00	
	Neutrogena Corporation	08 Annual Meeting Resident Housing Program	This program provides funding for four night's hotel accommodations (double occupancy) for first, second and third-year dermatology residents that participate in the program.	500,000.00	
	ProPath	09 Annual Meeting Take Five Express Spa	Meeting attendees use this lounge to relax and refresh while receiving seated upper body massages and foot massages.	25,000.00	

American Academy of Dermatology 2008 Corporate Supporters					Attachment B
	Stiefel Laboratories, Inc.	09 Annual Meeting Hotel Key Cards	Hotel Key Cards are distributed to registrants for entry into their hotel room upon check-in at the Annual Meeting headquarter hotel (s).	25,000.00	
	Stiefel Laboratories, Inc.	09 Annual Meeting e-Posters Exhibits Area	Fully-searchable, web based Electronic Poster Exhibits which are displayed on monitors for viewing by registrants of the meeting.	100,000.00	
	Stiefel Laboratories, Inc.	09 Annual Meeting Program-at-a-Glance Map and Floor Plan Divider	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	15,000.00	
	Upsher-Smith Laboratories, Inc.	09 Annual Meeting Press Office	Press Office hosts more than 100 representatives of worldwide consumer and trade media.	100,000.00	
Summer Academy Meeting Supported Activities Second largest Academy dermatologic scientific meeting during the year providing quality education for dermatologists.	Abbott Laboratories	08 Program-at-a-Glance Map and Floor Plan Divider	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	7,000.00	
	Amgen Wyeth	08 Summer Academy Meeting Hotel Key Cards	Hotel Key Cards are distributed to registrants for entry into their hotel room upon check-in at the Summer Academy Meeting headquarter hotel.	10,000.00	
	Amgen Wyeth	09 Summer Academy Meeting Cyber Center	An area in the meeting facility is setup with multiple computer terminals where registrants have the opportunity to retrieve and leave messages for other meeting attendees along with ability to access e-mail while attending the Summer Academy Meeting.	25,000.00	
	Amgen Wyeth	09 Summer Academy Meeting Hotel Cards	Hotel Key Cards are distributed to registrants for entry into their hotel room upon check-in at the Summer Academy Meeting headquarter hotel.	10,000.00	
	Astellas Pharma US, Inc.	08 Summer Academy Meeting AAD E-posters CD	Fully searchable CD-ROM of posters presented during the Summer Academy Meeting.	40,000.00	

American Academy of Dermatology 2008 Corporate Supporters					Attachment B
	Astellas Pharma US, Inc.	09 Summer Academy Meeting AAD e- Posters Exhibit Area	Fully-searchable, web based Electronic Poster Exhibits which are displayed on monitors for viewing by registrants of the meeting.	40,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	08 Summer Academy Meeting Program-at-a-Glance Program Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	8,000.00	
	Genentech, Inc.	08 Summer Academy Meeting News Preview Edition	Provides news and information about upcoming meeting, including interviews with speakers, session highlights, details of registration and information on the host city. Has a circulation of approximately 16,000.	45,000.00	
	Genentech, Inc.	08 Summer Academy Meeting WiFi Internet Lounges	Lounge type areas placed around the convention center to provide areas where meeting attendees may use their laptop computers to access the Internet remotely.	30,000.00	
	Genentech, Inc.	09 Summer Academy Meeting WiFi Internet Lounges	Lounge type areas placed around the convention center to provide areas where meeting attendees may use their laptop computers to access the Internet remotely.	30,000.00	
	Merz Pharmaceuticals, LLC	09 Summer Academy Meeting Pocket Guide	A condensed schedule of events and a quick reference tool that includes an overview of the educational program and technical exhibits.	10,000.00	
	Upsher-Smith Laboratories, Inc.	08 Summer Academy Meeting Lanyards	Necklace-type nylon cords that hold the attendee's name badge.	25,000.00	
	Upsher-Smith Laboratories, Inc.	09 Summer Academy Meeting Lanyards	Necklace-type nylon cords that hold the attendee's name badge.	25,000.00	
JAAD through Elsevier Publishers	Abbott Laboratories	2008 JAAD Poster Abstracts	Supplement with Poster Abstracts as presented at the 2008 Annual Meeting.		172,000.00
	Galderma Laboratories, L.P.	2008 JAAD Resident subscription program			134,715.00
	L'Oréal	2008 JAAD Supplement: Recent advances in photoprotection	Peer reviewed article on selected topic		66,000.00
	Sanofi Adventis	2008 JAAD Canadian resident subscription program			9,775.00
American Academy of Dermatology Association (AADA) Funds					

American Academy of Dermatology 2008 Corporate Supporters					Attachment B
Program	Company	Description		Amount	
Specialty Support	Amgen Wyeth	09 Electronic Membership Directory	This is a reference tool and one of the most widely utilized Academy publications.	25,000.00	
	Amgen Wyeth	09 Derm Coding Consult Newsletter	Quarterly medical coding and Medicare reimbursement newsletter.	45,000.00	
	Arcutis Pharmaceuticals, Inc.	08 Leadership Forum	An interactive conference that targets approximately fifty early career member dermatologists from a variety of practice settings with basic leadership concepts, models and tools. The objective is to educate and inspire these dermatologists to seek and take on leadership roles and responsibilities within various venues where they can impact the future of dermatology specifically and medicine in general.	25,000.00	
	Coria Laboratories, Ltd.	09 Derm Workforce Initiative	Provided support for resident training in academic settings. Administered by AAD committee.	25,000.00	
	Graceway Pharmaceuticals, LLC	08 Young Physician Focus Newsletter	Intended to provide information pertinent to young dermatologists' interests, foster leadership and facilitate the exchange of information between young physicians and the American Academy of Dermatology.	35,000.00	
	Graceway Pharmaceuticals, LLC	09 Young Physician Focus Newsletter	Intended to provide information pertinent to young dermatologists' interests, foster leadership and facilitate the exchange of information between young physicians and the American Academy of Dermatology.	45,000.00	
	Medicis Pharmaceutical Corporation	08 Leadership Forum	An interactive conference that targets approximately fifty early career member dermatologists from a variety of practice settings with basic leadership concepts, models and tools. The objective is to educate and inspire these dermatologists to seek and take on leadership roles and responsibilities within various venues where they can impact the future of dermatology specifically and medicine in general.	25,000.00	

American Academy of Dermatology 2008 Corporate Supporters					Attachment B
	Merz Pharmaceuticals, LLC	09 Leadership Forum	An interactive conference that targets approximately fifty early career member dermatologists from a variety of practice settings with basic leadership concepts, models and tools. The objective is to educate and inspire these dermatologists to seek and take on leadership roles and responsibilities within various venues where they can impact the future of dermatology specifically and medicine in general.	25,000.00	
Annual Meeting Supported Activities	Allergan, Inc.	09 Annual Meeting Resident Reception	Provides an informal environment that promotes networking opportunities and socializing for dermatology residents with colleagues and AAD leadership.	15,000.00	
	Amgen Wyeth	09 Sharing Mentoring Breakfast	Designed to help new and established dermatologists understand the benefits and limitations of a mentoring relationship and to develop skills to become effective mentors or mentees.	25,000.00	
	Genentech, Inc.	09 Annual Meeting New Member Reception	This event welcomes new dermatologist members to the Academy and provides an evening of food, fun and networking with colleagues and AAD leadership.	15,000.00	
	Graceway Pharmaceuticals, LLC	08 Young Physician Reception	This event welcomes young dermatologist members to the Academy and provides an evening of food, fun and networking with colleagues and AAD leadership.	15,000.00	
Summer Academy Meeting Supported Activities	Genentech, Inc.	09 Summer Academy Meeting Mentoring Reception	Provides an opportunity for up-and-coming leaders in dermatology who have attended past Leadership Forums to connect with established Academy leaders and mentors.	25,000.00	
		Total @ 12/31/08:		\$3,390,000.00	\$382,490.00
		Combined Total @ 12/31/08:		\$3,772,490.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
American Academy of Dermatology (AAD) Funds					
Program	Company	Description		Amount	Amount through Elsevier Publishers
Medical Education (CME)	Allergan, Inc.	2007 Dialogues in Dermatology	This audio subscription program, provides dermatologists with quality, cutting edge dermatologic information. This is the Academy's monthly audio journal providing current information on clinical subject matter in a practical and efficient format. This product offers up to 24 AMA PRA Category 1 Credits™ per year.	20,000.00	
	CollaGenex Pharmaceuticals, Inc.	07 Summer Academy Meeting Gold Level Symposium	Unrestricted educational grant.	50,000.00	
	PharmaDerm, a division of Nycomed US, Inc.	07 AAD Regional Practice Management Course	These courses are designed for dermatologists and provide a balanced overview of important practice management issues in dermatology and offer AMA PRA Category 1 CME Credits™.	100,000.00	
	PharmaDerm, a division of Nycomed US, Inc.	08 Dermatology Review Course	Two-day course designed for dermatologists and provides a balanced overview of important clinical developments in dermatology.	100,000.00	
	PharmaDerm, a division of Nycomed US, Inc.	08 Practice Management Course	These courses are designed for dermatologists and provide a balanced overview of important practice management issues in dermatology and offer AMA PRA Category 1 CME Credits™.	100,000.00	
	Stiefel Laboratories, Inc.	Dermatology Review Course	Two-day course designed for dermatologists and provides a balanced overview of important clinical developments in dermatology.	50,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Stiefel Laboratories, Inc.	Practical Approach to Patient Problems	Two-day regional CME course structured to allow four expert panels specializing in general dermatology, dermatologic surgery and pediatric dermatology, to answer questions and, in tandem with the audience, develop a series of therapeutic recommendations for dealing with a particular patient problem.	100,000.00	
Medical Education (non-CME)	Stiefel Laboratories, Inc.	08 Practice Management Symposium for Residents	Educational program offered to first, second and third year residents. It provides an opportunity to expand residents' knowledge about the "business side of dermatology" through a variety of topics.	200,000.00	
	Stiefel Laboratories, Inc.	Resident Practice Management	Educational program offered to first, second and third year residents. It provides an opportunity to expand residents' knowledge about the "business side of dermatology" through a variety of topics.	200,000.00	
	Allergan, Inc.	Educational Grant	Unrestricted educational grant.	5,000.00	
Journal of the American Academy of Dermatology (JAAD)	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	JAAD Physician Assistant Subscription code to 49020	An annual subscription provided to all members of the Society of Dermatologic Physician Assistants.	89,000.00	
Public Education	Amgen Wyeth	08 PsoriasisNet Web site	The Web sites are devoted to providing patient education for common dermatologic conditions. Patients and healthcare professionals use the Web sites as a resource for educational literature and health guideline descriptions.	70,000.00	
	Amgen Wyeth	Psoriasis Pamphlets 6/4/07-6/3/09	Pamphlets address the symptoms, diagnosis, and treatment options for various dermatologic conditions. While specific products are not mentioned, the latest treatments and therapies are discussed.	60,000.00	
	Graceway Pharmaceuticals, LLC	Actinic Keratoses Pamphlets 9/1/07-8/31/09	Pamphlets address the symptoms, diagnosis, and treatment options for various dermatologic conditions. While specific products are not mentioned, the latest treatments and therapies are discussed.	60,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Mary Kay Inc.	2007 Pamphlets	Pamphlets address the symptoms, diagnosis, and treatment options for various dermatologic conditions. While specific products are not mentioned, the latest treatments and therapies are discussed.	35,000.00	
	Procter & Gamble Company	07 Educational Grant	Unrestricted educational grant.	50,000.00	
	Beiersdorf, Inc.	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	25,000.00	
	Graceway Pharmaceuticals, LLC	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	25,000.00	
	Stiefel Laboratories, Inc.	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	25,000.00	
	Stiefel Laboratories, Inc.	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	25,000.00	
Humanitarian	Johnson & Johnson Consumer Products Company	Shade Structure Program 2008	The AAD Shade Structure Program awards \$8,000 to each recipient for the purchase of permanent shade structures that are designed to provide shade and ultraviolet (UV) ray protection for outdoor areas. This program is offered to non-profit organizations that serve children and teens and that are seeking permanent shade structures for outdoor locations that are not protected from the sun, such as playgrounds, pools, or recreation spaces.	250,000.00	
	Amgen Wyeth	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	50,000.00	
	Astellas Pharma US, Inc.	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	50,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Coria Laboratories, Ltd.	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	25,000.00	
	Coria Laboratories, Ltd.	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	25,000.00	
	Genentech, Inc.	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	20,000.00	
	Graceway Pharmaceuticals, LLC	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	10,000.00	
	Intendis, Inc.	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	25,000.00	
	Stiefel Laboratories, Inc.	Camp Discovery	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	25,000.00	
Specialty Support	Amgen Wyeth	07 Issues in Derm (President's Initiative)	Summits or meetings held to develop plans for future educational programs and/or strategic planning on a given topic.	25,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Amgen Wyeth	08 Dermatologic Calendar of Events	Calendar of dermatology/dermatology-related meetings organized chronologically and indexed by event host. The Calendar is sent to all Academy members and is distributed at the Annual and Summer Academy Meetings.	70,000.00	
	Amgen Wyeth	08 Mentoring Forum	Designed to help new and established dermatologists understand the benefits and limitations of a mentoring relationship and to develop skills to become effective mentors or mentees.	25,000.00	
	Astellas Pharma US, Inc.	Astellas Award	The Astellas Awards Program recognizes the achievements of three individuals and/or institutions that have made a significant contribution to scientific research that improved public health. Three awards of \$30,000 each are given to the winners and the remaining \$10,000 is to be used at the discretion of the Academy.	100,000.00	
	Graceway Pharmaceuticals, LLC	Derm World to Residents 11/1/07-10/31/08	An important source of socioeconomic and practice news available to dermatology residents.	75,000.00	
	PharmaDerm, a division of Nycomed US, Inc.	08 Directions in Residency Newsletter	This newsletter is a resource for dermatology residents providing news, information and analysis to help them prepare for their careers.	35,000.00	
	Stiefel Laboratories, Inc.	Autobiography "The Skin Around Me"	Funding provided for printing of publication.	30,700.00	
	Philip Frost	Philip Frost	Funding of named lectureship recognizing innovative therapies of the skin.	45,000.00	
Industry Supported Symposia	Abbott Laboratories	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Allergan, Inc.	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Amgen Wyeth	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Astellas Pharma US, Inc.	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Centocor, Inc.	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	73,200.00	
	Intendis GmbH	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Johnson & Johnson Consumer Products Company	08 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Obagi Medical Products	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Stiefel Laboratories, Inc.	08 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
Annual Meeting Supported Activities Largest dermatologic scientific meeting in the world providing quality education for dermatologists.	Abbott Laboratories	07 Annual Meeting News Post Edition	Mailed one month following the Annual Meeting. Its editorial mission is to highlight educational sessions, plenary speakers and award winners and presidential speeches. It serves as a recap of all educational and social activities.	45,000.00	
	Abbott Laboratories	08 Annual Meeting News Post Edition	Mailed one month following the Annual Meeting. Its editorial mission is to highlight educational sessions, plenary speakers and award winners and presidential speeches. It serves as a recap of all educational and social activities.	45,000.00	
	Amgen Wyeth	08 Annual Meeting E-News	Provides official live meeting coverage to all members, regardless of whether they attend the meeting. An e-mail is sent out on three consecutive days featuring highlights of main articles from the printed on-site newspaper.	45,000.00	
	Amgen Wyeth	08 Annual Meeting Shuttle Bus Service	Meeting attendees utilize an extensive shuttle bus service which operates approximately 25 motor coaches for six days between 20+ Academy official meeting hotels and the convention center.	183,000.00	
	Astellas Pharma US, Inc.	08 Annual Meeting City Guide	Informative guide that features comprehensive information about the city, including attractions, restaurants, public transportation, airline information, shuttle bus schedule, etc.	45,000.00	
	Cutera	07 Annual Meeting Scrolling Monitors	A series of monitors centrally located in the registration area of the meeting. These monitors are utilized to display the available ticketed sessions to registrants.	15,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	07 Annual Meeting Pocket Guide	A condensed schedule of events and a quick reference tool that includes an overview of the educational program and technical exhibits.	40,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	08 Annual Meeting Lanyards	Necklace-type nylon cords that hold the attendee's name badge.	75,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	08 Annual Meeting Pocket Guides	A condensed schedule of events and a quick reference tool that includes an overview of the educational program and technical exhibits.	40,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	08 Annual Meeting Scrolling Monitors	A series of monitors centrally located in the registration area of the meeting. These monitors are utilized to display the available ticketed sessions to registrants.	15,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	08 Annual Meeting Session Handouts on CD	Handouts for all education sessions are provided on CD to all professional meeting attendees.	75,000.00	
	Genentech, Inc.	08 Annual Meeting Lead Retrieval Cards	All medical personnel receive this card and use it throughout the exhibit hall. Provides exhibitors the ability to capture leads, qualify prospects and plan follow-up contact with physicians who visit their booth.	75,000.00	
	Genentech, Inc.	08 Annual Meeting Program-at-a-Glance Program Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	25,000.00	
	Genentech, Inc.	08 Annual Meeting Program-at-a-Glance Program Section (one additional page)	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	10,000.00	
	Intendis, Inc.	08 Annual Meeting Advance Registration Materials Folders	Pre-registered US and Canadian attendees have their name badge, tickets and expo card mailed to them in advance of the meeting and use the folder to carry their tickets and expo card throughout the week.	25,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Intendis, Inc.	08 Annual Meeting News Preview Edition	Provides news and information about upcoming meeting, including interviews with speakers, session highlights, details of registration and information on the host city. Has a circulation of approximately 16,000.	45,000.00	
	Intendis, Inc.	08 Annual Meeting Program-at-a-Glance Planner Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	45,000.00	
	Intendis, Inc.	08 Annual Meeting Registration Bags	All medical personnel receive a bag to carry their meeting information.	90,000.00	
	Merz Pharmaceuticals, LLC	08 Annual Meeting Wireless Internet (WiFi) Lounges	Lounge type areas placed around the convention center to provide areas where meeting attendees may use their laptop computers to access the Internet remotely.	50,000.00	
	Neutrogena Corporation	07 Annual Meeting Resident Housing	This program provides funding for five night's hotel accommodations (double occupancy) for first, second and third-year dermatology residents that participate in the program.	500,000.00	
	Ortho Neutrogena	08 Annual Meeting Air Travel Assistance Program	This program provides funding for air travel for first, second and third-year residents in dermatology who participate in the program.	300,000.00	
	PharmaDerm, a division of Nycomed US, Inc.	08 Annual Meeting Program-at-a-Glance Map and Floor Plan Divider	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	19,000.00	
	ProPath	08 Annual Meeting Take Five Express Spa	Meeting attendees use this lounge to relax and refresh while receiving seated upper body massages and foot massages.	20,000.00	
	sanofi-aventis	07 Annual Meeting Lanyards	Necklace-type nylon cords that hold the attendee's name badge.	75,000.00	
	Stiefel Laboratories, Inc.	08 Annual Meeting Hotel Key Cards	Hotel Key Cards are distributed to registrants for entry into their hotel room upon check-in at the Annual Meeting headquarter hotel (s).	25,000.00	
	Upsher-Smith Laboratories, Inc.	08 Annual Meeting Press Office	Press Office hosts more than 100 representatives of worldwide consumer and trade media.	10,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
Summer Academy Meeting Supported Activities Second largest Academy dermatologic scientific meeting during the year providing quality education for dermatologists.	Abbott Laboratories	07 Summer Academy Meeting News Post Edition (DIF)	Mailed approximately one month following the Summer Academy Meeting. It reports on the meeting's scientific program, presenting clinical and research news discussed during courses, focus sessions, forums and plenary session. Circulation is about 16,000.	45,000.00	
	Abbott Laboratories	07 Summer Academy Meeting News On-Site Edition	Provides news and information associated with the Summer Academy Meeting scientific program, including interviews with plenary session presenters and other key speakers. Circulation is to all meeting attendees (approximately 4,000).	35,000.00	
	Amgen Wyeth	07 Summer Academy Meeting Hotel Room Key	Hotel Key Cards are distributed to registrants for entry into their hotel room upon check-in at the Summer Academy Meeting headquarter hotel.	10,000.00	
	Astellas Pharma US, Inc.	07 AC Posters2View	Fully searchable CD-ROM of Posters presented during the Summer Academy Meeting.	40,000.00	
	Astellas Pharma US, Inc.	07 Summer Academy Meeting Program-Glance	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	6,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	07 Summer Academy Meeting Program-at-a-Glance	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	8,000.00	
	Intendis, Inc.	07 Summer Academy Meeting Lead Retrieval Cards	All medical personnel receive this card and use it throughout the exhibit hall. Provides exhibitors the ability to capture leads, qualify prospects and plan follow-up contact with physicians who visit their booth.	10,000.00	

American Academy of Dermatology 2007 Corporate Supporters					Attachment B
	Intendis, Inc.	07 Summer Academy Meeting Program-Glance Planner Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	12,000.00	
	Intendis, Inc.	07 Summer Academy Meeting Registration Bags	All medical personnel receive a bag to carry their meeting information.	25,000.00	
	Intendis, Inc.	08 Summer Academy Meeting Lead Retrieval Cards	All medical personnel receive this card and use it throughout the exhibit hall. Provides exhibitors the ability to capture leads, qualify prospects and plan follow-up contact with physicians who visit their booth.	10,000.00	
	Intendis, Inc.	08 Summer Academy Meeting Program-at-a-Glance Planner Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	12,000.00	
	Intendis, Inc.	08 Summer Academy Meeting Registration Bags	All medical personnel receive a bag to carry their meeting information.	25,000.00	
	SkinMedica, Inc.	07 Summer Academy Meeting Pocket Guides	A condensed schedule of events and a quick reference tool that includes an overview of the educational program and technical exhibits.	10,000.00	
JAAD through Elsevier Publishers	Abbott Laboratories	2007 JAAD Poster Abstracts	Supplement with Poster Abstracts as presented at the 2007 Annual Meeting.		164,000.00
	Abbott Laboratories	2007 JAAD Abbott Field force subscriptions	Field force subscriptions		30,800.00
	Carruthers	2007 JAAD Canadian resident subscription program			6,580.00
	Galderma Laboratories, L.P.	2007 JAAD Resident subscription program			140,061.00
	Merck & Co., Inc.	2007 JAAD Supplement: Alleviating the burden of herpes zoster through vaccination	Peer reviewed article on selected topic		84,099.00
American Academy of Dermatology Association (AADA) Funds					
Program	Company	Description		Amount	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
American Academy of Dermatology (AAD) Funds					
Program	Company	Description		Amount	Amount through Elsevier Publishers
Medical Education (CME)	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	2006 Abstract and Commentary Publications	This is a bi-monthly subscription that keeps dermatologists up to date by scanning recent research in the area of dermatology, summarizing the research and providing expert commentary indicating what is relevant. This product offers AMA PRA Category 1 CME Credit™.	40,000.00	
	Amgen Wyeth	2006 Dialogues in Dermatology	This audio subscription program, provides dermatologists with quality, cutting edge dermatologic information. This is the Academy's monthly audio journal providing current information on clinical subject matter in a practical and efficient format. This product offers up to 24 AMA PRA Category 1 Credits™ per year.	75,000.00	
	Allergan, Inc.	2006 Maintenance of Certification Manual for Dermatology MOCmd	This program serves as the Academy's self-assessment activity. Over 400 questions on general dermatology, dermatopathology, pediatric dermatology and dermatologic surgery make this a valuable tool for dermatologists who want to review and enhance their knowledge. This product offers up to 50 AMA PRA Category 1 CME Credits™.	90,000.00	
	PharmaDerm, a division of Nycomed US, Inc.	2006 Practice Management Courses in Boston and Tucson	These courses are designed for dermatologists and provide a balanced overview of important practice management issues in dermatology and offer AMA PRA Category 1 CME Credits™.	150,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Amgen Wyeth	2007 Dialogues in Dermatology	This audio subscription program, provides dermatologists with quality, cutting edge dermatologic information. This is the Academy's monthly audio journal providing current information on clinical subject matter in a practical and efficient format. This product offers up to 24 AMA PRA Category 1 Credits™ per year.	75,000.00	
Medical Education (non-CME)	Doak Dermatologics	2007 Educational Grant	Unrestricted educational grant.	25,000.00	
Journal of the American Academy of Dermatology (JAAD)	Stiefel Laboratories, Inc.	2006 JAAD Case Report Supplements (First Quarter)	Case Reports are published quarterly and include 40 pages of clinical cases in each supplement.	50,000.00	
	Stiefel Laboratories, Inc.	2006 JAAD Case Report Supplements (Fourth Quarter)	Case Reports are published quarterly and include 40 pages of clinical cases in each supplement.	50,000.00	
	Stiefel Laboratories, Inc.	2006 JAAD Case Report Supplements (Second Quarter)	Case Reports are published quarterly and include 40 pages of clinical cases in each supplement.	50,000.00	
	Stiefel Laboratories, Inc.	2006 JAAD Case Report Supplements (Third Quarter)	Case Reports are published quarterly and include 40 pages of clinical cases in each supplement.	50,000.00	
Public Education	3M Pharmaceuticals	2006 ActinicKeratosisNet Website	The Web sites are devoted to providing patient education for common dermatologic conditions. Patients and healthcare professionals use the Web sites as a resource for educational literature and health guideline descriptions.	80,000.00	
	Amgen Wyeth	2007 PsoriasisNet Website	The Web sites are devoted to providing patient education for common dermatologic conditions. Patients and healthcare professionals use the Web sites as a resource for educational literature and health guideline descriptions.	70,000.00	
	Intendis, Inc.	Rosacea Pamphlet (two years 11/1/06 to 10/31/08)	Pamphlets address the symptoms, diagnosis, and treatment options for various dermatologic conditions. While specific products are not mentioned, the latest treatments and therapies are discussed.	75,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Amgen Wyeth	Educational Grant for General Support	General support of public awareness programs.	175,000.00	
	3M Pharmaceuticals	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	25,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	26,000.00	
	Galderma Laboratories, L.P.	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	20,000.00	
	Novartis Pharmaceuticals Corp.	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	35,000.00	
	Ortho Neutrogena	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	15,000.00	
	Procter & Gamble Company	SKINnovations	A program to educate the public about a variety of skin conditions and why and when they should see a dermatologist,	50,000.00	
Humanitarian	Johnson & Johnson Consumer Products Company	2006 Shade Structure Grant Program	The AAD Shade Structure Program awards \$8,000 to each recipient for the purchase of permanent shade structures that are designed to provide shade and ultraviolet (UV) ray protection for outdoor areas. This program is offered to non-profit organizations that serve children and teens and that are seeking permanent shade structures for outdoor locations that are not protected from the sun, such as playgrounds, pools, or recreation spaces.	250,000.00	
	Johnson & Johnson Consumer Products Company	2006 Shade Structure Grant Program	The AAD Shade Structure Program awards \$8,000 to each recipient for the purchase of permanent shade structures that are designed to provide shade and ultraviolet (UV) ray protection for outdoor areas. This program is offered to non-profit organizations that serve children and teens and that are seeking permanent shade structures for outdoor locations that are not protected from the sun, such as playgrounds, pools, or recreation spaces.	8,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Johnson & Johnson Consumer Products Company	2007 AAD Shade Structure Program	The AAD Shade Structure Program awards \$8,000 to each recipient for the purchase of permanent shade structures that are designed to provide shade and ultraviolet (UV) ray protection for outdoor areas. This program is offered to non-profit organizations that serve children and teens and that are seeking permanent shade structures for outdoor locations that are not protected from the sun, such as playgrounds, pools, or recreation spaces.	250,000.00	
	Allergan, Inc.	Camp Discovery Endowment	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	10,000.00	
	Amgen Wyeth	Camp Discovery Endowment	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	34,000.00	
	Astellas Pharma US, Inc.	Camp Discovery Endowment	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	50,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	Camp Discovery Endowment	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	50,000.00	
	Genentech, Inc.	Camp Discovery Endowment	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	20,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Intendis, Inc.	Camp Discovery Endowment	Camp Discovery provides children with chronic skin diseases an opportunity to experience a full-range of summer camp activities they would not be able to experience due to physical or financial limitations. There is no fee to attend Camp Discovery.	25,000.00	
Specialty Support	Intendis, Inc.	2006 Issues in Dermatology (President's Initiative)	Summits or meetings held to develop plans for future educational programs and/or strategic planning on a given topic.	25,000.00	
	Astellas Pharma US, Inc.	2006 Astellas Award	The Astellas Awards Program recognizes the achievements of three individuals and/or institutions that have made a significant contribution to scientific research that improved public health. Three awards of \$30,000 each are given to the winners and the remaining \$10,000 is to be used at the discretion of the Academy.	100,000.00	
	Genentech, Inc.	2006 Continuity Summit (December 2006)	Summits or meetings held to develop plans for future educational programs and/or strategic planning on a given topic.	25,000.00	
	3M Pharmaceuticals	2006 Gold Triangle Awards Benefactor Table	Purchase a table at the Gold Triangle Awards.	5,000.00	
	Galderma Laboratories, L.P.	2006 Gold Triangle Awards Benefactor Table	Purchase a table at the Gold Triangle Awards.	5,000.00	
	Galderma Laboratories, L.P.	2006 Gold Triangle Awards Benefactor Table	Purchase a table at the Gold Triangle Awards.	5,000.00	
	Intendis, Inc.	2006 Gold Triangle Awards Benefactor Table	Purchase a table at the Gold Triangle Awards.	5,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	2006 Gold Triangle Awards Patron Table (2)	Purchase a table at the Gold Triangle Awards.	20,000.00	
	Barrier Therapeutics, Inc.	2006 Gold Triangle Awards Seating	Purchase seating at the Gold Triangle Awards.	900.00	
	Niadyne, Inc./ NIA24	2006 Gold Triangle Awards Seating	Purchase seating at the Gold Triangle Awards.	600.00	
	Supergoop! Corporate	2006 Gold Triangle Awards Seating	Purchase seating at the Gold Triangle Awards.	1,500.00	
	HMP Communications	2006 Gold Triangle Awards Seating (eight seats)	Purchase seating at the Gold Triangle Awards.	2,400.00	
	Del-Ray Dermatologicals, a Division of Crown Laboratories	2006 Gold Triangle Awards Seating (two seats)	Purchase seating at the Gold Triangle Awards.	600.00	
	Genentech, Inc.	2006 Gold Triangle Awards Sponsor Table	Purchase a table at the Gold Triangle Awards.	5,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Intendis, Inc.	2006 Gold Triangle Awards Travel Stipend	Provide a travel stipend for the Gold Triangle Awards.	15,000.00	
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC	2006 Issues in Dermatology	Summits or meetings held to develop plans for future educational programs and/or strategic planning on a given topic.	25,000.00	
	Amgen Wyeth	2006 Issues in Dermatology (Continuity Summit December 2006)	Summits or meetings held to develop plans for future educational programs and/or strategic planning on a given topic.	25,000.00	
	Ortho Neutrogena	2006 Issues in Dermatology (Continuity Summit)	Summits or meetings held to develop plans for future educational programs and/or strategic planning on a given topic.	25,000.00	
	Galderma Laboratories, L.P.	2006 Issues in Dermatology (President's Initiative)	Summits or meetings held to develop plans for future educational programs and/or strategic planning on a given topic.	25,000.00	
	Novartis Pharmaceuticals Corp.	2006 Issues in Dermatology (President's Initiative)	Summits or meetings held to develop plans for future educational programs and/or strategic planning on a given topic.	25,000.00	
	Genentech, Inc.	2006 Synergy Summit (February 2006)	Summits or meetings held to develop plans for future educational programs and/or strategic planning on a given topic.	25,000.00	
	Amgen Wyeth	2007 Dermatologic Calendar of Events	Calendar of dermatology/dermatology-related meetings organized chronologically and indexed by event host. The Calendar is sent to all Academy members and is distributed at the Annual and Summer Academy Meetings.	61,000.00	
Industry Supported Symposia	Genentech, Inc.	06 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Johnson & Johnson Consumer Products Company	06 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	La Roche-Posay Laboratoire Pharmaceutique	06 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Genentech, Inc.	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
	Johnson & Johnson Consumer Products Company	07 Diamond Level Industry Supported Symposium	The Academy offers organizations the right to hold an Industry Supported Symposia at its Summer Academy Meeting. Industry Supported Symposia are independently organized and not an official part of Summer Academy Meeting. All Industry Supported Symposia are required to secure AMA PRA Category 1 Credit™ through an ACCME accredited provider.	75,000.00	
Annual Meeting Supported Activities Largest dermatologic scientific meeting in the world providing quality education for dermatologists.	Genentech, Inc.	06 Annual Meeting City Guide	Informative guide that features comprehensive information about the city, including attractions, restaurants, public transportation, airline information, shuttle bus schedule, etc.	45,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Genentech, Inc.	06 Annual Meeting Lead Retrieval Cards	All medical personnel receive this card and use it throughout the exhibit hall. Provides exhibitors the ability to capture leads, qualify prospects and plan follow-up contact with physicians who visit their booth.	75,000.00	
	Intendis, Inc.	06 Annual Meeting News Preview Edition	Provides news and information about upcoming meeting, including interviews with speakers, session highlights, details of registration and information on the host city. Has a circulation of approximately 16,000.	45,000.00	
	Upsher-Smith Laboratories, Inc.	06 Annual Meeting Press Office	Press Office hosts more than 100 representatives of worldwide consumer and trade media.	10,000.00	
	Genentech, Inc.	06 Annual Meeting Program-at-a-Glance Program Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	25,000.00	
	Merz Pharmaceuticals, LLC	06 Annual Meeting Wireless (WiFi) Lounges	Lounge type areas placed around the convention center to provide areas where meeting attendees may use their laptop computers to access the Internet remotely.	50,000.00	
	Intendis, Inc.	07 Annual Meeting Registration Bags	All medical personnel receive a bag to carry their meeting information.	90,000.00	
	Abbott Laboratories	07 Annual Meeting AAD News Network	There are four 30-minute programs to be shown a total of 192 times throughout the meeting. Up to six minutes of each program are available for supporter ads.	55,000.00	
	Intendis, Inc.	07 Annual Meeting Advance Registration Materials Folders	Pre-registered US and Canadian attendees have their name badge, tickets and expo card mailed to them in advance of the meeting and use the folder to carry their tickets and expo card throughout the week.	25,000.00	
	Genentech, Inc.	07 Annual Meeting Lead Retrieval Cards	All medical personnel receive this card and use it throughout the exhibit hall. Provides exhibitors the ability to capture leads, qualify prospects and plan follow-up contact with physicians who visit their booth.	75,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Intendis, Inc.	07 Annual Meeting News Preview Edition	Provides news and information about upcoming meeting, including interviews with speakers, session highlights, details of registration and information on the host city. Has a circulation of approximately 16,000.	45,000.00	
	Upsher-Smith Laboratories, Inc.	07 Annual Meeting Press Office	Press Office hosts more than 100 representatives of worldwide consumer and trade media.	10,000.00	
	PharmaDerm, a division of Nycomed US, Inc.	07 Annual Meeting Program-at-a-Glance Map and Floor Plan	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	19,000.00	
	Genentech, Inc.	07 Annual Meeting Program-at-a-Glance Program Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	25,000.00	
	Ortho Neutrogena	07 Annual Meeting Resident Air Travel Assistance Program	This program provides funding for air travel for first, second and third-year residents in dermatology who participate in the program.	300,000.00	
	Amgen Wyeth	07 Annual Meeting Shuttle Bus Service	Meeting attendees utilize an extensive shuttle bus service which operates approximately 25 motor coaches for six days between 20+ Academy official meeting hotels and the convention center.	175,000.00	
	ProPath	07 Annual Meeting Take Five...Express Spa	Meeting attendees use this lounge to relax and refresh while receiving seated upper body massages and foot massages.	15,000.00	
	Merz Pharmaceuticals, LLC	07 Annual Meeting Wireless Internet (WiFi) Lounges	Lounge type areas placed around the convention center to provide areas where meeting attendees may use their laptop computers to access the Internet remotely.	50,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Intendis, Inc.	2007 Annual Meeting Program-at-a-Glance Personal Planner Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	45,000.00	
Summer Academy Meeting Supported Activities Second largest Academy dermatologic scientific meeting during the year providing quality education for dermatologists.	Galderma Laboratories, L.P.	06 Summer Academy Meeting Advance Registration Materials Folders	Pre-registered US and Canadian attendees have their name badge, tickets and expo card mailed to them in advance of the meeting and use the folder to carry their tickets and expo card throughout the week.	10,000.00	
	Amgen Wyeth	06 Summer Academy Meeting Afternoon Break	Breaks are offered in the exhibit hall. Snacks and beverages are included.	15,000.00	
	Genentech, Inc.	06 Summer Academy Meeting City Guide	Informative guide that features comprehensive information about the city, including attractions, restaurants, public transportation, airline information, shuttle bus schedule, etc.	20,000.00	
	Upsher-Smith Laboratories, Inc.	06 Summer Academy Meeting Lanyards	Necklace-type nylon cords that hold the attendee's name badge.	25,000.00	
	Intendis, Inc.	06 Summer Academy Meeting Lead Retrieval Card	All medical personnel receive this card and use it throughout the exhibit hall. Provides exhibitors the ability to capture leads, qualify prospects and plan follow-up contact with physicians who visit their booth.	10,000.00	
	Centocor, Inc.	06 Summer Academy Meeting News Preview Edition	Provides news and information about upcoming meeting, including interviews with speakers, session highlights, details of registration and information on the host city. Has a circulation of approximately 16,000.	45,000.00	
	Abbott Laboratories	06 Summer Academy Meeting News On-Site Edition	Provides news and information associated with the Summer Academy Meeting scientific program, including interviews with plenary session presenters and other key speakers. Circulation is to all meeting attendees (approximately 4,000).	35,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Abbott Laboratories	06 Summer Academy Meeting News Post Edition	Mailed approximately one month following the Summer Academy Meeting. It reports on the meeting's scientific program, presenting clinical and research news discussed during courses, focus sessions, forums and plenary session. Circulation is about 16,000.	45,000.00	
	Triax Pharmaceuticals, L.L.C.	06 Summer Academy Meeting Portfolio and Pen	All medical personnel receive the portfolio with a pad of paper and pen to be used for note taking and any other written communication at the meeting.	30,000.00	
	Amgen Wyeth	06 Summer Academy Meeting Program-at-a-Glance Map and Floor Plan Divider	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	6,000.00	
	Intendis, Inc.	06 Summer Academy Meeting Program-at-a-Glance Personal Planner Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	12,000.00	
	Centocor, Inc.	06 Summer Academy Meeting Program-at-a-Glance Program Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	8,000.00	
	Centocor, Inc.	06 Summer Academy Meeting Program-at-a-Glance Program Section	All registrants receive the final program and daily planner/notebook. The booklet contains general meeting information, scientific program, list of exhibitors/booth numbers and exhibit hall floor plan. The center divider pages contain room locator maps and are followed by pages for note taking.	10,000.00	
	Johnson & Johnson Consumer Products Company	06 Summer Academy Meeting Session Handouts on CD	Handouts for all education sessions are provided on CD to all professional meeting attendees.	30,000.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Amgen Wyeth	07 Summer Academy Meeting Cyber Center	An area in the meeting facility is setup with multiple computer terminals where registrants have the opportunity to retrieve and leave messages for other meeting attendees along with ability to access e-mail while attending the Summer Academy Meeting.	25,000.00	
	Upsher-Smith Laboratories, Inc.	07 Summer Academy Meeting Lanyards	Necklace-type nylon cords that hold the attendee's name badge.	25,000.00	
JAAD through Elsevier Publishers	Abbott Laboratories	2006 JAAD Poster Abstracts	Supplement with Poster Abstracts as presented at the 2006 Annual Meeting.		159,000
	Abbott Laboratories	2006 JAAD Abbott field force subscription	Field force subscriptions		30,800
	Amgen Inc. and Wyeth Research	2006 JAAD Supplement: The evolution of dermatologic therapeutics: Current uses of etanercept in psoriasis and other dermatoses	Peer reviewed article on selected topic		138,750.00
	Carruthers	2006 JAAD	Canadian resident subscription program		6,519.00
	Galderma Laboratories, L.P.	2006 JAAD Supplement: Management of pigmentary disorders: a report from the Pigmentary Disorders Academy	Peer reviewed article on selected topic		81,000.00
	Galderma Laboratories, L.P.	2006 JAAD	Resident subscription program		130,173.00
	Genetech, Inc. and Serono International SA	2006 JAAD Supplement: Practical guidelines for the long-term treatment of psoriasis with efalizumab	Peer reviewed article on selected topic		94,308.00
	Novartis Pharmaceuticals	2006 JAAD bound volume CD rom sponsorship			95,000.00
American Academy of Dermatology Association (AADA) Funds					
Program	Company	Description		Amount	
Specialty Support	Amgen Wyeth	2006 Derm Coding Consult Newsletter	Quarterly medical coding and Medicare reimbursement newsletter.	45,000.00	
	Amgen Wyeth	2006 Medical Director's Summit and Webinar on Psoriasis	Academy convened a summit on psoriasis aimed at education medical directors and pharmaceutical directors from insurance carriers on the practice and key role that dermatology plays in treating patients with psoriatic conditions as well as current and emerging psoriasis treatment therapies performed by dermatologists.	34,500.00	

American Academy of Dermatology 2006 Corporate Supporters					Attachment B
	Johnson & Johnson Consumer Products Company	2006 Medical Director's Summit and Webinar on Psoriasis	Academy convened a summit on psoriasis aimed at education medical directors and pharmaceutical directors from insurance carriers on the practice and key role that dermatology plays in treating patients with psoriatic conditions as well as current and emerging psoriasis treatment therapies performed by dermatologists.	34,500.00	
	Abbott Laboratories	2007 AAD Print and Electronic Membership Directory	This is a reference tool and one of the most widely utilized Academy publications.	25,000.00	
	Amgen Wyeth	2007 AAD Print and Electronic Membership Directory	This is a reference tool and one of the most widely utilized Academy publications.	25,000.00	
	Coria Laboratories, Ltd.	Dermatology Workforce Initiative	Provided support for resident training in academic settings. Administered by AAD committee.	25,000.00	
	3M Foundation	Restricted Grant in support of Dermatology Workforce Initiative	Provided support for resident training in academic settings. Administered by AAD committee.	67,000.00	
Annual Meeting Supported Activities	Amgen Wyeth	2006 Young Physician Forum	Designed to help new dermatologists understand the benefits and limitations of a mentoring relationship and to develop skills to become effective mentors or mentees.	25,000.00	
		Total @ 12/31/06:		\$4,536,000.00	\$735,550.00
		Combined Total @ 12/31/06:		\$5,271,550.00	

American Academy of Dermatology	
2006 In-Kind Support	
	Attachment C
Following is a listing of companies that donated products in 2006 in support of Academy programs.	
Program	Item/Description
2006 Annual Meeting Live Patient Demonstration	1 Scientific Session - Multiple products are used at each scientific session to demonstrate a variety of treatment modalities on patients.
	BioForm Medical, Inc.
	INAMED Aesthetics
	Medicis Pharmaceutical Corporation
	Reliant Technologies, Inc.
2006 Summer Academy Meeting Live Patient Demonstration	1 Scientific Session - Multiple products are used at each scientific session to demonstrate a variety of treatment modalities on patients.
	Allergan, Inc.
	BioForm Medical, Inc.
	Cynosure, Inc.
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC
	Laserscope
	Medicis Pharmaceutical Corporation
	WaveLight Inc.
2006 Play Sun Smart™	Program to educate Major League Baseball players, coaches, staff and others about the dangers of exposure to the sun and provide free skin cancer screenings. Samples of sun-protective products are distributed to screening participants.
	Beiersdorf, Inc.
	Del-Ray Dermatologicals, a Division of Crown Laboratories
	Kinesys Sport
	Ortho Dermatologicals
	Upsher-Smith Laboratories, Inc.
	UVShield Window Film
2006 Make Sun Safety Your Goal®	Program to educate soccer players and others about the dangers of exposure to the sun and provide free skin cancer screenings. Samples of sun-protective products are distributed to skin cancer screening participants.
	Del-Ray Dermatologicals, a Division of Crown Laboratories
	Kinesys Sport
	Ortho Dermatologicals
	Upsher-Smith Laboratories, Inc.
	UVShield Window Film
2006 Gold Triangle Awards	Program to recognize the efforts of companies and organizations to increase public awareness of dermatologic conditions and promote healthy care of the skin, hair, and nails. Product samples provided to attendees.
	Au Courant Cosmetics
	Beiersdorf, Inc.
	Blistex, Inc.
	Del-Ray Dermatologicals, a Division of Crown Laboratories
	DERMAdoctor, Inc.
	Galderma Laboratories, L.P.
	LaJolla Spa MD
	Niadyne, Inc./ NIA24
	Ortho Dermatologicals
	Skin Effects
	Upsher-Smith Laboratories, Inc.
	UVShield Window Film
	Xenna Corporation
	Yu-Be Moisturizing Skin Cream

American Academy of Dermatology	
2007 In-Kind Support	
	Attachment C
Following is a listing of companies that donated products in 2007 in support of Academy programs.	
Program	Item/Description
2007 Annual Meeting Live Patient Demonstration	2 Scientific Sessions - Multiple products are used at each scientific session to demonstrate a variety of treatment modalities on patients.
	Allergan, Inc.
	BioForm Medical, Inc.
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC
	Henry Schein, Inc.
	Medicis Pharmaceutical Corporation
	MidMark Corporation
2007 Summer Academy Meeting Live Patient Demonstration	3 Scientific Sessions - Multiple products are used at each scientific session to demonstrate a variety of treatment modalities on patients.
	Allergan, Inc.
	Artes Medical, Inc.
	BioForm Medical, Inc.
	Cynosure, Inc.
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC
	Medical Technology Industries, Inc.
	Medicis Pharmaceutical Corporation
	Palomar Medical Technologies, Inc.
	Reliant Technologies, Inc.
2007 Teen Summit	Convening a focus group of teens to help the Academy develop effective messaging for teens regarding sun safety, skin cancer prevention and other programs. Samples of sun protective products were distributed to focus group participants.
	Bobbi Brown Cosmetics, Inc.
	Clinique Laboratories, Inc.
	Del-Ray Dermatologicals, a Division of Crown Laboratories
	Edelman
	Estee Lauder Companies, Inc.
	Johnson & Johnson Consumer Products Company
	Procter & Gamble Company
	RPR Marketing Communications
	San Diego Hat Company
	Seventeen Magazine
	Sunless Beauty Ltd
	Tractenberg & Company
	U.S. Environmental Protection Agency
2007 Play Sun Smart™	Program to educate Major League Baseball players, coaches, staff and others about the dangers of exposure to the sun and provide free skin cancer screenings. Samples of sun-protective products are distributed to screening participants.
	Beiersdorf, Inc.
	Blistex, Inc.
	Del-Ray Dermatologicals, a Division of Crown Laboratories
	Iredale Mineral Cosmetics, LTD
	Johnson & Johnson Consumer Products Company
	N. V. Perricone, MD, Ltd
	Niadyne, Inc./ NIA24
	Philosophy
	Procter & Gamble Company
	San Diego Hat Company
	Stiefel a GSK company
	UVShield Window Film
	Warner Chilcott
	Yu-Be Moisturizing Skin Cream

American Academy of Dermatology	
2008 In-Kind Support	
	Attachment C
Following is a listing of companies that donated products in 2008 in support of Academy programs.	
Program	Item/Description
2008 Annual Meeting Live Patient Demonstration	2 Scientific Sessions - Multiple products are used at each scientific session to demonstrate a variety of treatment modalities on patients.
	Allergan, Inc.
	Artes Medical, Inc.
	BioForm Medical, Inc.
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC
	Medicis Pharmaceutical Corporation
	MidMark Corporation
2008 Summer Academy Meeting Live Patient Demonstration	1 Scientific Session - Multiple products are used at each scientific session to demonstrate a variety of treatment modalities on patients.
	Allergan, Inc.
	Biopelle, Inc.
	Medical Technology Industries, Inc.
	Medicis Pharmaceutical Corporation
	Allergan, Inc.
	Artes Medical, Inc.
	BioForm Medical, Inc.
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC
	Galderma Laboratories, L.P.
	Medical Technology Industries, Inc.
	Medicis Pharmaceutical Corporation
	Mentor Corporation
	Ortho Dermatologics
2008 AAD Camp Discovery	Summer camp for children with chronic skin conditions. Products used in the treatment of skin conditions for campers.
	Denison Pharmaceuticals, Inc.
2008 St. Lucia	Program to train physicians, nurses and residents in a St. Lucia hospital on various dermatological topics. Product will improve quality of care.
	Delasco Dermatologic Lab & Supply, Inc.
2008 Play Sun Smart™	Program to educate Major League Baseball players, coaches, staff and others about the dangers of exposure to the sun and provide free skin cancer screenings. Samples of sun-protective products are distributed to screening participants.
	Blistex, Inc.
	Delasco Dermatologic Lab & Supply, Inc.
	Del-Ray Dermatologicals, a Division of Crown Laboratories
	Murad, Inc.
	Niadyne, Inc./ NIA24
	Upsher-Smith Laboratories, Inc.
	UVShield Window Film

American Academy of Dermatology	
2009 In-Kind Support	
	Attachment C
Following is a listing of companies that donated products in 2009 in support of Academy programs.	
Program	Item/Description
2009 Annual Meeting Live Patient Demonstration	2 Scientific Sessions - Multiple products are used at each scientific session to demonstrate a variety of treatment modalities on patients.
	Allergan, Inc.
	BioForm Medical, Inc.
	Biopelle, Inc.
	Central Avenue Pharmacy
	Custom Scripts Pharmacy
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC
	Medicis Pharmaceutical Corporation
	Medline Industries, Inc.
	Mentor Corporation
	MidMark Corporation
	Ortho Dermatologics
	SmartPractice Canada
2009 Summer Academy Meeting Live Patient Demonstration	1 Scientific Session - Multiple products are used at each scientific session to demonstrate a variety of treatment modalities on patients.
	Allergan, Inc.
	BioForm Medical, Inc.
	Central Avenue Pharmacy
	Custom Scripts Pharmacy
	Dermik Laboratories, a business of sanofi-aventis U.S. LLC
	Medicis Pharmaceutical Corporation
	Mentor Corporation
	MidMark Corporation
	Ortho Dermatologics
2009 Annual Meeting Patch Test Demonstration	1 Scientific Session - Multiple products used to demonstrate allergy testing on patients.
	Dormer Laboratories, Inc.
2009 Kentucky State Fair Skin Cancer Screening	Free skin cancer screenings offered at the Kentucky State Fair. Samples of sun-protective products were distributed to screening participants.
	Johnson & Johnson Consumer Products Company
	Niadyne, Inc./ NIA24
2009 AAD Camp Discovery	Summer camp for children with chronic skin conditions. Products donated to campers.
	Intendis, Inc.
	National Rehab Equipment, Inc.
	Sun Protection Zone
2009 Play Sun Smart™	Program to educate Major League Baseball players, coaches, staff and others about the dangers of exposure to the sun and provide free skin cancer screenings. Samples of sun-protective products are distributed to screening participants.
	Beiersdorf, Inc.
	Blistex, Inc.
	Del-Ray Dermatologicals, a Division of Crown Laboratories
	Johnson & Johnson Consumer Products Company
	Niadyne, Inc./ NIA24
	Upsher-Smith Laboratories, Inc.

American Academy of Dermatology Gross Exhibit Revenue, 2006-2009

	<u>Annual</u>	<u>Summer</u>	<u>Total</u>
2006	\$3,757,580	\$369,200	\$4,126,780
2007	\$4,112,900	\$428,687	\$4,541,587
2008	\$4,836,475	\$417,875	\$5,254,350
2009	\$4,979,913	\$382,575	\$5,362,488

American Academy of Dermatology Gross Advertising Revenue, 2006-2009**Gross Advertising Revenue**

Dermatology World
Annual Meeting Program Book
Annual Meeting News and Doctor Bag
Annual Meeting Televator
Summer Academy Meeting Program Book
Summer Academy Meeting Doctor Bag
Summer Academy Meeting Televator
JAAD Advertising

<u>2006</u>	<u>2007</u>	<u>2008</u>	<u>2009</u>
\$285,183	\$334,987	\$395,624	\$412,439
\$263,050	\$230,590	\$277,639	\$229,578
\$461,127	\$458,591	\$453,555	\$551,800
n/a	n/a	n/a	\$42,000
\$135,765	\$154,797	\$136,060	\$127,265
\$55,920	\$64,400	\$67,800	\$36,700
\$19,600	n/a	n/a	n/a
\$2,529,489	\$2,650,252	\$2,549,338	\$1,774,630

Approved: Board of Directors – 12/03/05

PRINCIPLES OF CORPORATE RELATIONSHIPS

The mission of the American Academy of Dermatology (Academy) is dedicated to supporting its members in achieving the highest quality of dermatologic care while maintaining professional and ethical standards through education, research and advocacy of socioeconomic and other professional activities. The Academy supports this mission by developing and supporting the education, research, advocacy and public service activities of dermatologists.

The Academy has mutually beneficial relationships with corporations and offers opportunities to work effectively and appropriately with industry in support of our mission. As such, all corporate arrangements must relate to the organization's mission, and are subject to the following guidelines.

General Guidelines

- 1) When appropriate, the Academy may pursue corporate relationships to support activities that further the Academy's mission. These relationships primarily include grants and sponsorships. Advertising, exhibiting, member service providers and affinity relationships also constitute corporate relationships, and are governed by the policies for those respective programs.
- 2) The Academy maintains complete control of the development, implementation and assessment of all content and materials related to its programs.
- 3) Corporate donors and sponsors must represent a product or service that is compatible with the Academy's mission, its policies and its values.
- 4) The Academy accepts support from corporations only if acceptance does not pose or imply a conflict of interest and in no way impacts the objectivity of the Academy and its programs.
- 5) Where appropriate, the Academy seeks funding from a variety of sources. Occasions may arise when support of a specific program from a single source is necessary or appropriate, but special care will be taken in these circumstances to avoid conflicts of interest or any perception of conflict of interest.
- 6) Solicitation of support (grants, contributions, sponsorships, underwriting, etc.) for the Academy and its programs are to be coordinated through the

Governance Policy on Principles of Corporate Relationships

Development Department. Individual members and chairs of programs may work with the Director of Development to identify potential grant sources.

- 7) Corporations providing support to the Academy are regularly recognized in appropriate forums, including, but not limited to, the program funded. No product brand names will be used in recognition or on sponsored items.
- 8) The Academy name, logos and/or other identifying information are valued and may only be used on non-Academy materials with the approval and written consent of the Academy Board of Directors or their designees and in accordance with an appropriate license/royalty agreement.
- 9) No funds should be accepted with real or apparent expectations of reciprocity from industry.

The Academy supports ethical relationships between members and industry and provides guidance for this relationship in the following:

- AAD Code of Medical Ethics for Dermatologists
- AAD Principles of Professional Conduct

All member relationships with industry are disclosed in writing or verbally when decisions are made on Academy matters at official Academy group meetings.

The forms and guidelines for appropriate disclosure can be found on the AAD Website under Dermatology Professional. These forms are periodically reviewed and updated.

- Officers, Board of Directors, members and senior staff are required to submit, yearly, a completed Academy and Association Disclosure Statement of Potential Conflict of Interest
 - Disclosure Statement guidelines are outlined in the Administrative Regulation (AR) on Policy and Procedures Regarding Actual or Potential Conflicts of Interest
- Speakers and Faculty at AAD meetings are required to submit:
 - A Pre-Invitation Disclosure Form
 - Program Book Comprehensive Disclosure Form
- Authors submitting a manuscript to *Journal of the American Academy of Dermatology (JAAD)* are required to submit:
 - Author Conflict of Interest Statement



Approved: Board of Directors – 4/17/05

PROMOTION OF NON-ACADEMY PRODUCTS & SERVICES POLICY

The American Academy of Dermatology and AAD Association (collectively, “the Academy”) seeks to advance the science and art of dermatology and to promote community health, patient welfare, and public education in the field of dermatology. In meeting these objectives, the Academy communicates through various media with dermatology professionals, allied health professionals, and the public regarding products and services available from the Academy. . The Academy owns or controls a variety of communications vehicles, including, but not limited to: direct mail, educational materials, meetings, periodicals, and web sites. The Academy permits and encourages other organizations to promote products and services in its communications vehicles, provided that the products or services are deemed appropriate and relevant to the practice of dermatology and do not compete directly with those offered by the Academy. .Promotion by other organizations is governed by the following general guidelines, and by the more specific guidelines referenced in the endnotes, below:

RIGHT OF REFUSAL

The Academy reserves the right to reject requests for promotions, or not to renew previously approved promotions, at any time for any reason or no reason at all. Promotions that conflict, or have the appearance of conflicting, with Academy policy are prohibited (see also, Non-AAD Guidelines section, below).

TERMINATION

The Academy reserves the right to terminate any promotion that could reasonably be determined to affect adversely the goodwill or reputation of the Academy or its affiliates.

LOGO USE

Use of the Academy’s name and/or logo is prohibited without the Academy’s prior written approval. The use of non-Academy corporate names and logos is generally permissible, except where prohibited by other Academy guidelines.

COMPETITION

Promotion of products, meetings, and services that compete directly with those offered by the Academy is generally prohibited. Membership solicitation by organizations other than the Academy and the members of the Intersociety Liaison Committee and state dermatology societies, which have established reciprocal agreements, is prohibited. Fundraising by organizations or individuals other than the Academy is strictly prohibited.

ENDORSEMENT

Governance Policy on Promotion of Non-Academy Products and Services

The Academy's acceptance of promotion is not intended to convey Academy approval, endorsement, certification, acceptance, or referral of any particular organization, or any product or service manufactured or distributed by that organization. Promotion permitted in Academy communications vehicles is not to be construed or publicized as an endorsement or approval by the Academy, nor may the promoter state that its claims are approved or endorsed by the Academy. The fact that a promotion for an organization, a product, or a service has appeared in an Academy-sponsored communications vehicle, shall not be referred to in collateral advertising or literature by that organization.

DISTRIBUTION OF ACADEMY MEMBER INFORMATION

The Academy rents its membership mailing list, which includes mailing addresses only, in accordance with these and other, more specific, guidelines. The Academy does not rent or otherwise disseminate other member information, including but not limited to e-mail addresses and fax numbers, to other organizations.

PRODUCT REFERENCES

Reference to product brands by commercial supporters is prohibited except in advertisements, the content of which is governed by more specific guidelines for Academy publications that accept advertising.

COMPARISONS

Comparison to the Academy's products or services is prohibited. Comparisons to a competitor's products or services in Academy communications vehicles are prohibited.

PROPRIETY

Promotions deemed by the Academy, in its sole judgment, to be indecent, offensive or otherwise inappropriate in content are prohibited.

ELECTRONIC PROMOTION

The Academy may take under consideration requests for advertising and promotion on its Web sites. Requests for links to and from its Web sites are governed by specific Academy guidelines.

NON-AAD GUIDELINES

Promotion must be in compliance with all applicable continuing medical education guidelines (AMA, ACCME, etc.) as well as all appropriate industry, state and federal regulatory and governmental agency guidelines (PhRMA, FDA, OIG, FCC, FTC, etc.)

LIMITATIONS OF ACADEMY LIABILITY

The Academy will endeavor to disseminate promotions promptly and accurately. The Academy assumes no responsibility to verify statements contained in a promotion. Any inadvertent errors by the Academy will be corrected promptly upon discovery, without additional charge, and such obligation to correct shall constitute the sole liability of the Academy.

Governance Policy on Promotion of Non-Academy Products and Services

REVIEW PROCESS

All requests for promotion must be submitted in writing to the appropriate review body. Academy reviewers are responsible for ensuring that Academy guidelines are followed with respect to all promotion. The decisions of Academy reviewers are final.

INTERPRETATION AND APPLICATION OF GUIDELINES

All matters and questions not specifically covered by these Guidelines, or other specific Academy guidelines, are subject to the final decision of the Executive Committee of the Academy.

VIOLATIONS

Specific actions may be taken by the Academy for violation of any provision of these guidelines. The action taken will be determined on the basis of the particular circumstances of the violation, but in cases involving major violations, may include legal action.

REFERENCE: SUPPORTING ACADEMY GUIDELINES INCLUDE:

- Administrative Regulation: Guidelines for Cooperative Print and Electronic Public Education Programs with Industry. Administered by: Executive Director
- Technical Exhibit Rules & Regulations (Reviewed and approved annually, most recently on April 9, 2004.). Administered by: Scientific Assembly Council
- Advertising Guidelines (approved 1994; amended 1999). Administered by: Physician Reviewer/Board of Directors.
- Administrative Regulation: Guidelines for Production of Public Service Announcements (approved 7/17/87). Administered by: Communications Council
- Guidelines for the Approved Use of the American Academy of Dermatology and American Academy of Dermatology Association Membership Mailing List (approved May 22, 2004). Administered by: Executive Director).
- American Academy of Dermatology Digital Advertising and Sponsorship Guidelines (approved 1999). Administered by: Executive Director.
- Industry Supported Symposia Policies & Guidelines (approved 10/22/04). Administered by: Scientific Assembly Council
- Departmental Management Guidelines for AAD.org (revised 7/01). Administered by: Director, Web Services.



Approved: AAD Board of Directors 11/22/03

American Academy of Dermatology Corporate Partner Recognition Program

The American Academy of Dermatology Development and Industry Liaison Committee and Academy Board of Directors have announced the Corporate Partner Recognition Program that was adopted by the Board on November 21, 2003 for implementation in 2004. The program was designed to recognize the significant role that corporations play in furthering dermatology and the mission of the Academy. The Academy's Corporate Partner Recognition Program honors corporations that provide unrestricted educational grants and/or contributions with three types of recognition:

1. EVENT/PROGRAM SPECIFIC

Recognition provided for supporting a specific item, program or educational event at any dollar level:

- The supporting company will have its name and logo on the item and in most instances include a phrase referencing the grant;
- If an activity occurs in a room, the name of the company with logo will be placed upon a tripod outside of the room;
- If the item supports an event such as the Annual or Summer Academy Meeting, all companies will be listed on a display board and include the items supported; and
- Listing will also be included in various publications such as *Dermatology World* and if event specific at the Academy's Annual or Summer Academy Meeting, in the appropriate *Program-at-a-Glance* and *AAD Annual Meeting* or *Summer Academy Meeting News* Post Edition.

2. ANNUAL CUMULATIVE GIVING

Recognition provided for total dollars in one year in support of educational events, items or programs of \$25,000 and above:

Diamond	\$500,000 and above
Sapphire	\$250,000 - \$499,999
Ruby	\$100,000 - \$249,999
Emerald	\$ 50,000 - \$99,999
Bronze	\$ 25,000 - \$49,999

- Exhibit Booth Recognition at both the Annual and Summer Academy Meetings;
- Annual Corporate Partner Lapel Pins provided for wear all year;
- Name Badge recognition at the Annual and Summer Academy Meetings;
- Listing on AAD Corporate Partner Recognition Video played at Annual and Summer Academy Meetings;
- One invitation to attend the Development and Industry Liaison Committee Corporate Partner Recognition Reception held during the Annual Meeting based on level of support: Diamond = six guests; Sapphire = five guests; Ruby = four guests; Emerald = three guests; Bronze = two guests; and
- One invitation for two to attend President's Dinner held during the Annual Meeting (Emerald and above).



*American Academy of Dermatology
and AAD Association*
Physicians Dedicated to Excellence in Dermatology™

Governance Policies

Approved: Board of Directors – 11/21-22, 2003
Revised by Development and Industry Liaison Committee
Approved July 26, 2006

Fundraising Activities Independently Initiated on Behalf Of AAD/A Programs Policy

The Academy deeply appreciates the effort made by individuals and organizations that fundraise on behalf of Academy programs and activities. It is because of this support, both financially and in volunteer hours that the Academy is able to provide these important programs and activities.

Following are guidelines that were established to facilitate fundraising activities on behalf of AAD/A programs and activities:

Individuals and organizations requesting approval to conduct a fundraising activity or event on behalf of an Academy program must submit a written request to the Academy at least 60 days in advance of the proposed activity/event date. The request must include:

- Name of the individual or organization responsible for initiating the activity;
- Identification of the Academy program or project that proceeds will support;
- A description of the fundraising activity;
- Affirmation that all contributions will be forwarded to the Academy and that no expenses have been or will be charged to contributors;
- Date and location of the fundraising activity or event;
- A description of the audience targeted for participation; and
- Complete contact person information.

Requests will be reviewed by the Development Committee and /or the Secretary Treasurer, and the applicant will receive written notification of approval or denial of the request. Requests will be acknowledged within 30 days of receipt and final notification is contingent upon completeness of the request and scheduled meetings for review of proposals.

Individuals and outside organizations are prohibited from using the Academy logo or any Academy program logo without the prior written consent of the Academy. Any materials that use the name of the Academy or reference a program or project of the Academy must be reviewed by the Academy and

approved in writing prior to distribution. The Academy assumes no liability that may arise from fundraising activities independently initiated on behalf of AAD/A programs.

Members and outside organizations are prohibited from soliciting the Academy's industry partners on behalf of the Academy. This includes all pharmaceuticals, equipment, and medical practice service companies that exhibit or have exhibited at the Annual or ACADEMY Meeting.

Requests for fundraising will not be approved if there is a conflict with an Academy-scheduled activity or event, such as the Annual Meeting.

Individuals or organizations conducting fundraising activities/events must agree to cooperate fully with Academy cash management procedures. Organizers should encourage donations in the form of checks. The Academy will provide "payable to" wording for the checks and a remittance address. The Academy will also provide procedures for processing cash donations. All contributions must be forwarded to the Academy within 7 days of receipt.

The Academy will acknowledge all contributions, individual or organizational, in accordance with Academy and IRS guidelines, send thank you letters to each donor for whom contact information is provided by the organizer, and may offer other recognition as is appropriate. In order to accomplish this, the following procedures apply:

- Names, addresses and amounts of those contributing should be forwarded to the Academy within 7 days.
- Names and addresses of individual volunteers or outside organizations involved in the fundraising activity should be forwarded to the Academy.
- Verification for in-kind contributions, including description of contribution with name and address of donor, should be submitted to the Academy. The value of in-kind contributions will be documented according to IRS regulations.



Approved: Board of Directors – 04/21/07

Revised: Board of Directors – 8/2/08

Industry Access to Ticketed Sessions

PURPOSE

In order to provide an opportunity for corporate partners to have access to ticketed Academy educational sessions during the Annual and Summer Academy Meetings and to be consistent with established process for corporate partner recognition benefits, the following apply:

ELIGIBILITY

- Corporate partners that are members of the AAD Corporate Partner Circle Recognition Program will be eligible. The Corporate Partner Circle Recognition Program honors corporate partners that have supported Academy programs over a three year period at the Ruby Level of support and above (Ruby, Sapphire and Diamond). The Corporate Partner must be an exhibitor and a current Corporate Partner Circle member at time of registration.
- A point system has been developed to establish a point value over a three year period that encourages movement within the three levels with commensurate benefits.
- The number of eligible tickets has been determined based upon the final point value achieved over the previous three year period. The number may vary annually (higher or lower) depending upon final tier achieved.
- There are three tiers. The highest tier has access to 10 tickets, the second tier six tickets and the third tier three tickets.
- Corporate partner representatives must register for the meeting at the Non-Member & Office Staff/RN rate and pay for tickets to educational sessions. They must also register at the appropriate time. Representatives must hold a high level management, professional relations or medical education position.
- The number of tickets awarded based upon the tier will be the same for both the Annual and Summer Academy Meetings. Tickets will be assigned during the advance registration process with no on-site registration.
- Corporate partners will be notified by the Development Department at the end of the year as to eligibility for inclusion in this pilot program for the upcoming year's meetings and of their tier level as part of the Corporate Partner Circle communication.
- Tickets are not transferable, unused tickets are forfeited.

Governance Policy on Industry Access to Ticketed Sessions

EDUCATIONAL SESSIONS

- Educational sessions are defined as the ticketed larger sessions such as symposia and include surgical sessions.
- A process for registering for industry has a defined sign-up time so that any unused seats will be made available on a timely basis.
- Industry representatives will be observers only and not allowed to ask questions or participate in discussion. Industry representative must have their badges clearly displayed at all times.
- A company may be assigned no more than 1% of the total tickets available for any session. Only one individual from a company may attend a session if session capacity is 100 registrants or less.

VIOLATION OF GUIDELINES

- Any violation of the guidelines may be cause for expulsion from this program and possible other sanctions by the Academy.
- As this is a “pilot” program, violations may cause the Academy to end the program after the first year.

Essential Area 2: Educational Planning (Criterion 7: ACCME's Standard for Commercial Support – Independence)

Describe how your organization makes the following decisions free of the control of a commercial interest: (a) identification of needs; (b) the determination of educational objectives; (c) the selection and presentation of content; (d) the selection of all persons and organizations in a position to control the content; (e) the selection of educational methods; and (f) the evaluation of the activity.

The development of all CME activities – including the identification of needs, determination of educational objectives, selection and presentation of content, selection of all persons and organizations in a position to control the content, and evaluation of the activity – is solely controlled by the Council on Education and its constituent committees, task forces, and workgroups. These groups include staff from members of the Department of Education. Commercial funds to support CME activities are secured by the Academy's Development Department.

Needs are derived from sources listed under educational planning (criteria 2-3) on page 18, and overall learning objectives are established by the appropriate planning committee and faculty. Faculty are selected by the respective planning committee based on expertise in a content area and conflicts of interest are resolved as described in Section V. E. on page 103. Evaluation data from previous CME activities are also used to assess an individual's effectiveness as a teacher. Evaluation data processes are established by Academy educational staff with input from members of the Academy's Annual Meeting Evaluation Task Force, Scientific Assembly Committee, Regional Course Workgroup, and other planning committees when appropriate.

Commercial supporters are not permitted to recommend or suggest content, faculty/authors, delivery methods, evaluation methods, or any other aspect of the CME activity. The Council on Education and its respective committees/task forces along with staff in the Department of Education maintain control of these decisions.

The primary purpose of commercial support is to underwrite the costs associated with the logistical aspects of delivering a CME activity and will only be accepted from companies who agree to follow ACCME, AMA, Office of the Inspector General, FDA,

and Academy policies. Letters of Agreement with commercial supporters are secured by the Development Department. Post-activity information, such as attendance reports and income and expense reports, is shared with commercial supporters upon request.

If your organization enters into joint sponsorship relationships with non-accredited providers, show that these organizations are not commercial interests.

The Academy does not participate in joint sponsorships with non-accredited providers. At its November 3, 2007 meeting, the American Academy of Dermatology's Board of Directors considered the option of providing joint sponsorship to non-accredited providers. To ensure high quality content through proper needs assessment, selection of appropriate faculty, and independence from commercial influence, the Board reaffirmed its current policy.

Show the mechanism(s) your organization uses to ensure that everyone in a position to control educational content has disclosed to your organization relevant financial relationships with commercial interests.

All committee members are required to submit a detailed disclosure of their financial relationships to qualify for a position on the planning committee. Disclosures are reviewed, updated, and discussed at the beginning of the planning meeting and individuals who have an actual or perceived conflict with a specific topic area are recused from participating in the development of that area. All relevant disclosures are also made at the time of the activity.

A web-based system was created to store this data and allow committee members, faculty, and authors a streamlined method to submit their disclosure information electronically and view disclosures from fellow committee members. The system retains the disclosure information and allows individuals to update it as needed, but at a minimum annually. The system has also eliminated the need to submit the same information multiple times when a contributor serves in multiple roles within the Academy.

Session Directors, faculty members, and authors are required to complete a similar disclosure of financial relationships form and attestation form. Staff is responsible for

tracking the collection of disclosure forms and following up with any faculty who have not submitted their paperwork. Any faculty who have not submitted completed disclosure and attestation forms are informed that they will not be permitted to participate in the activity. Individuals who refuse to comply are disqualified from participating, and a replacement faculty member or author is found.

Attachments

Attached are the Academy's Administrative Regulations, Policy and Procedures Regarding Actual or Potential Conflicts of Interest, Policy to Ensure Independence in Continuing Medical Education Activities, and a sample checklist used by staff.


See Attachment F



Not included here.

Attachment

Mechanisms to Ensure Disclosure of Relevant Financial Relationships



Policy to Ensure Independence in Continuing Medical Education Activities

The mission of the Academy's continuing medical education program is to improve patient care and health care outcomes by maintaining, developing and enhancing medical knowledge, patient care, interpersonal and communication skills, and professionalism. As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME) and in support of this mission, the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective, and free of commercial bias.

The Academy employs several strategies to ensure these standards will be met. The planning committee members submit and consider their own disclosure information and recuse themselves from planning educational activities should they have conflicts related to the subject area presented. When developing an educational program, the planning committee reviews applications and disclosure of interest forms, along with needs assessment and evaluative data from past activities in order to develop programming. Potential participants are sent detailed guidelines which provide direction on the following necessary components to ensure independence in continuing medical education activities and to resolve conflict, as itemized below:

DISCLOSURE OF FINANCIAL RELATIONSHIPS

The Board of Directors requires that all participants in the Annual and Summer Meeting comply with all applicable laws and regulations governing disclosure. Session directors and faculty are required to provide the Academy a comprehensive disclosure of financial relationships with a commercial interest producing health care goods or services consumed by, or used on patients. Individuals who refuse to disclose financial relationships are disqualified from participation in the educational program(s).

Disclosure statements must include all financial relationships occurring within 12 months of the educational activity. If no financial relationships exist, the individual is required to indicate such on their disclosure form.

A comprehensive disclosure of financial relationships is published in the Program Book and Program-at-a-Glance and is available online on the Academy's website at www.aad.org. In addition, directors/faculty are expected to make a verbal disclosure of relevant financial relationships or indicate that no conflicts exist at the beginning of their presentation. A PowerPoint-based slide with a disclosure template will be provided to the speaker for inclusion in their presentation prior to the meeting. **Failure to disclose will result in a denial of the opportunity to participate in the CME activity.**

It is the responsibility of the session director to ensure balance with regards to disclosure of potential conflicts of interest. In addition, all faculty are required to complete the speaker attestation form indicating their compliance with these policies.

CONTENT VALIDATION

Academy-sponsored educational activities are designed to promote improvements or quality in healthcare and not promote a specific proprietary business interest of a commercial interest.

Presentations and related materials must be based on scientific methods generally accepted by the medical community. Presentations should be evidence-based and discuss the validity of the evidence upon which they base the opinion(s) (See Sackett et al, BMJ 1996;312:71-2). This ensures the audience that the recommendations are supported by the evidence and contributes to management of any potential conflicts of interest. Further, if the presentation includes discussion of unlabeled or investigational use of a commercial product, this also must be disclosed to the participants.

CME must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If CME educational material or content includes trade names, trade names from several companies should be used where available, as opposed to using trade names from just a single company. Educational materials such as slides, abstracts, and handouts cannot contain any advertising or product-group messages.

OUTCOMES MEASUREMENT

Several methods of evaluation are utilized in assessing the educational program. Session directors, faculty, attendees, and formal observers are all given the opportunity to evaluate the educational content and speaker performance. Included in this process are measures to rate the success of the Academy's policies regarding independence in continuing medical education activities with particular focus on the absence of commercial bias.

In addition, the Academy may review speaker presentations stored on the meeting servers to collect aggregate data regarding disclosure. This data is only used to determine effectiveness of the Academy's policies and procedures regarding disclosure.

Should it be determined that a member of the Academy's educational program violated the Academy's "Policy to Ensure Independence in Continuing Medical Education," the individual may not be asked to participate in future educational programs.

Describe the mechanism(s) your organization uses to identify conflicts of interest prior to an activity.

All task forces, committees, and councils are required to disclose financial relationships at the beginning of each planning and committee meeting. Financial relationship disclosures for contributors are reviewed by the respective planning task force or committee, session director, and education department staff. All contributors are required to attest in writing their willingness and ability to comply with Academy and ACCME policy. Live activities are monitored to ensure compliance.

Some participants who have conflicts have been denied participation due to violation of these policies. The Academy reserves the right to deny participation if it determines that a conflict cannot be resolved.

All conflicts of interests must be resolved before an individual can participate in an educational activity.

Describe the mechanism(s) your organization uses to resolve conflicts of interest prior to an activity.

Planning committee members with a potential conflict of interest are recused from participating in discussion where a conflict may exist. Balance of members with expertise in given areas and the need for a majority consensus to approve a motion also contributes to the resolution of an actual or perceived conflict.

For the Annual Meeting, Summer Academy Meetings, and Regional Courses, the respective planning committee reviews the individuals' disclosures of financial relationships and evaluation history for actual or perceived biases detected in prior presentations (when available) before inviting the individual to direct a scientific session or regional course.

It is the responsibility of the director to resolve potential conflicts of interest for individual speakers. All faculty members must submit a disclosure of financial relationships. Directors and speakers are informed in writing of the Academy's Policy to Ensure

Independence in Continuing Medical Education and are advised to resolve conflicts of interest by utilizing one of the following methods:

- Change the scope of the session to eliminate the focus on commercial products or services
- Limit presentations to areas not affected by conflicts of interests
- Select a speaker with no conflicts of interest
- Review the presentation materials to ensure therapeutic options are balanced, evidence-based and do not promote a specific proprietary business interest

To participate in the activity, each individual is required to attest in writing that he/she will comply with all Academy policies, which reflect ACCME policies and regulations.

In addition, presentation materials for live activities are reviewed by staff. If content is called into question, the materials are forwarded to a physician expert for review. Any changes to ensure balanced content are then communicated to the presenter. To ensure compliance, live activities are then monitored and evaluated for balance, scientific rigor, and freedom from commercial bias through attendee evaluations and Professional Expert Evaluation Reviewers (PEER - formerly known as formal observers).

Enduring materials are reviewed by staff and physician experts to ensure balance, scientific rigor, and freedom from commercial bias prior to release. If bias is detected, the materials are edited prior to release.

Show your organization's process(es) and mechanism(s) for disclosure to the learners of (1) relevant financial relationships of all persons in a position to control educational content and (2) the source of support from commercial interests, if applicable.

For all live activities, disclosures of commercial relationships of the planning committee and faculty are published in the program book and/or the syllabus. Faculty are also required to disclose relationships verbally prior to the delivery of the activities and to include a disclosure slide in the PowerPoint presentation. For enduring materials, disclosures of commercial relationships are published with the corresponding materials

preceding the educational content. *Dialogues in Dermatology*, the audio subscription product, also provides verbal disclosures at the beginning of each dialogue.

Commercial support for an activity (when applicable) is disclosed in promotional materials, syllabus, and/or signage at the activity.

Attachments

Attached are the disclosures made to learners in the Program-At-A-Glance for the 2007 Summer Academy Meeting which was distributed with the registration materials, a sample of a disclosure slide from a live presentation, and disclosures published in the enduring CME activity *DERMCLIPS*.

Attachment

Processes and Mechanisms for Disclosure to Learners



Physicians Dedicated to
Excellence in Dermatology™

2007

SUMMER ACADEMY MEETING

Hilton New York | August 1-5, 2007 | New York, NY

Program-At-A-Glance & Personal Planner

Supported by:





Physicians Dedicated to
Excellence in Dermatology™

The American Academy of Dermatology gratefully acknowledges the following industries for support of the Summer Academy Meeting 2007

PROVIDERS OF UNRESTRICTED EDUCATIONAL GRANTS AND/OR SUPPORTED ACTIVITIES



ACADEMY MEETING NEWS ON-SITE EDITION
ACADEMY MEETING NEWS POST EDITION



CYBER CENTER
HOTEL KEY CARDS



PROGRAM-AT-A-GLANCE MAP & FLOOR PLAN DIVIDER
POSTERS2VIEW



PROGRAM-AT-A-GLANCE
PROGRAM SECTION



LEAD RETRIEVAL CARDS
PROGRAM-AT-A-GLANCE
PERSONAL PLANNER SECTION
REGISTRATION BAGS



POCKET GUIDES



LANYARDS

INDUSTRY SUPPORTED SYMPOSIA DIAMOND LEVEL



MULTI-INDUSTRY SUPPORTED SYMPOSIUM DIAMOND LEVEL



UNRESTRICTED EDUCATIONAL GRANT GOLD LEVEL



(Current contributors at time of publication)

Summer Academy Meeting 2007

SPEAKER DISCLOSURES

Type of Relationship:

- A** Advisory Board
- B** Board of Directors
- C** Consultant
- E** Employee
- F** Founder
- I** Investigator
- O** Other
- SP** Speaker
- SH** Stockholder

Nature of Compensation:

- EQ** Equipment (dept or practice)
- G** Grants
- H** Honoraria
- IP** Intellectual Property Rights
- NC** No Compensation Received
- OB** Other Financial Benefit
- R** Royalty
- RF** Residency or Fellowship Program Funding
- S** Salary
- ST** Stock
- SO** Stock Options

ALPHABETICAL DIRECTORY OF FACULTY DISCLOSURES

Disclosures received as of June 15, 2007:

SCIENTIFIC ASSEMBLY COMMITTEE

Cooper, Kevin D., MD; A – Genmab; C – Centocor, Estee Lauder, GlaxoSmithKline, L'Oreal, Proctor & Gamble; F – Pyruvate Esters, LFA3-TIP; I – Biogen, Centocor, Zymogenetics; SB – Biogen, Fujisawa, Novartis; SH – Genmab, Ketopharma, Medarex.

Eichenfield, Lawrence F., MD; A – Chester Valley, Connetics, GSK, Novartis, Medics, Skin Medica; C – Connetics, Galderma, Novartis, Steifel; H – Astellas, Connetics, Galderma, GSK, Novartis, Nucryst, OrthoNeutrogena, Medics, Skin Medica; I – Allergan, Amgen, Astellas, Connetics, Dermik, Galderma, Hili, Novartis, Nucryst, OrthoNeutrogena, Sinclair; O – Elsevier; R – Novartis; SP – Astellas, Novartis, Connetics, Medics.

Elmets, Craig A. MD; A – Abbott, Amgen; C – Astellas, Vaxin; G – Abbott, Amgen, Connetics, Genentech, Genmab; H – Abbott, Amgen, Astellas; I – Abbott, AGI Dermatics, Amgen, Connetics, Genentech, Genmab, Pfizer; SO – Vaxin.

Grant-Kels, Jane M., MD; G – Electro-Optical Sciences; I – 3M, Electro-Optical Sciences; NC – 3M.

Whitaker, Duane C., MD; no financial relationships exist with commercial interests.

A

Ackerman, A. Bernard, MD; no financial relationships exist with commercial interests.

Alam, Murad, MD; G – Allergan, Ulithers; PI – Allergan, Ulithers.

Alexis, Andrew F., MD; A – Connectics; C – Estee Lauder; G – L'Oreal; H – Amgen, Collagene, Dermik, Estee Lauder; O – L'Oreal; SP – Amgen, Collagene, Connectics, Dermik.

Anderson, Dina N., MD; A – Dermik; SP – Allergan, Dermik.

Arbuckle, H. Alan, MD; C – Smith & Nephew; H – Smith & Nephew.

Argenziano, Giuseppe, MD; A – Shire; H – Shire.

B

Baldwin, Hilary E., MD; A – CollaGenex; H – Allergen, CollaGenex, Galderma, L'Oreal, Medics, Ortho-Neutrogena, Ranbaxy, Steifel; SP – Allergen, CollaGenex, Galderma, L'Oreal, Medics, Ortho-Neutrogena, Ranbaxy, Steifel.

Bank, David E., MD; C – 3M, Allergan, Inamed, Medics; G – Medics; H – 3M, Allergan, Inamed, Medics; I – Allergan, Medics; OB – Allergan; SP – Medics.

Barbosa, Victoria, MD; E – L'Oreal; S – L'Oreal.

Baron, Elma D., MD; C – Estee Lauder, Therakids; G – Estee Lauder, Novartis, Therakids, Steifel; H – Estee Lauder, Therakids; I – Estee Lauder, Novartis, Therakids, Steifel.

Barrio, Victoria R., MD; C – Connectics; H – Connectics.

Baugh, William Preston, MD; A – Children's Network International; G – Amgen; I – Amgen; NC – Children's Network International.

Baumann, Leslie, MD; A – Avon, Galderma, Johnson & Johnson, Philosophy, Stiefel, Unilever; G – Allergan, Avon, Galderma, Johnson & Johnson, Medics, Stiefel; H – Avon, Galderma, Johnson & Johnson, Mary Kay, Philosophy, Stiefel; I – Allergan, Avon, Galderma, Johnson & Johnson, Medics, Stiefel; O – Mary Kay.

Bennett, Daniel D., MD; no financial relationships exist with commercial interests.

Bergfeld, Wilma Fowler, MD; A – Pfizer, Johnson & Johnson; G – Genentech; H – Johnson & Johnson, Pfizer; I – Genentech, Pfizer.

Bernstein, Leonard J., MD; I – Cynosure; EQ – Cynosure.

Bikowski, Joseph B., MD; no financial relationships exist with commercial interests.

Bolognia, Jean L., MD; no financial relationships exist with commercial interests.

Border, Norma; no financial relationships exist with commercial interests.

Brown, Stuart M., MD; no financial relationships exist with commercial interests.

Buka, Robert L., MD; F – Dr. Bobby-Skin Care for Kids; ST – Dr. Bobby-Skin Care for Kids.

Burdick, Anne E., MD, MPH; G – Galderma, Ortho-Neutrogena; O – Galderma, Ortho-Neutrogena.

Burgess, Cheryl M., MD; A – Allergan, Bioform, Johnson & Johnson, Medics, Sanofi-aventis; C – Allergan, Sanofi-aventis; G – Medics; H – Allergan, Bioform, Johnson & Johnson, Medics, Sanofi-aventis; I – Medics; SH – Allergan, Medics; SP – Sanofi-aventis.

Butterwick, Kimberly J., MD; A – Allergan, Dermik, Medics; C – Allergan, Dermik, Medics; H – Allergan, Dermik, Medics; I – Mentor; NC – Mentor, Skin Medica; SH – Skin Medica.

Bystryn, Jean-Claude, MD; no financial relationships exist with commercial interests.

C

Callen, Jeffrey Phillip, MD; no financial relationships exist with commercial interests.

Callender, Valerie D., MD; C—Allergan, Barrier Therapeutics, Galderma, Johnson & Johnson, Medicis, Proctor & Gamble, Skin Medica, Steifel; G—Allergan, Amgen, Barrier Therapeutics, Galderma, Medicis, Steifel; H—Allergan, Barrier Therapeutics, Galderma, Medicis, Steifel; I—Allergan, Amgen, Barrier Therapeutics, Galderma, Medicis.

Camisa, Charles, MD; A—Genentech; H—Genentech, Steifel, Warner-Chilcott; SP—Genentech, Steifel, Warner-Chilcott.

Carucci, John A., MD; no financial relationships exist with commercial interests.

Ceilley, Roger I., MD; O—Galderma; H—Ortho-Neutrogena, Novartis.

Chang, Helen Shim, MD; no relationships exist with commercial interests.

Chang, Mary Wu, MD; A—Shire; H—Astellas, Connecticut, Novartis, Shire; SP—Astellas, Connecticut, Novartis.

Cockerell, Clay J., MD; A—Galderma, PTV; B—AmeriPath; F—SKinAware, SKinScreen Development; H—Galderma, PTV; IP—SKinScreen Development; S—AmeriPath; SH—AmeriPath; ST—AmeriPath.

Coffey, Jr., William J., MD; NC—Blue Cross; O—Blue Cross.

Cohen, David E., MD; A—Amgen-Wyeth, CollaGenex, Johnson & Johnson, Neosil, Steifel; C—Amgen-Wyeth, CollaGenex, Galderma, Genentech, Johnson & Johnson, Neosil, Steifel; SP—Amgen-Wyeth, CollaGenex, Novartis, Steifel.

Coldiron, Brett M., MD; no financial relationships exist with commercial interests.

Comite, Stephen L., MD; C—Allergan; H—Allergan, Bioform, Dermik; O—Dermik; SP—Bioform.

Connolly, Suzanne Marie, MD; no financial relationships exist with commercial interests.

Cook, Joel, MD; no financial relationships exist with commercial interests.

Costner, Melissa I., MD; no financial relationships exist with commercial interests.

Cowen, Edward W., MD; no financial relationships exist with commercial interests.

Cropley, Thomas G., MD; no financial relationships exist with commercial interests.

Cruz, Jr., Ponciano D., MD; C—Mary Kay Cosmetics, RCTS; H—Mary Kay Cosmetics, RCTS; I—Galderma; NC—Galderma.

D

Daniel, C. Ralph, MD; B—Bradley Pharm; SO—Bradley Pharm.

Day, Doris J., MD; A—Adventis, Galderma; H—Adventis, Galderma.

Deitchman, Bruce A., MD; no financial relationships exist with commercial interests.

DeLeo, Vincent A., MD; A—Schering Plough; C—Estee Lauder, Neutrogena, Pfizer; H—Schering Plough; OB—Estee Lauder, Neutrogena, Pfizer.

Del Rosso, James Q., DO; A—Astellas, Coria, Galderma, Intenides, Medicis, Novartis, Ortho-Neutrogena, Steifel, Warner Chilcott; C—Astellas, Coria, Galderma, Intenides, Medicis, Novartis Ortho-Neutrogena, Steifel,

Warner Chilcott; G—Galderma, Graceway, Intenides, Medicis, Ortho-Neutrogena, QLT, Steifel, Warner Chilcott; H—Astellas, Coria, Galderma, Intenides, Medicis, Ortho-Neutrogena, Steifel, Warner Chilcott; I—Galderma, Intenides, Medicis, Ortho-Neutrogena, Steifel, Warner Chilcott; SP—Astellas, Coria, Galderma, Graceway, Intenides, Medicis, Novartis, Ortho-Neutrogena, Steifel, Warner Chilcott.

Dhabhar, Firdaus S., PhD; H—Abbott, Avon, Mary Kay Inc., Unilever; NO—Abbott, Avon, Mary Kay Inc., Unilever; SP—Abbott, Avon, Mary Kay Inc., Unilever.

Dohil, Magdalene A., MD; H—Connectics, Hill; I—Hill; SP—Connectics.

Draeos, Zoe Diana, MD; no financial relationships exist with commercial interests.

Drage, Lisa A., MD; no financial relationships exist with commercial interests.

Dyer, Jonathan A., MD; no financial relationships exist with commercial interests.

E

Eichenfield, Lawrence F., MD; A—Astellas, Chester Valley, Dermik, GSK, Medicis, Novartis, Skin Medica, Steifel; C—Astellas, Chester Valley, Dermik, GSK, Medicis, Novartis, Skin Medica, Steifel; G—Allergan, Amgen, Astellas, Dermik, Galderma, GlaxoSmithKline, Hill Dermaceuticals, Novartis, Nucryst, OrthoNeutrogena, Sinclair Pharmaceuticals, Steifel; I—Allergan, Amgen, Astellas, Dermik, Galderma, GlaxoSmithKline, Hill Dermaceuticals, Novartis, Nucryst, OrthoNeutrogena, Sinclair Pharmaceuticals, Steifel.

Elenitsas, Rosalie, MD; no financial relationships exist with commercial interests.

Elewski, Boni E., MD; C—Abbott, Amgen, Anacor, Intendis, Merck, Merz, Novartis; G—Abbott, Amgen, Astellas, Barrier, Centacor, Galderma, Mediquet, Novartis; H—Abbott, Amgen, Anacor, Intendis, Merck, Merz, Novartis; I—Abbott, Amgen, Astellas, Barrier, Centacor, Galderma, Mediquet, Novartis; SH—Amgen; ST—Amgen.

Elias, Peter Michael, MD; C—Ceragenic Corp; S—Ceragenic Corp; SO—Ceragenic Corp.

Elston, Dirk Michael, MD; A—Abbott, Medicis; H—Abbott, Medicis.

F

Feldman, Steven R., MD, PhD; C—Amgen, Biogen, Centocor, Genentech, Therakos; G—3M, Abbott, Acuderm, Advanced Tissue Sciences, Allergan, American Society for Dermatologic Surgery, Amgen, Aventis, Bristol-Myers Squibb, Centocor, Chilcott, Combe, Connetics, Curatek, Dermatology Foundation, Ferndale, Fujisawa, Galderma, Genderm, Glaxo Wellcome, Hermal, Hill, Hoffman LaRoche, Janssen, Mayrand, NeoStrata, Neutrogena, Novartis, Oclassen, Ortho, Person & Covey, Photomedex, Proctor & Gamble, RJR Nabisco, Roche, Schering-Plough, Shelton, SmithKline, Steifel, United Catalyst, Upjohn, Warner, Wolff Systems; H—3M, Amgen, Biogen, Bristol-Myers Squibb, Centocor, Connetics, Galderma, Genentech, Novartis; SB—3M, Amgen, Biogen, Bristol-Myers Squibb, Centocor, Connetics, Galderma, Genentech, Novartis; I—Amgen, Astellas, Centocor; SB—Abbott, Amgen, Galderma, Genentech, Novartis, Warner Chilcott.

Florentino, David Franklin, MD, PhD; A—Abbott, Genentech; H—Abbott, Amgen, Genentech; I—Alza, Amgen, Mediquet, Novartis; O—Alza, Amgen, Centocor; SP—Amgen, Genentech.

Fleischer, Jr., Alan, MD; A—Astellas; C—Astellas, Intendis, Kikaku America, Merz, Novartis; G—Astellas, Galderma, Genentech, Intendis, Medicis, Novartis, Steifel; H—Astellas, Galderma, Intendis, Kikaku America, Medicis, Merz, Novartis, Steifel; I—Astellas, Galderma, Genentech, Intendis, Medicis, Novartis, Steifel; SP—Astellas, Galderma, Intendis, Medicis, Steifel.

Fowler, Jr., Joseph F., MD; C—CollaGenex, Connectics, Coria, Ferndale, Hyland, Intendis, Johnson & Johnson, Ligand, Novartis, Shire, Skinmedica, Steifel; I—3M, Abbott, Alerderm, Allergan, Amgen, Astellas, Centocor, CollaGenex, Connectics, Dermik, Dow, Ferndale Labs, Galderma, Genentech, Glaxo Dermatology, Johnson & Johnson, Ligand, Medicis, Ponsus, Novartis, Shire, Steifel, Taro; SB—CollaGenex, Coria, Intendis, Johnson & Johnson, Novartis, Shire, Steifel.

Fox, Lindy Peta, MD; H—Bristol Myers Squibb, Galderma; O—Galderma; SP—Bristol Myers Squibb.

Fried, Richard G., MD; no financial relationships exist with commercial interests.

G

Garg, Amit, MD; C—Abbott Immunology; H—Abbott Immunology; S—Abbott Immunology.

Gehris, Robin P., MD; H—Novartis, Steifel; SP—Novartis, Steifel.

Gendler, Ellen C., MD; C—Allergan, Medicis; H—Allergan, Medicis.

Geronemus, Roy G., MD; A—Candela, Juiper, Lumenis, Photomedex, Rhytec, Syneron; I—Allergan, Cutera, Cynosure, DermTech, DUSA, Iridex, Light Bioscience, L'Oreal, Medicis, Reliant Technologies, Rhytec, Syneron; ST—Light Bioscience, Reliant Technologies, Thermage.

Ghannoum, Mahmoud A., PhD; A—Astellas, Enzon, Merz, Pfizer, Steifel; C—Novartis, Schering; G—Astellas, Enzon, Merck, Novartis, Pfizer, Schering; H—Astellas, Enzon, Merck, Merz, Novartis, Pfizer, Schering, Steifel; I—Astellas, Enzon, Merck, Novartis, Pfizer, Schering; SP—Enzon, Merck, Pfizer.

Gilliam, Amy, MD; H—Novartis; SP—Novartis.

Glaser, Dee Anna, MD; A—Allergan; C—Allergan, Proctor & Gamble, Stieffel; Unilever; G—Allergan; H—Allergan, Proctor & Gamble, Stieffel, Unilever; I—Allergan.

Goldberg, David J., MD, JD; C—PhotoTherapeutics, UltraShape; G—Alma, Cutera, Cynosure, Lumenis, PhotoTherapeutics, Thermage; H—Alma, Cynosure, Lumenis, Palomar, PhotoTherapeutics, UltraShape; I—Alma, Cutera, Cynosure, Lumenis, PhotoTherapeutics, Thermage; SP—Alma, Cynosure, Lumenis, Palomar, PhotoTherapeutics.

Goldenberg, Gary, MD; no financial relationships exist with commercial interests.

Gordon, Kenneth B., MD; A—Abbott, Amgen, Astellas, Centocor, Genentech; H—Abbott, Amgen, Astellas, Centocor, Genentech.

Gordon, Marsha L., MD; C—St. Ives; S—St. Ives.

Gotkin, Robert, MD; no financial relationships exist with commercial interests.

Granstein, Richard D., MD; A—AGI Dermatic, Inc.; C—DuPont; G—Clinique Laboratories, LLC., DuPont; SO—AGI Dermatics, Inc.

Gupta, Aditya K., MD, PhD; G—Dermik, Novartis; H—Dermik; I—Dermik, Novartis; SP—Dermik.

H

Halpern, Matthew, MD; no financial relationships exist with commercial interests.

Hartman, Corey L., MD; A—Allergan; H—Allergan.

Heald, Peter W., MD; C—Eisai; G—Merck; H—Eisai, Therakos; I—Merck; SP—Eisai, Therkos.

High, Whitney A., MD; no financial relationships exist with commercial interests.

Hinshaw, Molly A., MD; no financial relationships exist with commercial interests.

Hughey, Lauren C., MD; C—Ligand; H—Ligand; I—Novartis; NC—Novartis.

J

Jacobe, Heidi Tewich, MD; H—Amgen; SP—Amgen.

James, William D., MD; H—Emedicine; O—Elsevier, Emedicine; R—Elsevier.

Jellinek, Nathaniel J., MD; no financial relationships exist with commercial interests.

Johr, Robert H., MD; H—3 Gen; SP—3 Gen.

Jorizzo, Joseph L., MD; H—Amgen, Astellas, Collagenix, Dermik, Galderma, Warner Chilcott; SP—Amgen, Astellas, Collagenix, Dermik, Galderma, Warner Chilcott.

Junkins-Hopkins, Jacqueline M., MD; no financial relationships exist with commercial interests.

K

Kalb, Robert E., MD; C—Abbott, Amgen, Centocor, Genentech, Steifel; H—Abbott, Amgen, Centocor, Genentech, Steifel.

Kane, Michael, MD; A—Allergan, Bioform, Medicis, Revance, Sanofi-Aventis, Steifel; C—Allergan, Medicis, Mentor, Revance, Sanofi-Aventis; H—Allergan, Bioform, Medicis, Mentor, Revance, Sanofi-Aventis, Steifel; I—Medicis; SH—Allergan, Medicis, Mentor; SP—Allergan, Medicis, Sanofi-Aventis.

Kaufman, Howard L., MD; A—Neugenix Oncology; NC—Neugenix Oncology, Novartis, Schering; SP—Novartis, Schering.

Kauvar, Arielle N.B., MD; G—Sciton; I—Sciton.

Kerdel, Francisco, MD; G—Abbott, Amgen, Centocor; H—Abbott, Amgen, Centocor; I—Abbott, Amgen, Centocor; SP—Abbott, Amgen, Centocor.

Keri, Jonette E., MD; G—Amgen; I—Amgen.

Khachemoune, A., MD; no financial relationships exist with commercial interests.

Kim, Ellen J., MD; G—GenMab, Gloucester Pharmaceuticals, Merck, Yaupon Pharmaceuticals; I—GenMab, Gloucester Pharmaceuticals, Merck, Yaupon Pharmaceuticals.

Kimball, Alexandra Boer, MD; A—Abbott, Amgen, Centocor, Connectics, Intendis, Nuskin; C—3M, Connectics, Ivax, Procter & Gamble, Warner Chilcott; G—3M, Abbott, Centocor, Connectics, Cytochroma, Johnson & Johnson, Keraderm, LVMH Recherche, Neostrata, Nucryst, PathFormer, Pepgen, Warner Chilcott; H—3M, Abbott, Amgen, Centocor, Connectics, Genentech, Intendis, Ivax, Nuskin, Procter & Gamble, Warner Chilcott; I—3M, Abbott, Centocor, Connectics, Cytochroma, Johnson & Johnson, Keraderm, LVMH Recherche, Neostrata, Nucryst, PathFormer, Pepgen, Warner Chilcott; RF—Centocor; SP—Abbott, Amgen, Centocor, Genentech, Warner Chilcott.

Koo, John Y.M., MD; A—Abbott, Amgen, Astellas, Biogen, Connetics, Genentech, Novartis, Valiant; H—Abbott, Amgen, Astellas, Biogen, Centocor, Connetics, Genentech, Novartis, Valiant; I—Amgen, Astellas, Biogen, Connetics, Genentech, Novartis, Teikoku, Valiant; NC—Teikoku; SP—Amgen, Astellas, Biogen, Centocor, Connetics, Genentech, Novartis, Valiant.

Kovich, Olympia I., MD; no financial relationships exist with commercial interests.

Kress, Douglas W., MD; C—Amgen, Galderma, Graceway, Novartis, Pharmaderm, Steifel; H—Amgen, Galderma, Graceway, Novartis, Pharmaderm, Steifel; SP—Amgen, Galderma, Graceway, Novartis, Pharmaderm, Steifel.

L

Latkowski, Jo-Ann, MD; A—Therakos; H—Therakos.

Laumann, Anne E., MBChB; C—Warner Chilcott; H—Warner Chilcott; I—Alza, Astellas, Lilly, Soluble Systems, Steifel; NC—Alza, Astellas, Lilly, Soluble Systems, Steifel.

LeBoit, Philip E., MD; no financial relationships exist with commercial interests.

Lebwohl, Mark, MD; A—Abbott, Amgen, Centocor, Connectics, Galderma, Genentech, Novartis, Steifel, Warner Chilcott; C—Abbott, Adelion, Amgen, Astellas, Basilea, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers-Squibb, Centocor, Cephalon, Connetics, DermiPsor, DOV, Forward, Galderma, Genentech, Graceway, Helix BioMedix, Hoffman LaRoche, Isotechnika, Neosil, Novartis, Pepgen, Pfizer, Roche, Steifel, UCB, Warner Chilcott; G—Abbott, Amgen, Astellas, Centocor, Connetics, Galderma, Genentech, Novartis, PharmaDerm, Warner Chilcott; H—Abbott, Adelion, Amgen, Astellas, Basilea, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers-Squibb, Celtic Pharma, Centocor, Cephalon, Chatterm, Connetics, DermiPsor, Doak, DOV, Forward, Galderma, Genentech, GlaxoSmithKline, Graceway, Helix BioMedix, Hoffman LaRoche, Isotechnika, Ligand, Neosil, Novartis, OMP, Pepgen, Pfizer, PharmaDerm, Roche, Steifel, UCB, Warner Chilcott; I—Abbott, Amgen, Astellas, Centocor, Connetics, Galderma, Genentech, Novartis, Warner Chilcott; O—Celtic Pharma, GlaxoSmithKline, Ligand, OMP, PharmDerm.

Ledger, William J., MD; A—Procter & Gamble; G—Merck, Talieda; H—Merck, Procter & Gamble; I—Merck, Talieda; SP—Merck.

Levin, Nikki A., MD, PhD; G—Amgen; I—Amgen.

M

Maize, Jr. John C., MD; E—DermPath Diagnostics; S—DermPath Diagnostics.

Makkar, Hanspaul, MD; no financial relationships exist with commercial interests.

Malvey, Joseph, MD; O—Taylor & Francis; R—Taylor & Francis.

Manolidis, Spiros, MD; no financial relationships exist with commercial interests.

Marks, Jr., James Garfield, MD; no financial relationships exist with commercial interests.

Marks, Victor J., MD; H—Connectics; SP—Connectics.

Marmur, Ellen S., MD; G—Bioform; H—Bioform, Obagi; SP—Obagi.

Martin, Howard, MD; E—Ameripath; S—Ameripath.

Matarasso, Seth L., MD; C—Allergan, Medicis; H—Allergan, Medicis.

McBurney, Elizabeth I., MD; no financial relationships exist with commercial interests.

McDonnell, Jonelle K., MD; G—EISAI/Ligand; H—Abbott, Amgen; I—Amgen, Curagen; NC—Curagen; RF—EISAI/Ligand; SP—Amgen.

Miller, Christopher J., MD; no financial relationships exist with commercial interests.

Miller, Jeffrey J., MD; C—Pfizer; G—Pfizer; H—Pfizer; SP—Pfizer.

Miller, III O. Fred, MD; A—Dr. Scholls; H—Dr. Scholls.

Moore, Angela Yen, MD; A—3M Graceway, Abbott, Amgen, Centocor, Dermik, Galderma, Genentech, Medicis, Novartis, Steifel, Warner Chilcott; G—3M Graceway, Allergan, Amgen, Astellas, Collagenex, Galderma, Glaxo Smith Kline, Medicis, Novartis, Warner Chilcott; H—3M Graceway, Abbott, Allergan, Amgen, Astellas, Centocor, Dermik, Galderma, Genentech, Glaxo Smith Kline, Healthpoint, Medicis, Novartis, Steifel; I—3M Graceway, Allergan, Amgen, Astellas, Collagenex, Galderma, Glaxo Smith Kline, Medicis, Novartis; SP—3M Graceway, Abbott, Allergan, Amgen, Astellas, Centocor, Collagenex, Dermik, Galderma, Genentech, Glaxo Smith Kline, Healthpoint, Medicis, Novartis, Steifel, Warner Chilcott.

Mowad, Christen M., MD; I—Amgen.

Moy, Ronald L., MD; A—Rhytec; ST—Rhytec.

Mugalian, Ruth H.; no financial relationships exist with commercial interests.

N

Narins, Rhoda S., MD; A—Artes, Bioform, Medicis, Merz; C—Artes, Bioform, Medicis, Merz; H—Bioform; I—Colbar, Contura, FzioMed, Genzyme, Medicis, Merz; OB—Artes, Bioform, Colbar, Contura, FzioMed, Genzyme, Medicis, Merz; SO—Bioform; ST—Artes, Bioform.

Naylor, Mark F., MD; H—3Gen; SP—3Gen.

Nguyen, Keoni, DO; no financial relationships exist with commercial interests.

Northington, Marian E., MD; H—Bioform, Reliant; SP—Bioform, Reliant.

Nouri, Keyvan, MD; G—3M; H—Dermik; I—3M; O—Candela, Cure Light Lasers, Cynosure, Dermik; OB—Candela, Cure Light Laser, Cynosure.

Nousari, Carlos H., MD; no financial relationships exist with commercial interests.

O

- O'Donoghue**, Marianne N., MD; H—Galderma; SP—Galderma.
- Olsen**, Elise, MD; C—AstroZeneca, Biocryst, GlaxoSmithKline, Ligand, Merck, Neosil, Pfizer; G—Biocryst, GenMab, Ligand, Merck, Pfizer, Proctor & Gamble, Yaupon; H—AstroZeneca, Biocryst, GlaxoSmithKline, Ligand, Merck, Neosil, Pfizer; I—Biocryst, GenMab, Ligand, Merck, Proctor & Gamble, Yaupon; RF—Pfizer; SH—Genentech, Merck, Pfizer; SP—Ligand, Merck; ST—Genentech, Merck, Pfizer.
- Orentreich**, David S., MD; B—Orentreich Foundation for the Advancement of Science Inc.; C—Clinique; NC—Orentreich Foundation for the Advancement of Science Inc.; OB—Clinique.
- Orlow**, Seth J., MD, PhD; A—Astellas, Graceway Pharmaceuticals, Novartis; H—Astellas, Dermik, Graceway Pharmaceuticals, Novartis, Ranbaxy; SP—Astellas, Dermik, Novartis, Ranbaxy.

P

- Pride**, Howard B., MD; no financial relationships exist with commercial interests.
- Phelps**, Robert G., MD; no financial relationships exist with commercial interests.
- Puig**, Susana, MD; O—Taylor & Francis; R—Taylor & Francis.

R

- Rao**, Babar K., MD; no financial relationships exist with commercial interests.
- Ratner**, Desiree, MD; no financial relationships exist with commercial interests.
- Rich**, Phoebe, MD; A—3M; Abbott, Amgen, Bradley Pharmaceuticals, Centocor, Doak Dermatologists, Genentech, Merz, Novartis, Schering-Plough, Steifel, Warner-Chilcott; I—3M, Altana, Amgen, Antigenics, Barrier, Berlex/Intendis, Bertec, Bravarian Nordic, Centocor, Clay-Park Labs, Collagenex, Connectics, Covalent, Dermik, Dow Pharmaceuticals, DUSA, Galderma, Genentech, Glaxo-SmithKline, Hill Dermaceuticals, Johnson & Johnson, Medicis, Merz, Myan, Neutrogena, Novartis, Novartis Consumer Health, Park Davis, Pfizer, Pharmacia & Upjohn, Photocure, Regeneratio Pharma AG, Roche, Schering-Plough, Steifel, Symbio, Warner-Lambert, Watson Laboratories, Xoma.
- Richard**, Gabriele, MD; E—BioReference Laboratories, Inc.; Gene Dx, Inc.
- Roberts**, Wendy E., MD; A—Clarisonic, Steifel; C—Isolagen; H—Dermik, Ortho Neutrogena, Steifel; S—Isolagen; SP—Dermik, Ortho Neutrogena; ST—Clarisonic.
- Robinson-Bostom**, Leslie, MD; no financial relationships exist with commercial interests.
- Rokhsar**, Cameron K., MD; H—Bioform, Reliant; SP—Bioform, Reliant.
- Rosen**, Robert, MD; C—Allergan, Galderma, Gene Pharm, Peplin; H—Peplin; I—Allergan, Galderma, Peplin; NC—Allergan, Galderma, Gene Pharm; SP—Peplin.
- Rosen**, Theodore, MD; S—Amgen, Centacor, Collagenex, Genentech, GlaxoSmithKline, 3M Graceway.
- Rubin**, Adam, MD; no financial relationships exist with commercial interests.

S

- Sadick**, Neil S., MD; A—Dior; B—Radiancy; C—Bioform, Diomed, Syneron; EQ—CoolTouch, Syneron; H—Dermik, Diomed, PhotOapeutics, Syneron; I—CoolTouch, Dermik, Syneron; O—Dior, PhotOapeutics, Radiancy; SO—Bioform.
- Sami**, Naveed, MD; I—Genentech; NC—Genentech.
- Sanchez**, Miguel R., MD; no financial relationships exist with commercial interests.
- Sanguenza**, Omar P., MD; no financial relationships exist with commercial interests.
- Schaffer**, Julie V., MD; no financial relationships exist with commercial interests.
- Scher**, Richard K., MD; A—Abbott, Avacor, Brovail, Dr. Reddy, Galderma, GSK, Merz, Novartis, Ortho-Neutrogena, Steifel; C—Abbott, Avacor, Barrier, Del Labs, Dr. Reddy, MacroChem, Merz, Novartis, QLT, Wave-Rx; G—Abbott, Allergan, Avacor, Barrier, MacroChem, Merz, Novartis; H—Abbott, Avacor, Barrier, Brovail, Del Labs, DOAK, Dr. Reddy, Galderma, GSK, MacroChem, Medicis, Merz, Novartis, Ortho-Neutrogena, QLT, Steifel, WaveRx; I—Abbott, Allergan, Avacor, Barrier, DOAK, MacroChem, Merz, Novartis; S—DOAK; SP—Abbott, Galderma, Medicis, Novartis, Ortho-Neutrogena.
- Schwartz**, Robert A., MD; no financial relationships exist with commercial interests.
- Schwarzenberger**, Kathryn, MD; no financial relationships exist with commercial interests.
- Seykora**, John T., MD; C—Merck; S—Merck.
- Shama**, Steven Kenneth, MD; H—Connetics, Dermik Labs, Steifel; SP—Connetics, Dermik Labs, Steifel.
- Shapiro**, Jerry, MD; C—Johnson & Johnson, Pfizer, Shire; H—Johnson & Johnson, Pfizer, Shire.
- Shapiro**, Richard L., MD; no financial relationships exist with commercial interests.
- Shear**, Neil, MD; A—Galderma; C—Astellas, Galderma, Glaxo, Leo, Oscient, Novartis; H—Astellas, Galderma, Glaxo, Leo, Novartis, Oscient; O—Abbott, Amgen, Astellas, Dermik, Leo; RF—Abbott, Amgen, Astellas, Leo.
- Siegel**, Daniel M., MD; A—Photomedex, Ratio LLC; B—Ratio LLC; C—Connectics, EOS, Galderma, Hamilton Beach, Steifel, Teikoku, Telederm Solutions, Valeant; H—Collagenix, Connectics, Galderma, Hamilton Beach, Teikoku, Steifel, Valeant; NC—Ratio LLC; S—Collagenix; SH—Ratio LLC; SO—EOS, Photomedex, Telederm Solutions.
- Smith**, Barry L., MD; H—Ferndale Laboratories, Inc.; SP—Ferndale Laboratories, Inc.
- Smith**, Molly, MD; no financial relationships exist with commercial interests.
- Spencer**, James M., MD; C—L'Oreal, Neutrogena; H—L'Oreal, Neutrogena.
- St. John**, Vernell; no financial relationships exist with commercial interests.
- Stanley**, John Roger, MD; no financial relationships exist with commercial interests.
- Stein**, Linda F., MD; C—Novartis, Steifel, Warner Chilcott; H—Galderma, Novartis, Steifel, Warner Chilcott; I—Galderma; SP—Galderma.

Sternberg, Esther M., MD; A—Academy of Architecture for Neuroscience, Sister-to-Sister Everyone has a Heart Foundation; NC—Academy of Architecture for Neuroscience, Sister-to-Sister Everyone has a Heart Foundation.

Stone, Stephen P., MD; A—Amgen, Basilia, Genentech, Pharmaderm; C—Biovail Corp., Bradley Pharm, Proctor & Gamble, Warner Chilcott; G—Abbott, Amgen; H—Amgen, Basilia, Biovail Corp., Bradley Pharm, Genentech, Pharmaderm, Proctor & Gamble, Warner Chilcott; I—Abbott, Amgen; O—Johnson & Johnson; NC—Accuderm, Medicis; SH—Accuderm, Johnson & Johnson, Medicis; SP—Warner Chilcott.

Stratman, Erik J., MD; no financial relationships exist with commercial interests.

Strober, Bruce E., MD; A—Abbott, Amgen, Astellas, Centocor, Genentech, Genzyme, Novo Hordisk, Roche; H—Abbott, Amgen, Astellas, Centocor, Genentech, Genzyme, Novo Hordisk, Roche; I—Abbott, Amgen, Astellas, Centocor, Genentech, Roche; G—Abbott, Amgen; RF—Abbott, Amgen; SP—Abbott, Amgen, Astellas, Genentech.

T

Taback, Bret, MD; NC—Columbia Presbyterian; SP—Columbia Presbyterian.

Tamburro, Joan, DO; no financial relationships exist with commercial interests.

Taylor, Susan C., MD; A—Barrier Therapeutics, Biersdorf, Dermik, Galderma, Johnson and Johnson, Medicis, Procter & Gamble, Steifel; EQ—Palomar; F—T2 Skincare LLC; G—Aczone, Amgen, Atrix, Barrier Therapeutics, Biersdorf, Doak, Galderma, Genzyme, Medicis, Johnson & Johnson, Leo Pharmacy, Steifel, Teva; H—Allergan, Barrier Therapeutics, Biersdorf, Dermik, Doak, Galderma, Johnson and Johnson, Medicis, Novartis, Procter & Gamble, Steifel; I—Aczone, Amgen, Atrix, Barrier Therapeutics, Biersdorf, Doak, Galderma, Genzyme, Johnson & Johnson, Leo Pharmacy, Medicis, Palomar, Steifel, Teva; OB—T2 Skincare LLC; SP—Allergan, Barrier Therapeutics, Dermik, Galderma, Johnson & Johnson, Medicis, Novartis.

Telang, Gladys H., MD; no financial relationships exist with commercial interests.

Theos, Amy J., MD; G—Amgen, RegeneRx; H—Astellas, Novartis; I—Amgen, RegeneRx; SP—Astellas, Novartis.

Thiers, Bruce Harris, MD; no financial relationships exist with commercial interests.

Tomecki, Kenneth J., MD; SH—Abbott Labs, Medtronic.

Tsao, Hensin, MD, PhD; G—Schering; O—Schering.

Tyring, Stephen K., MD, PhD; A—Abbott, Amgen, Catalyst, Doak, Graceway, GSK, Leo, Merck, Novartis; C—Abbot, Amgen, Catalyst, Doak, Graceway, GSK, Merck, Novartis; G—Abbott, Amgen, Catalyst, Graceway, GSK, Leo, Merck, Novartis; H—Abbott, Amgen, Catalyst, Doak, Graceway, GSK, Merck, Novartis; I—Abbott, Amgen, Catalyst, Graceway, GSK, Leo, Merck, Novartis; SP—Abbott, Amgen, Catalyst, Doak, Graceway, Leo.

W

Wagner, Leigh A.; no financial relationships exist with commercial interests.

Waldorf, Heidi A., MD; A—Unilever; C—Allergan; H—Allergan, Unilever; SP—Allergan.

Wang, Timothy S., MD; no financial relationships exist with commercial interests.

Warschaw, Karen, MD; no financial relationships exist with commercial interests.

Webster, Stephen Burtis, MD; no financial relationships exist with commercial interests.

Werschler, William P., MD; A—Allergan, BioForm, Clarisonic, Dermik, Johnson & Johnson, MyaScience; B—MyaScience; C—Allergan, Clarisonic, Dermik, MyaScience; G—Allergan, Amgen, Dermik, Galderma, Genentech, Johnson & Johnson; H—Allergan, BioForm, Dermik, Johnson & Johnson, Medicis; I—Allergan, Amgen, Dermik, Galderma, Genentech, Johnson & Johnson; OB—Clarisonic, MyaScience; SP—Allergan, BioForm, Dermik, Johnson & Johnson, Medicis.

Weinkle, Susan H., MD; A—Allergan, Bioform, Clarisonics, Dermik, Galderma, Ortho-Neutrogena; SP—Bioform, Ortho-Neutrogena, P&G.

Weinstock, Martin A., MD, PhD; C—Abbott, Schering-Plough; H—Abbott, Schering-Plough.

Winterfield, Laura S., MD; no financial relationships exist with commercial interests.

Wirtzer, Allan S., MD; C—Medicis; H—Allergan; NC—Medicis; SP—Allergan.

Y

Yan, Albert C., MD; A—Astellas, Graceway, Medicis, Novartis, Skin Medica, Steifel; C—Novartis; G—Astellas, Novartis; H—Astellas, Graceway, Medicis, Novartis, Skin Medica, Steifel; I—Astellas, Novartis.

Yosipovitch, Gil, MD; A—Acologix, Alza, Proctor & Gamble; G—Celgene, Steifel; H—Acologix, Alza, Proctor & Gamble; I—Celgene, Steifel.

Z

Zaenglein, Andrea L., MD; G—Astellas, Dow Pharmaceuticals; H—Galderma, Novartis; I—Astellas, Dow Pharmaceuticals; SP—Galderma, Novartis.

Zaladek, Iris, MD; no financial relationships exist with commercial interests.

Zalla, James A., MD; A—Caldeama, Inga Ellzey Practice Group, Intendis; B—Ratio Networks LLC; H—Caldeama, Connectics, Intendis; I—Derm Tech International; NC—Acuderm Inc., Derm Tech International, Inga Ellzey Practice Group, Ratio Networks LLC; O—Derm Tech International; OB—Derm Tech International; SH—Acuderm Inc., Derm Tech International, Ratio Networks LLC; SP—Intendis.

Zanolli, Michael D., MD; A—Abbott, Amgen; C—Amgen; H—Abbott, Amgen; I—Amgen, Centocor; SP—Abbott, Amgen.

Zone, John Joseph, MD; no financial relationships exist with commercial interests.

Zug, Kathryn A., MD; no financial relationships exist with commercial interests.

Jeffrey P. Callen, MD

DISCLOSURE (previous 12 months)

- Honorarium – Amgen**, Abbott*, and Stiefel*
- Consultant – EOS*, Amgen*, & Abbott*
- Safety Monitoring Committees – Genmab*
- Editorial Board – Archives of Dermatology**, Journal Watch Dermatology*, Journal of Rheumatology, Cutis, emedicine.com
- Stock – DUSA 172 shares

* Less than 10,000; ** 10-20,000/year

March 2007

In primary CMM, melanophages were highly enriched in hypermelanotic tumor regions. The same areas also stained intensely with LPHA, indicating that they were rich in β 1,6-branched oligosaccharides. Melanophages in the hypermelanotic regions of tumors were 10 to 100 times larger than were macrophages in less pigmented regions. Although melanophages were present only in hypermelanotic, LPHA-positive tumor areas, in some instances not all nests of melanoma cells in these regions were infiltrated with melanophages, the presence of which correlated with positive LPHA staining. There appeared to be two types of β 1,6-branched oligosaccharide-producing melanoma cells: one that attracted melanophages and was associated with better outcomes, and one that did not and had poorer outcomes. These findings suggest that LPHA-positive cases associated with a better outcome are those in which melanophage infiltration predominates, whereas cases having worse outcomes are those in which a lack of melanophage infiltration predominates.

Commentary

by Molly K. Smith, MD, Eastern Virginia Medical School

The authors point out in this article that cutaneous melanoma is one of a few cancers that evokes a strong immune response and can undergo spontaneous regression. Numerous studies in the past have looked at the role of lymphocytes in melanoma regression, but far fewer studies have evaluated the role of the macrophage. Macrophages are known to play both a positive and negative role in tumor progression in a variety of other malignancies. Macrophage density has been associated with a poor prognosis in several cancers, such as uveal melanoma, while other cancers associated with macrophage infiltration have revealed improved survival rates, such as with non-small cell lung carcinoma.

This group used LPHA staining to highlight the presence of sugars found on melanophages and hypermelanotic melanocytes. It was noted that hypermelanotic regions within the evaluated melanomas were rich in coarse-melanin-producing melanocytes and melanophages, both of which stained prominently with LPHA. Patients who had primary tumors with melanophages present had improved outcome at both 10-year and 20-year follow-ups. However, the use of LPHA stain intensity cannot be used alone as a marker for outcome, as it also highlights some of the melanin-producing, invasive melanocytes. This study provides us with the knowledge that macrophages likely play a significant role in the immune response to cutaneous melanomas and highlights the need for more research into the area.

Further Study:

Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. *J Pathol.* 2002;196:254-265.

Psoriatic arthritis

Subclinical Atherosclerosis Is More Frequent than Expected in Patients with Psoriatic Arthritis

Source: Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. *Arthritis Rheum.* 2007;57:1074-1080.

Dr. Garg has disclosed that he is an investigator for Centocor. He is involved with the Advisory Board for and has received honoraria from Abbott Immunology. This commentary does not contain discussion of a commercial product/device. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.

Objective: At the end of this activity, the general dermatologist will be able to recognize the possible association between the chronic inflammatory state in psoriatic arthritis and microvascular atherosclerosis.

Previous studies suggested that patients with psoriatic arthritis (PsA) have a higher mortality risk than the general population; that the risk is related to the severity of disease at presentation; and that — in some but not all studies — cardiovascular disease is a leading cause of death in PsA patients. This study, conducted at centers in Spain, examined the cardiovascular status of 59 patients who met the Moll and Wright criteria for PsA and the same number of healthy matched control patients. All patients had been treated at an outpatient rheumatology clinic for 12 months or longer. None of the participants had classical cardiovascular risk factors, and none were known to have experienced cardiovascular or cerebrovascular events. High-resolution B-mode ultrasonography was used to measure intima-media thickness (IMT) and visualize carotid plaque in the right common carotid artery.

Patients with PsA had greater carotid IMT than did matched control subjects. Carotid plaques were observed in 15% of the PsA group and 5% of control subjects, but this difference was not statistically significant. Age correlated positively and strongly with carotid IMT in patients with PsA. In addition, significant age-adjusted correlation was noted between carotid IMT and age at diagnosis of PsA, duration of disease, and total and low-density lipoprotein cholesterol levels. In contrast, no significant correlation was observed between carotid IMT and disease activity score (DAS), laboratory markers of inflammation, or the cumulative dose of corticosteroids. Compared to PsA patients lacking carotid plaque, those with plaque were older, had a marginally increased duration of disease at the time of study, and had greater carotid IMT.

Commentary

by Amit Garg, MD, University of Massachusetts Medical School

The recognition of PsA as an immunologically driven inflammatory disease forces us to consider the consequences of the chronic inflammation observed in psoriasis patients on tissues other than the skin and joints. While accelerated atherogenesis and increased cardiovascular mortality have been observed in other chronic inflammatory diseases like RA¹, assessment of these outcomes in PsA is just beginning to be investigated.

At referral centers, individuals with PsA have been shown to have an increased mortality rate compared to the general population, and cardiovascular disease was identified as one of the leading causes of death.^{2,3} Previously, the current authors demonstrated impaired endothelial function, which is seen among the earliest stages of atherosclerosis, in PsA patients without cardiovascular risk factors or events.⁴ In the present study, they demonstrated a significant increase in carotid IMT, a surrogate marker of generalized atherosclerosis and coronary artery disease, in patients with PsA who had no traditional cardiovascular risk factors or history of cardiovascular complication compared with healthy matched controls. After adjusting for age, carotid IMT correlated positively with age at PsA diagnosis, disease duration, total cholesterol, and low-density lipoprotein cholesterol. However, increased carotid IMT did not correlate significantly with joint activity. The authors did not take into consideration assessment of the skin as it may relate to carotid IMT. Carotid atherosclerotic plaques were more common in PsA patients, but not significantly so. Type II error was postulated as a reason for not approaching significance in this regard; however, it also may have been that mean PsA disease duration, 7.8 years in this study, was insufficient to achieve plaque formation.

This study provides further evidence for the presence of early subclinical atherosclerosis in patients with PsA. Evidence is mounting to suggest that PsA may be associated with cardiovascular morbidity and mortality, as is the case with RA. However, neither causality, nor putative mechanisms by which cardiovascular disease may be accelerated, has been established for PsA or RA. Nonetheless, improved characterization of cardiovascular disease in PsA may help identify high-risk individuals who would benefit from cardioprotective therapy. Future investigations may be directed toward critically evaluating a number of important clinical queries: 1) Is psoriatic arthritis associated with accelerated atherogenesis as manifested by plaque formation? 2) Does degree of skin or joint activity over time influence atherogenesis? 3) To what extent do independent cardiovascular risk factors alone influence rate of atherogenicity in PsA? 4) Do subclasses of PsA differ with respect to atherogenic potential? 5) To what extent does treatment of PsA influence atherosclerosis? 6)

Should consideration be given to adjusting normal lipid profile guidelines for PsA patients?

References:

1. Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. *J Rheumatol*. 2005;32:435-442.
2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis*. 2005;64 (Suppl 2):ii14-ii7.
3. Wong K, Gladman DD, Husted J, Long JA, Farwell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. *Arthritis Rheum*. 1997;40:1868-1872.
4. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. *Arthritis Rheum*. 2007;57:287-293.

Melanoma genetics

Genetic Studies in Mice Identify a Critical Tumor Suppressor

Source: Krimpenfort P, Ijpenberg A, Song J, et al. *P15^{Ink4b} is a critical tumour suppressor in the absence of p16^{Ink4a}*. *Nature*. 2007;448:943-946.

Dr. Leachman has disclosed no financial relationship relevant to this commentary. This commentary contains no discussion of a commercial product/device. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.

Objective: At the end of this activity, the physician will be able to recognize the three major tumor suppressors located at the major melanoma predisposition locus on chromosome 9p21.

It is common in cancer for the *CDKN2b-CDKN2a* locus on human chromosome 9p21 to be lost. This locus encodes three cell cycle inhibitory proteins: *p15^{INK4b}*, encoded by *CDKN2b*; *p16^{INK4a}*, encoded by *CDKN2a*; and *p14^{ARF}* (*p19^{Arf}* in mice), encoded by an alternative reading frame of *CDKN2a*. Tumor suppressor function has been clearly established for *p16^{INK4a}* and *p14^{ARF}*, but the role of *p15^{INK4b}* remains uncertain. Because many 9p21 deletions also remove *CDKN2b*, researchers from Amsterdam, The Netherlands, hypothesized a synergistic effect from combined deficiencies of all three inhibitory proteins. The effects of the additional loss of *p15^{INK4b}* on tumorigenesis were studied in two new mouse strains, one in which both *p15^{INK4b}* and *p16^{INK4a}* were inactivated (*Ink4ab^{-/-}*), and one deficient for all three cell cycle inhibitory proteins (*Cdkn2ab^{-/-}*).

Within 7 months, all *Cdkn2ab^{-/-}* mice had developed one or more tumors, the most prominent of which were

Attach an example of the mechanism(s) your organization uses to collect relevant financial relationship information of everyone in a position to control educational content.

Attached is a completed attestation form for a live activity and disclosure of conflict of interest forms for a live CME activity, an enduring material, and a committee member.

To review the online disclosure process:

- Go to www.aad.org
- Log into the members-only section (case sensitive user id: ACCME; password: AADWEB)
- Go to the member center/my account
- Click on disclosure form under Academy Member Tools

Attachment

Example of Mechanism Used to Collect Disclosures

PRINTED NAME: ARTHUR SOBER, MD

Thank you for reviewing the program development information, please indicate your acceptance and understanding of and willingness to comply with each statement below. **Please note that the acceptance is to be relevant to the lecture(s) given at the stated meeting and is not applicable to any other Academy function.**

If you have any questions regarding your ability to comply, please contact Molly Pierce, Program Development Coordinator, via phone at (847) 240-1679 or email at speakers@aad.org as soon as possible.

Please read each of the following below and initial:

☒ I agree to read and abide by the Guidelines for Program Development and the Policy to Ensure Independence in CME Activities.

☒ I have disclosed to the AAD my comprehensive conflicts of interest for my presentation(s). I will verbally disclose to the audience any relevant conflicts of interest at the onset of the presentation and include a disclosure slide at the start of my presentation. I understand that my comprehensive disclosure will be printed in the Annual Meeting Program Book.

☒ I understand that the AAD may need to review my presentation and/or content prior to the activity, and I will provide educational content and resources in advance as requested.

☒ I agree to ensure that speakers participating in this session properly disclose potential conflicts of interest, manage potential conflicts as per the Academy guidelines, and to also complete the On-Site Session Disclosure Verification Form following the session and return the form to the Academy office.

☒ I agree to remind the audience to disclose any conflicts of interest prior to asking a question during the Question & Answer portion of the session.

☒ I have not and will not accept any honoraria, additional payments or reimbursements beyond that which has been agreed upon directly with the AAD in relation to this meeting only.

☒ I understand that a formal observer may be attending the event to ensure that my presentation is educational, and not promotional, in nature.

☒ If I am providing recommendations involving clinical medicine, they will be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support of justification of a patient care recommendation will conform to the generally accepted standards of experimental design, data collection and analysis.

☒ If I am discussing specific health care products or services, I will use generic names to the extent possible. If I need to use trade names, I will use trade names from several companies when available, and not just trade names from any single company.

☒ If I am discussing a product use that is off label, I will disclose that the use or indication in question is not currently approved by the FDA for labeling or advertising.

☒ If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker's bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way in this activity.

☒ If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.

_____ I agree to provide handouts to the Academy office by the specified deadline of December 1, 2007, for production. I understand that all sessions are required to have handouts and all session handouts will be placed on the Academy web site 3 weeks prior to the meeting and placed on CD-ROM for distribution to all meeting attendees. I understand that handouts will not be distributed at the session room and reimbursement is not provided.

☒ I understand that the AAD will review the session's presentation(s) and/or content prior to the activity to ensure the Policy to Ensure Independence is being followed.

_____ I agree to read and abide by the Academy's Antitrust Compliance Policy.

☒ I understand that 35 mm projectors are no longer available in any session.

☒ I accept the invitation to direct the session at the 66th Annual Meeting. I have carefully read and considered each item on this form, and have completed it to the best of my ability. By accepting this invitation I also agree to meet all deadlines set forth by the Academy.

☒ **Yes**, I accept the invitation to participate at the 2008 Annual Meeting. I have carefully read and considered each item on this form, and have completed it to the best of my ability. By accepting this invitation I also agree to meet all deadlines set forth by the Academy.

Signature

Arthur J. Sober MD

Date

1/7/08

Printed Name

Arthur J. Sober

Please return to:
Molly Pierce, Program Development Coordinator
FAX: (847) 330-1135

2008 Annual Meeting

PROGRAM BOOK INFORMATION FORMS

Program Book Comprehensive Disclosure Form

Page 2 of 2

Fax (847) 330-1135

TYPE OF RELATIONSHIP:

A Advisory Board
 B Board of Directors
 C Consultant
 E Employee
 F Founder
 I Investigator
 O Other
 SP Speaker
 SH Stockholder

NATURE OF COMPENSATION:

EQ Equipment (dept or practice)
 G Grants
 H Honoraria
 IP Intellectual Property Rights
 NC No Compensation Received
 OB Other Financial Benefit
 R Royalty
 RF Residency or Fellowship Program Funding
 S Salary
 ST Stock
 SO Stock Options

Company Name	Type of Relationship [Abbreviation]	Nature of Compensation [Abbreviation]	Relevant to Presentation Content [If yes, indicate below]
EOS	C	OB	No

In addition to the above items, please describe any other special circumstances, such as (1) if your department or practice receives compensation that does not benefit you directly, or (2) if you have an agreement with a company not to disclose your interest.

ACKNOWLEDGEMENT: I have read and understood my disclosure obligations as outlined above.

Arthur J. Sober MM
 Signature

1/2/08
 Date

Arthur J. Sober
 Print Name

DERMCLIPS

Conflict of Interest Disclosure Statement – Feb 2008
(A separate form must be submitted by each author)

Please only disclose those conflicts relevant to the article below

I, **Maxwell A. Fung, MD** have submitted ***Perivascular Epithelioid Cell Tumor (PEComa): A Rare Tumor with Malignant Potential that Must be Distinguished from Melanoma*** for the February issue of the American Academy of Dermatology's **DERMCLIPS™**.

I hereby certify that, to the best of my knowledge, (1) neither the scientific work which is reported on in said article nor any other work of mine involving similar subject matter has received financial support from any pharmaceutical company or other commercial source except as described below within the past 12 months, and (2) neither I nor any first degree relative has any special financial interest in the subject matter discussed in said commentary, except as described below within the past 12 months. (I understand that an example of one type of such special financial interest would be ownership, by me or a first degree relative, of a company which sells a product relating to the subject matter of the commentary.)

If there are any exceptions to the above, please describe as instructed below. Use additional page(s) if space below is insufficient.

Industry Relationships. For you and your first degree relatives, please indicate on the grid below the type and nature of any industry relationships that you or they have had within the past year that may be relevant to the subject matter. Use the appropriate abbreviation for each type of relationship; for example, "C" if you were a consultant and "I" if you were an investigator. If you have no such relationships, please write "none" on the grid.

TYPE OF RELATIONSHIP:

A	Advisory Board
B	Board of Directors
C	Consultant
E	Employee
F	Founder
I	Investigator
O	Other
SP	Speaker
SH	Stockholder

NATURE OF COMPENSATION:

EQ	Equipment (dept or practice)
G	Grants
H	Honoraria
IP	Intellectual Property Rights
NC	No Compensation Received
OB	Other Financial Benefit
R	Royalty
RF	Residency or Fellowship Program Funding
S	Salary
ST	Stock
SO	Stock Options

Company Name	Type of Relationship [Abbreviation]	Nature of Compensation [Abbreviation]
NONE		

In addition to the above items, please describe any other special circumstances, such as (1) if your department or practice receives compensation that does not benefit you directly, or (2) if you have an agreement with a company not to disclose your interest.

A conflict of interest statement will be published prior to each article.

I hereby grant permission for any such information, or an appropriate summary thereof, to be published in DERMCLIPS.

Date

2/7/08

Signature

Maxwell A. Fung, MD

Printed Name



American Academy of Dermatology & Association Disclosure Statement of Potential Conflict of Interest

By an Officer; Director; Chair or Member of a Council, Committee or Task Force; Candidates for Office or for the Board of Directors; Editors of Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff Member I, Robert T. Brodell MD, FAAD , hereby acknowledge that, as a (indicate role(s) or potential roles(s)) in the Academy:

Annual Meeting Evaluation Task Force - Deputy Chair

Dermatopathology Task Force - Member

RosaceaNet Workgroup - Member

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with whom I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following:

Describe any exceptions. Use additional page(s) if space below is insufficient.

1. Industry Relationships.

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships with a value of over \$500 within the past 12 months. Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a value of over \$500 that company or organization has had

with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Allergan	Speaker	"H" - Honoraria
Janssen	Speaker	"H" - Honoraria
Pfizer	Speaker	"H" - Honoraria
Novartis	Speaker	"H" - Honoraria
Galderma	Speaker	"H" - Honoraria
3M	Speaker	"H" - Honoraria
Connetics	Advisory Board	"OB" - Other Financial Benefit
Glaxo	Speaker	"H" - Honoraria
Dermik	Speaker	"H" - Honoraria
Genentech	Speaker	"H" - Honoraria
Collagenix	Other	"H" - Honoraria
Pedinol	Speaker	"H" - Honoraria

In addition to the above items, please describe any other special circumstances, such as (1) if your department or practice receives compensation that does not benefit you directly, or (2) if you have an agreement with the company to not disclose your interest.

2. Boards/Officer of Public or Academic Organizations.

National Assembly of the American Cancer Society National Board of the American Cancer Society
 Society Cancer Action Network

3. Government Affiliation.

4. Dermatology Society Membership

5. Editor or Author of Non-Scientific Publications.

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.



GUIDELINES FOR PROGRAM DEVELOPMENT SPEAKER

68th Annual Meeting / March 5-9, 2010 / Miami, FL

The following guidelines have been developed by the Scientific Assembly Committee (SAC) to assist you in planning for your speaking engagement(s).

ABOUT THE ANNUAL MEETING

The American Academy of Dermatology takes great pride and puts forth extraordinary efforts to present an unparalleled CME program at its Annual Meeting. Several hundred speakers are asked to dedicate/donate their time and expertise in making this important meeting a valuable learning experience. Because of this, the meeting attracts over 17,000 attendees.

PROGRAM FORMAT

All Academy sessions must be designed to qualify for category 1 credit toward the AAD Continuing Medical Education (CME) Award. To meet the criteria for category 1 designation, a session should be planned, coordinated, administered and evaluated in terms of educational objectives. A specific level of knowledge or performance skill should be defined in the educational objective of the program.

SPEAKER DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The Scientific Assembly Committee (SAC) requires that meeting speakers comply with the Policy to Ensure Independence in Continuing Medical Education Activities. The following steps must be taken in order to comply for the Annual Meeting:

1. Session speakers must submit their comprehensive disclosure to the SAC for review and complete the Speaker Response & Attestation Form .
2. All comprehensive disclosures will be printed in the the Annual Meeting Program-at-a-Glance.
3. All speakers must include a disclosure slide listing their relevant disclosure and make a verbal disclosure at the beginning of their presentation.

SPEAKER PARTICIPATION IN INDEPENDENTLY-SPONSORED EDUCATIONAL SESSIONS

AAD Speakers are prohibited from participating as speakers in education sessions sponsored by an exhibiting, non-exhibiting, or continuing medical education company, 24 hours before or during (until 5:00pm Tuesday) the Annual Meeting, in the city/location where the AAD Annual Meeting is taking place. Physician member organizations may hold educational sessions during the 24 hours prior to the AAD Annual Meeting and after educational programming each day (after 5:00pm). Physician-member organizations are organizations whose membership is comprised primarily of physicians and programming is aimed at physicians versus other dermatologic personnel (ex.: administrators, nurses, physician assistants, etc.)

(Exceptions to this rule include the Industry Supported Symposia [please see the policy below] and the following organizations: American College of Mohs Micrographic Surgery & Cutaneous Oncology, American Contact Dermatitis Society, American Dermatological Association, American Society for Dermatologic Surgery, American Society of Dermatopathology, American Society for Mohs Surgery, Association of Military Dermatologists, Association of Professors of Dermatology, Council for Nail Disorders, Lymphoma Society, Medical Dermatology Society, Noah Worcester Dermatological Society, North American Contact Dermatitis Group, Photomedicine Society, Skin of Color Society, Society for Pediatric Dermatology, and Women's Dermatologic Society). Additional exceptions to the above list can be made by special request to the SAC Program Chair.

An Educational Session is any meeting that has a set agenda with speakers, has a list of invited attendees, and/or exceeds 50 participants. Exhibiting and Non-Exhibiting companies as well as Medical Education Companies may not hold educational sessions unless they are more than 24 hours before or after (may start at 5:00pm Tuesday) the AAD Annual Meeting. This policy pertains only to sessions held in the same city as the AAD Annual Meeting.

AAD Speakers may participate in workgroups, advisory boards, investigator meetings, or discussion groups with exhibiting or non-exhibiting companies during the AAD Annual Meeting; however, these

sessions must not have a set agenda with speakers, must not have a list of invited attendees, and must not exceed 25 participants. Sessions with greater than 25 participants must meet at the following times.

Wednesday, March 4, 2009	All Day
Thursday, March 5, 2009	After 6:00pm
Friday, March 6, 2009	Before 7:15am & After 7:00pm
Saturday, March 7, 2009	Before 7:15am & After 7:00pm
Sunday, March 8, 2009	Before 7:00am & After 7:00pm
Monday, March 9, 2009	Before 7:15am & After 5:30pm
Tuesday, March 10, 2009	Before 7:15am & After 5:00pm
Wednesday, March 11, 2009	All Day

AAD Speakers participation in the Academy's Annual Meeting is contingent upon compliance with this policy. AAD Speakers may participate as speakers in meetings at any other time throughout the year.

COMMERCIAL SUPPORT FOR SESSIONS/SPEAKERS

Meeting speakers are prohibited from obtaining commercial support for:

- Travel & Housing – Speakers cannot accept free or discounted travel expenses or reimbursement for travel expenses in order to participate as a speaker at the Annual Meeting.
- Honorarium –Speakers cannot accept an honorarium to participate as a speaker at the Annual Meeting.
- Session Equipment –Speakers cannot request equipment or materials for the session in which they are participating. All requests must be directed to the Academy which will then determine whether commercial support needs to be obtained and obtain the necessary commercial support.
- Receptions & Other Events Before/After Sessions –Speakers cannot obtain commercial support in order to host a reception before/after their session.

Requests for exceptions to this policy should be directed to the Education Department via fax at (847) 330-1135 or via e-mail to mpierce@aad.org.

REGISTRATION

Please note the registration policies for all speakers at the Annual Meeting:

- Members of the Academy must register and pay the appropriate registration fee.
- Non-member dermatologist speakers must register and pay the non-member registration fee.
- Non-member, non-dermatologist speakers who qualify for Affiliate Membership must register and pay the non-member registration fee. An Affiliate member is defined by the Academy Bylaws {please refer to Article III, Section 2(d)}.
- Non-member, non-dermatologists who qualify for Adjunct Membership must register and pay the appropriate registration fee as set by the AAD Secretary Treasurer. An Adjunct member is defined by the Academy Bylaws {please refer to Article III, Section 2(h)}.
- Non-member, non-dermatologist speakers who are affiliated with exhibiting companies must register and pay the non-member registration fee.
- Non-member, non-dermatologist speakers who do not qualify for membership must register but will receive waived registration fees.

CLASS LISTS

Class lists of registered attendees are available to session directors only. Speakers must request a copy of the class list through their session director.

HANDOUTS

Handouts are required for all sessions. Handouts will be placed on the Academy web site approximately two weeks prior to the meeting and placed on a CD-ROM for distribution to all attendees. Paper handouts will not be available on-site and reimbursement for handout reproduction is not permitted.

The Academy office will coordinate the production of the Handout web site and CD-ROM. The SAC recommends a limit of five pages double-sided (10 pages single-sided) per lecture.. Handouts may not be self-promotional in nature and must adhere to Academy policy regarding usage of trade names.

Handouts should be submitted to the Academy office for inclusion in the Handout CD-ROM by **mid - November**. An exact deadline will be sent in an email with submission instructions. Handouts received after the deadline will be placed on the Handout web site ONLY.

AUDIO VISUAL and ROOM SET-UP

Focus Session

AUDIO VISUAL NEW THIS YEAR YOU NO LONGER HAVE TO BRING YOUR LAPTOP. A COMPUTER WILL BE AVAILABLE IN EACH ROOM. BRING YOUR PRESENTATION ON A MEMORY STICK.

A computer, LCD projector, screen, lectern microphone, and laser pointer will be provided. An audio visual technician will be available for assistance. If your session requires any audio visual equipment that is not listed please email your request to aadmeetings@aad.org for consideration. Session directors are required to check-in at the speaker ready room at least four (4) hours prior to their presentation to ensure that their presentation is compatible with the audio visual equipment that will be in the session room.

35mm slide projectors are no longer available.

ROOM SET-UP

The meeting room will be set with maximum theater seating, a head table for one and a tabletop lectern.

Discussion Groups

AUDIO VISUAL NEW THIS YEAR YOU NO LONGER HAVE TO BRING YOUR LAPTOP. A COMPUTER WILL BE AVAILABLE IN EACH ROOM. BRING YOUR PRESENTATION ON A MEMORY STICK.

A computer, LCD projector, screen, lectern microphone, and laser pointer will be provided. An audio visual technician will be available for assistance. If your session requires any audio visual equipment that is not listed please email your request to aadmeetings@aad.org for consideration. Session directors are required to check-in at the speaker ready room at least four (4) hours prior to their presentation to ensure that their presentation is compatible with the audio visual equipment that will be in the session room.

35mm slide projectors are no longer available.

ROOM SET-UP

The meeting room will be set with maximum theater seating at a limit of 25 attendees, a head table for one, and a tabletop lectern.

Workshops

AUDIO VISUAL

An LCD projector, screen, lectern microphone, and laser pointer will be provided. An audio visual technician will be assigned to your room. If your session requires any audio visual equipment that is not listed please email your request to aadmeetings@aad.org for consideration. All speakers are required to submit their presentation via the Speaker Presentation Submission System. Each speaker will receive an email containing your user name and password about eight (8) weeks prior to the start of the Meeting. Session directors are required to check-in at the Speaker Ready Room at least four (4) hours prior to their presentation. 35mm slide projectors are no longer available.

ROOM SET

Workshop rooms will be set based on the nature of the session's activities. The Academy staff will determine the capacity and layout of the session room.

Courses, Forums, Symposiums

AUDIO VISUAL

An LCD projector, screen, lectern microphone, table microphones, aisle microphones, and laser pointer will be provided. An audio visual technician will be assigned to your room. If your session requires any audio visual equipment that is not listed please email your request to aadmeetings@aad.org for consideration. All speakers are required to submit their presentation via the Speaker Presentation Submission System. Each speaker will receive an email containing your user name and password about eight (8) weeks prior to the start of the Meeting. Session directors are required to check-in at the Speaker Ready Room at least four (4) hours prior to their presentation. 35mm slide projectors are no longer available.

ROOM SET-UP

The room will be set with maximum theater seating, a standing lectern with a microphone, a head table for four people with table microphones, and aisle microphones. The Academy staff will determine the capacity and layout of the session room.

USE OF TRADE NAMES

The SAC discourages the use of trade names unless required for an educational or clarifying purpose. The use of trade names should contain no advertising or product-group message. The use of generic names should be used whenever possible.

REPURPOSING MEETING MATERIAL

Under no circumstances can content and presentations from the Annual Meeting be reprinted or published outside the meeting unless specifically authorized by the Academy.

Annual Meeting Evaluation Task Force INFORMATION REPORT August 1, 2008

Conflict of Interest Definition

When individuals have a financial relationship with a commercial interest **and** the opportunity to affect the content of CME about the products or services of that commercial interest. When interests are aligned with those of a commercial interest the interests are in 'conflict' with the interests of the public.

The potential for increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. Commercial bias is prohibited in CME.

Commercial Bias Definition

ACCME defines commercial bias as a personal judgment in favor of a specific proprietary business interest of a commercial interest.

Perceived Commercial Bias

Detection of commercial bias in a presentation is often subjective. Attendees may perceive commercial bias when in fact, presenters have made recommendations based on evidence or have no relationship with the company that produces the product being discussed.

The top actions that are perceived as commercial bias according to an article published in *Journal of Continuing Education in the Health Professions* are:

Table 1 Top 10 Actions Perceived by Health Care Professionals (N = 212) as Commercial Bias

Action	Responses	
	No.	(%)
Focusing on 1 agent, device, or procedure when others exist	96	(74)
Not providing a balanced presentation of the benefits and adverse effects for all agents, methods, or procedures in an activity	86	(66)
Most of the faculty have relationships with the grantor sponsoring the activity	79	(63)
References to inappropriate studies (promotional, bad design, etc.)	73	(57)
Inconsistent use of brand names	72	(56)
Misleading title	77	(56)
Lack of appropriate scientific references	69	(53)
Misleading learning objectives	67	(52)
Misleading overview statement	65	(51)
Endorsement of a particular product or practice by a respected and well-known expert in the field	58	(46)

Source: *The Journal of Continuing Education in the Health Professions*, Vol. 26 No. 1, Winter 2006

The top actions that are perceived as personal opinion according to an article published in *Journal of Continuing Education in the Health Professions* are:

Table 2 Top 10 Actions Perceived by Health Care Professionals as Personal Opinion

Action	Responses	
	No.	(%)
Influence of mentors: eg, well-respected faculty that may teach based on their own practice biases	105	(86)
Cultural differences: eg, dietary habits associated with Mediterranean cultures	105	(86)
Relating general practice habits from the faculty member's own experience	101	(85)
Ethnic differences: eg, Pima Indian, Black, Hispanic, etc	99	(82)
Geographic differences: eg, back East, down in the South, etc	96	(80)
Case studies of patients who fall out of general practice habits	98	(80)
Enthusiasm or lack of enthusiasm on the part of the speaker for a particular product	90	(70)
Requirements imposed by medical institutions or organizations: eg, formularies, treatment protocols, etc	70	(58)
Generalized endorsement or negative statement without factual supporting references	71	(55)
Endorsement of a particular product or practice by a respected and well-known expert in the field	69	(54)

Source: *The Journal of Continuing Education in the Health Professions*, Vol. 26 No. 1, Winter 2006

To combat these perceptions directors and speakers should be:

- Educated about what triggers perceived commercial bias
- Provided instruction on methods to avoid perceived commercial bias
- Provided training on the differences between a promotional presentation and a certified-CME presentation

In addition, the audience also needs to be educated about what constitutes conflict of interest and commercial bias.

Plans are in place to develop a web-based director and faculty tutorial. A paper-based tutorial exists and is sent to directors and speaker who have evaluation data that indicate commercial bias was perceived.

Dermatology World and *Annual Meeting News* have been vehicles used to education the audience.

AAD Policy

Academy Speaker Guidelines for Program Development state:

The SAC discourages the use of trade names unless required for an educational or clarifying purpose. The use of trade names should contain no advertising or product-group message. The use of generic names should be used whenever possible.

Academy Policy to Ensure Independence in CME Activities state:

Presentations and related materials must be based on scientific methods generally accepted by the medical community. Presentations should be evidence-based and discuss the validity of the evidence upon which they base the opinion(s) (See Sackett et al, BMJ 1996;312:71-2). This ensures the audience that the recommendations are supported by the evidence and contributes to management of any potential conflicts of interest. Further, if the presentation includes discussion of unlabeled or investigational use of a commercial product, this also must be disclosed to the participants.

CME must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If CME educational material or content includes trade names, trade names from several companies should be used where available, as opposed to using trade names from just a single company. Educational materials such as slides, abstracts, and handouts cannot contain any advertising or product-group messages.

AAD Procedures

Directors and speakers are advised in writing of Academy policy. They are required to complete the attestation form that indicates an agreement to:

- Read and abide by the and the Speaker Guidelines for Program Development Policy to Ensure Independence in CME Activities
- Disclose to the AAD my comprehensive conflicts of interest for my presentation(s) and verbally disclose to the audience any relevant conflicts of interest at the onset of the presentation
- Understand that the AAD may need to review my presentation and/or content prior to the activity, and agreeing to provide educational content and resources in advance as requested
- Not accept any honoraria, additional payments or reimbursements
- Understand that a professional expert evaluation reviewer may be attending the event to ensure that my presentation is educational, and not promotional, in nature.
- Provide recommendations involving clinical medicine, they will be based on evidence that is accepted within the profession of medicine
- Use generic names to the extent possible. If I need to use trade names, I will use trade names from several companies when available, and not just trade names from any single company.
- To not include in the presentation promotional aspects for any commercial interest
- To present information based on generally accepted scientific principles and methods, and will not promote a commercial interest

It is important to note that ACCME requires the CME provider (AAD) to resolve conflicts of interest. Disclosure of financial relationships does not satisfy this requirement.

Directors are also instructed that part of their responsibility is manage and resolve conflicts for any speakers in their session.

Monitoring of compliance is managed through analysis of evaluation data and PEER member reports. Letters are sent to the session director if evaluation data show that 15% more of the attendees perceived commercial bias. A speaker will also receive a letter if specifically mentioned in the comments. PEER reports are review when available to determine if the review supported the attendee perceptions.

Speakers who have 3 or more evaluation reports indicating commercial bias are asked to submit their presentation slides in advance for review. This is not meant to penalize the speaker, but rather is meant to assist with determining the root of the complaint and providing guidance of how to avoid these perceptions in the future.

2008 Annual Meeting Results

Number of letters sent notifying them that the audience perceived commercial bias	25
Number of individuals sent letters (some individuals had multiple notices)	22
Number of individuals agreeing with the audience	10
Number of individuals disagreeing with the audience	9
No reply	3

Two speakers met the criteria for a slide review, one of which was scheduled to speak at the Summer Academy Meeting. Upon request, the individual refused to submit the slides. The speaker felt the because all presentations were not reviewed, this process was discriminatory.



Approved: Board of Directors – 6/18/88
 Revised: Board of Directors – 2/27/98
 Revised: Board of Directors – 3/19/99
 Revised: Board of Directors – 5/20/06
 Revised: Board of Directors – 02/3/07
 Revised: Board of Directors – 4/21/07

ADMINISTRATIVE REGULATION

POLICY AND PROCEDURES REGARDING ACTUAL OR POTENTIAL CONFLICTS OF INTEREST

In order for the Academy to operate most effectively to further the purposes for which it is organized, it is important that Academy decisions and actions not be unduly influenced by any special interests of individual members. Therefore, it has always been and continues to be important to identify actual or potential conflicts of interest which might improperly affect Academy activities. As the professional, business and personal settings and relationships in which Academy members play significant roles become increasingly varied and complex, informal means of identifying actual or potential conflicts of interest become increasingly inadequate. Therefore, a formal system for the disclosure and evaluation of possible conflicts of interest has been adopted by the Board of Directors of the Academy. Set forth below is a description of the principal features of that system.

Possible Conflicts of Interest

1. Interests which may affect significant economic transactions to which the Academy is or may be a direct party. An example would be ownership by an Academy officer of a company from which the Academy makes major purchases of goods or services.
2. Interests which might cause a representative of the Academy to abuse an Academy position in order to achieve objectives which are inconsistent with the purposes of the Academy. An example of such abuse would be a council or committee chairman taking advantage of that position to damage unfairly the commercial standing of a company competing with a company in which the chairman had a personal financial interest.
3. Interests which do not relate directly to an interest of the Academy as an organization but bear significantly on issues of importance to the Academy membership and about which different components of the Academy membership might hold widely differing views. An example would be the interests associated with a member being employed by a government agency, which interests would very likely affect that member's position on a proposed assessment for a campaign on behalf of direct access.

In many cases, disclosure of the conflicting or potentially conflicting interest will itself suffice to protect the integrity of Academy operations. In other words, once such an interest is fully disclosed to the other participants in any related Academy activity, those other participants will generally be able to evaluate and adjust for the possible influence of the disclosed interest. However, it is important to bear in mind that in certain situations adequate protection of the interests of the Academy may require scrupulous avoidance of even the appearance of conflict of interest, abuse or impropriety. In those situations where mere disclosure does not appear adequate to deal with actual or potential problems, additional action may be necessary, and the subject of enforcement is addressed in greater detail below.

Administrative Regulations on Conflict of Interest Disclosure

Disclosure Process

1. Identifying possible conflicts of interest by individuals occupying leadership positions. The individuals covered by this procedure are the officers, all other members of the Board of Directors, the editors of *Journal of American Academy of Dermatology (JAAD)* (including associate and assistant editors), all chairmen and members of councils, committees and task forces, and senior staff. Each fall, the individuals covered will be required to sign and submit a disclosure statement acknowledging a duty to serve the Academy in good faith and with undivided loyalty. These individuals are to describe all personal or professional circumstances which might create a private interest in conflict with the interests of the Academy. Accompanying this policy statement as Exhibit A is a sample copy of such a disclosure statement.

Members who do not submit a yearly conflict of interest disclosure, may lose the right to hold office and, except in unusual circumstances approved in advance by the Board of Directors, to participate in Academy programs as a faculty member, presenter, or scientific exhibit contributor, or participate on a council, committee or task force.

Review Process

1. Officers, directors, chairmen and members of councils, committees, and task forces, the editors of *JAAD* and senior staff will submit their statements directly to the Secretary-Treasurer in care of the Academy office.
2. The statements from committee and task force chairmen and members will be forwarded to their appropriate council chairmen to review. If necessary, the chairmen will forward those that appear to have conflicts which could prevent them from serving to the Secretary-Treasurer with any relevant observations or recommendations.
3. The Secretary-Treasurer will review the statements submitted by the council chairs and those for council chairs, officers, the editor of *JAAD* and senior staff that require further review will be forwarded to the Ethics Committee by the Secretary-Treasurer, while at the same time informing the Board of Directors of any conflicts that appear especially significant.
4. The Ethics Committee will review and initiate any request for further information and promptly prepare a report to the Secretary-Treasurer regarding its findings. The Secretary-Treasurer will report to the Board of Directors on any items found by the Committee to be of special significance.

All disclosure statements will be retained at the Academy headquarters office. They will be available electronically for review by members of the Board of Directors and staff, and upon request by Academy members. They will be available to the council, committee and task force members to review prior to all conference calls and meetings. All members filing an annual disclosure statement will be obligated to make a prompt written report to the Secretary-Treasurer regarding any change in circumstances which might give rise to an actual or potential conflict of interest. Chairmen of councils, committee and task forces are required to make a statement in the summation reports of any conflict of interests that have been expressed by a member during a meeting or conference call.

Members also should verbally disclose and update their conflict of interest form for any relevant conflicts that may occur during a conference call or meeting that do not already appear on the disclosure form.

Administrative Regulations on Conflict of Interest Disclosure

As noted above, some situations involving actual or potential conflicts of interest may call for action beyond disclosure. However, no special enforcement rules or procedures have been adopted with respect to conflicts of interest. Rather, the basic authority and procedures established by corporate law and the bylaws of the Academy will be available to deal with any substantial conflict of interest problems. For example, the normal disciplinary standards and procedures described in Sections 7 and 8 of Article IV of the Academy bylaws can be invoked to discipline any member whose conflict of interest produces a violation of those standards. As another example, council, committee and task force chairmen, all of whom serve by virtue of approval by the Board of Directors, are subject to removal by the Board if a particular conflict of interest is deemed sufficiently serious. Similarly, senior staff members are subject to the direction of, and possible removal by, the Board of Directors. As to the officers and directors themselves, they continue to be subject to basic legal constraints arising out of the fiduciary nature of their relationships with the Academy, and in appropriate circumstances the Board of Directors can deal with misconduct in office or court intervention can be sought.

2. Standing Rule Regarding Disclosure of Interests by Participants in Debate at an Academy Membership Meeting. Accompanying this policy statement as Exhibit B is a copy of this standing rule. As suggested by the terms of the rule, its basic purpose is to inform the audience of aspects of a speaker's personal or professional circumstances which might affect significantly the speaker's attitude or judgment regarding the particular matter under consideration. Written notice of this rule is to be included with membership meeting notices, and the rule is also to be announced at each meeting by the presiding officer.

3. Standing Rule Regarding Disclosure of Interests by Speakers at Academy Scientific Sessions. Accompanying this policy statement as Exhibit C is a copy of that rule. As in the case of the rule regarding disclosure during debate at a business meeting of the Academy membership, this rule is intended to bring possible bias to the attention of the audience so that the members of the audience can evaluate the program content accordingly. Written notice of this rule is to be sent to the directors of, and prospective speakers at, symposia and other scientific programs, and the directors are to announce the rule at each scientific session.

4. Journal of the American Academy of Dermatology (JAAD) Conflict of Interest Statement. This is very similar to the third point in that it involves, for the most part, disclosure of potential sources of bias which might affect the presentation of scientific analysis or opinion. It relates to disclosure of certain types of interests by the authors of manuscripts submitted for possible publication in *JAAD*. The primary areas of concern are (1) financial support from pharmaceutical companies or other commercial sources for research which is the subject of a *JAAD* manuscript and (2) financial interests on the part of authors in any products or services related to the subject matter of a *JAAD* manuscript. Accompanying this policy statement as Exhibit D is a sample copy of a disclosure statement to be signed by each author of a manuscript submitted to *JAAD*. Disclosure of any potential conflict will alert the editors to the possibility of bias in the presentation, and it might also be appropriate in certain circumstances to publish information about the disclosed interest with the article in question so that each reader will have an opportunity to evaluate and adjust for the possible bias.

Because proper disclosure by each individual author, speaker or Academy leader is essential if the system is to function satisfactorily, it is important for everyone involved to approach with the proper perspective the question of what types of circumstances call for disclosure. The purpose of the procedures is not to discourage all involvement by Academy members in outside activities which might produce actual or potential conflicts with interests of the Academy. Neither is the objective to intrude into aspects of an individual's professional or personal life which are, realistically, unlikely to have any significant bearing on Academy activities. Common sense should guide all decisions about what to disclose, and one reasonable test is whether a particular circumstance, interest or relationship, if made known to the full membership of the Academy or to the general public, would be likely to cause embarrassment for the Academy and/or the individual involved or evoke suspicion about the motives behind any Academy action.*

Administrative Regulations on Conflict of Interest Disclosure

Exhibit A



Physicians Dedicated to
Excellence in Dermatology™

American Academy of Dermatology & Association **Disclosure Statement of Potential Conflict of Interest**

I, _____, hereby acknowledge that, I am currently serving as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the *Journal of the American Academy of Dermatology* or *Dialogues in Dermatology*; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with whom I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following:

Describe any exceptions. Use additional page(s) if space below is insufficient.

1. **Industry Relationships.** For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships with a value of over \$500 within the past 12 months and that raise a potential conflict of interest. Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a value of over \$500 that company or organization has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Administrative Regulations on Conflict of Interest Disclosure

TYPE OF RELATIONSHIP:

A Advisory Board
 B Board of Directors
 C Consultant
 E Employee
 F Founder
 I Investigator
 O Other
 SP Speaker
 SH Stockholder

NATURE OF COMPENSATION:

EQ Equipment (dept or practice)
 G Grants
 H Honoraria
 IP Intellectual Property Rights
 NC No Compensation Received
 OB Other Financial Benefit
 R Royalty
 RF Residency or Fellowship Program Funding
 S Salary
 ST Stock
 SO Stock Options

Company Name	Type of Relationship [Abbreviation]	Nature of Compensation [Abbreviation]

Company Name	Type of Relationship [Abbreviation]	Nature of Compensation [Abbreviation]

In addition to the above items, please describe any other special circumstances, such as (1) if your department or practice receives compensation (refer to the Nature of Compensation list above) that does not benefit you directly, or (2) if you have an agreement with the company to not disclose your interest.

2. **Boards/Officer of Public or Academic Organizations.** *Examples: Trustee, American Board of Dermatology; Officer, Alternative Delivery System Corp.*

Administrative Regulations on Conflict of Interest Disclosure

3. **Government Affiliation.** *Examples: Consultant, FDA or National Library of Medicine; Research Review Committee for Applications of Computers in Medicine.*
4. **Dermatology Society Membership** *(officer, director, member or chair of a committee).*
5. **Editor or Author of Non-Scientific Publications.** *Examples: Assistant Editor, Journal of Dermatology Marketing and Practice Management; Author, Cosmetics for the Lay Person.*

My principal professional activities relating to dermatology are conducted in the following setting(s):
Example: Private practice, Indianapolis, IN; Adjunct Associate Professor, Department of Dermatology, Indiana University.

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest to the best of my knowledge that this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

Signature

Date

Printed Name

Administrative Regulations on Conflict of Interest Disclosure

Exhibit B

Standing Rule Regarding Disclosure of Interests by Participants in Debate at an Academy Membership Meeting

In order for the members in attendance at an Academy membership meeting to evaluate properly statements and arguments presented during debate, it is important that the members be informed of any aspect of a speaker's personal or professional circumstances which might affect significantly the speaker's attitude or judgment regarding the particular matter under consideration. Therefore, during any debate at a membership meeting, the presiding officer will ask each speaker participating in the discussion of a particular issue to introduce himself or herself by name and professional position and to identify any aspect of the speaker's personal or professional circumstances which might reasonably be expected to affect significantly the speaker's views on the subject under discussion. Any member who refuses to provide such information will be denied the opportunity to address the membership during the debate on that particular issue.

Administrative Regulations on Conflict of Interest Disclosure

Exhibit C

Standing Rule Regarding Disclosure of Interests by Speakers at An Academy Scientific Session

In order for the audience at an Academy scientific session to evaluate properly information, analysis and opinions presented during the session, it is important that the audience be informed of any aspect of a speaker's personal or professional circumstances which might affect significantly the speaker's attitude or judgment regarding the particular matter under consideration. Therefore, during any presentation or discussion at a scientific session, the director will ask each speaker participating in the discussion of a particular issue to introduce himself or herself by name and professional position and to identify any aspect of the speaker's personal or professional circumstances which might reasonably be expected to affect significantly the speaker's views on the subject under discussion. Any individual who refuses to provide such information or has been found to violate the Academy's Policy to Ensure Independence in Continuing Medical Education will be denied the opportunity to speak.

Circumstances calling for disclosure would include, but not be limited to:

Industry Relationships. The speaker must indicate the type of relationship and the nature of any industry relationships that he/she and their first degree relatives have had within the past 12 months relative to the presentation's subject matter in all disclosure forms, which must be submitted by the indicated due dates as a condition of participation. Also the same information for any company or foundation in which the speaker or any first degree relative has an interest should be indicated. See attached representative disclosure form.

Disclosures must then be verbally presented, with any updates, prior to the presentation. If there are no such relationships, that must also be communicated verbally to the audience prior to the presentation.

Administrative Regulations on Conflict of Interest Disclosure

Scientific Assembly Committee
Comprehensive Disclosure Form

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure.

All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations.

The comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. Any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services must be disclosed regardless of whether it will be discussed in a presentation. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following:

Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships. For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships that you have had within the past 12 months and that raise a potential conflict of interest. Also for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationship that company or organization has had with industry within the past twelve months. Use the appropriate abbreviation and one line for each type of relationship; for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally prior to your presentation. If you have no such relationships, please write in "none."

TYPE OF RELATIONSHIP:

A	Advisory Board
B	Board of Directors
C	Consultant
E	Employee
F	Founder
I	Investigator
O	Other
SP	Speaker
SH	Stockholder

NATURE OF COMPENSATION:

EQ	Equipment (dept or practice)
G	Grants
H	Honoraria
IP	Intellectual Property Rights
NC	No Compensation Received
OB	Other Financial Benefit
R	Royalty
RF	Residency or Fellowship Program Funding
S	Salary
ST	Stock
SO	Stock Options

Administrative Regulations on Conflict of Interest Disclosure

Company Name	Type of Relationship [Abbreviation]	Nature of Compensation [Abbreviation]	Relevant to Presentation Content [If yes, indicate below]

In addition to the above items, please describe any other special circumstances, such as (1) if your department or practice receives compensation (refer to the Nature of Compensation list above) that does not benefit you directly, or (2) if you have an agreement with a company not to disclose your interest.

ACKNOWLEDGEMENT: I have read and understood my disclosure obligations as outlined above.

Signature

Date

Print Name

Administrative Regulations on Conflict of Interest Disclosure

Exhibit D



**Physicians Dedicated to
Excellence in Dermatology™**

Journal of the American Academy of Dermatology
Authors' Conflict of Interest Disclosure Statement
(A separate form must be submitted by each author)

I, _____, have submitted for consideration for possible publication in the *Journal of the American Academy of Dermatology (JAAD)* a manuscript entitled

I hereby certify that, to the best of my knowledge, (1) the work which is reported on in said manuscript has not received financial support from any pharmaceutical company or other commercial source except as described below, and (2) neither I nor any first degree relative has any special financial interest in the subject matter discussed in said manuscript, except as described below. (I understand that an example of one type of such special financial interest would be ownership, by me or a first degree relative, of a company which sells a product relating to the subject matter of the manuscript.)

If there are any exceptions to the above, I/we have described them in the grid which follows. Use additional page(s) if space below is insufficient.

Industry Relationships. For you and your first degree relatives, please indicate on the grid below the type and nature of any industry relationships that you or they have had within the past five years that may be relevant to the subject matter. Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships that company or organization has had with industry within the past 5 years. Use the appropriate abbreviation for each type of relationship; for example, "C" if you were a consultant and "I" if you were an investigator. If you have no such relationships, please write "none" on the grid.

Administrative Regulations on Conflict of Interest Disclosure

TYPE OF RELATIONSHIP:

A Advisory Board
 B Board of Directors
 C Consultant
 E Employee
 F Founder
 I Investigator
 O Other
 SP Speaker
 SH Stockholder

NATURE OF COMPENSATION:

EQ Equipment (dept or practice)
 G Grants
 H Honoraria
 IP Intellectual Property Rights
 NC No Compensation Received
 OB Other Financial Benefit
 R Royalty
 RF Residency or Fellowship Program Funding
 S Salary
 ST Stock
 SO Stock Options

Company Name	Type of Relationship [Abbreviation]	Nature of Compensation [Abbreviation]

Company Name	Type of Relationship [Abbreviation]	Nature of Compensation [Abbreviation]

In addition to the above items, please describe any other special circumstances, such as (1) if your department or practice receives compensation (refer to the Nature of Compensation list above) that does not benefit you directly, or (2) if you have an agreement with the company to not disclose your interest.

IMPORTANT: The title page of our manuscript contains a publishable statement of all funding sources for the work and a publishable conflict of interest disclosure statement that summarizes the information I have provided above.

I hereby grant permission for any such information, or an appropriate summary thereof, to be published in *JAAD* with the manuscript if the manuscript is accepted for publication.

 Signature

 Date

 Printed Name

FROM THE ACADEMY

Position statement on contemporary issues: Conflict of interest

Approved by the American Academy of Dermatology Board of Directors, August 2008
Schaumburg, Illinois

Concern about and scrutiny of conflict of interest issues by regulatory bodies such as the Accreditation Council for Continuing Medical Education, American Association of Medical Colleges, Office of the Inspector General, and Congress has intensified over the past year. In recent years the medical and lay media have highlighted failures of individuals and institutions to disclose and appropriately manage financial ties with industry. The public, the regulatory bodies, and, for professional associations, the members, expect no less than complete transparency and objectivity. As medical research, professional education, health care, and institutional management have become vastly more complex and expensive, the task of managing conflicts of interest has become more challenging.¹⁻¹¹

The Institute of Medicine (IOM) has undertaken the task of coordinating a variety of associations involved in health care and education and will conduct 6 meetings throughout 2008 to hear testimony on this issue. By early 2009, the IOM will prepare a consensus report that provides guidelines for addressing conflicts of interest.⁷

All of medicine is being sensitized about the real and perceived effect relationships may have on decisions and actions of individuals and organizations. Frequently the discussion about conflict of interest focuses on a financial interest, but other forms of interest can raise conflicts as well, such as membership in another organization, having a family member with a significant conflicting relationship, or having an emotional attachment to an organization or cause.

Organizations operate best in a climate of trust, openness, and objective decision-making, believing

that all involved are putting the interests of the organization and its members first. This is also part of the fiduciary responsibility of elected and appointed leaders.

Every individual is influenced by relationships that color opinions, behavior, and participation in group discussions and decision-making. The simple existence of a relationship is not categorically improper. Recognizing a potential conflict because of that relationship and managing it are essential to achieving an unbiased outcome in an organization.

Recognizing relationships and managing them can be a difficult process. The disclosing individual and the audience may have differing opinions about whether a relationship is material. It is not possible, nor is it necessary, to eliminate all perceived, potential, or real conflicts of interest but it is in the best interests of the organization and the public to effectively acknowledge and manage potential conflicts. The existence of a potential conflict is not necessarily a problem; it is how individuals and institutions respond to potential conflicts that may be problematic. An essential requirement for achieving objective discussion and decision-making is to foster a culture that encourages open discussion of the issues when they arise. Everyone needs to take responsibility for establishing a climate of objectivity, but those in positions of authority can set the tone, welcome open discussion, and push for resolution of any potential bias.⁴

DEFINITION

A generally accepted working definition of a conflict of interest is a situation in which financial or other personal considerations have the potential to compromise or bias judgment and objectivity. While conflicts of interest apply to a wide range of behaviors and circumstances, they all involve the use (or potential use) of a person's authority for personal and/or financial gain rather than the best interests of the organization. For professional associations, conflict of interest is often defined as the situation where a personal or financial interest conflicts with the objectives and purposes of the association as set forth in its bylaws.

Funding sources: None.

Conflicts of interest: None declared.

Reprint requests: Eileen M. Murray, CFRE, CAE, Deputy Executive Director, American Academy of Dermatology, 930 E Woodfield Rd, Schaumburg, IL 60173. E-mail: emurray@aad.org.

J Am Acad Dermatol 2008;59:1005-8.

0190-9622/\$34.00

© 2008 by the American Academy of Dermatology, Inc.

doi:10.1016/j.jaad.2008.08.024

EXAMPLES OF POSSIBLE CONFLICTS OF INTEREST

Examples of conflicts that could result in placing one's self-interest or a third-party interest above that of the association include:

- Introducing or advocating for an activity for discussion and action that would benefit an individual's own company or other organization in which the individual has a personal or financial interest, whether or not it is consistent with the mission of the Academy.
- Using board membership or an association's resources for personal or third-party gain or pleasure.
- Unfairly taking advantage of an authoritative position to affect the commercial or professional standing of a company or organization in which an individual has a personal financial interest or that is a competitor.
- Using information made available because of an individual's position that is proprietary or confidential or otherwise not generally known to the public for personal advantage.
- Accepting a service, discount, concession, fee for advice, or other thing of value from a person or organization with an interest in an issue or transaction under discussion by the Academy.
- Withholding disclosure of relationships with industry, institutions, and other organizations.
- Presenting unsupported information or data that have been biased or unduly influenced by a personal or financial relationship.
- Participating in discussions on policy issues relating to other professional organizations in which the individual has a fiduciary position.
- Spouses or other first-degree relatives (children, parents, and siblings) who are executives or have an interest in other organizations or companies.

DISCLOSURE

Conflicts of interest must be recognized, identified, and resolved. Disclosure of all relationships with the potential to bias judgment is the first step for the person and the audience to become aware of the influence these relationships may have on decisions, discussions, or actions. Often disclosure of the conflict or potentially conflicting interest will protect the integrity of the situation. Once disclosed, the other participants will be able to evaluate and adjust for the possible influence of the disclosed interest. Disclosure may not suffice. Appropriate resolution of actual, potential, and apparent disclosures is necessary to ensure objective discussion and decision-making.

RESOLUTION BEYOND DISCLOSURE

The disclosing individual, the oversight individual or group, and the audience all have responsibilities in managing and resolving actual or potential conflicts of interest for which disclosure is not sufficient. In such circumstances, the disclosing individual should take action, on his or her own, to manage the conflict through recusal or resignation. Ultimately, the organization is responsible for resolving the conflict, whether through recusal or resignation. An actual, potential, or apparent conflict of interest for which disclosure does not suffice may be resolved in one of the following manners:

- Recuse the individual from all decision-making related to the relevant transaction that gives rise to the conflict, but allow the individual to participate in discussion and deliberations on the transaction.
- Recuse the individual from all discussion, deliberations, and decision-making related to the relevant transaction that gives rise to the conflict.
- Determine that the individual has a pervasive and continuing conflict and, therefore, must resign his or her position with the organization.

ACADEMY POLICIES AND PROCEDURES

The American Association of Society Executives' Web site notes the high priority of the conflict of interest issue with the associations it represents. The American Medical Association (AMA) published conflict of interest guidelines for medical societies in 1999 that are still applicable. The American Academy of Dermatology (AAD) has also adopted guidelines that are consistent with the AMA document.

The AAD Board of Directors and any appointees of the Academy must act at all times in the best interests of the Academy and not for personal or third-party gain or financial benefit.

The Academy has long understood the need for comprehensive disclosure policies and first developed an Administrative Regulation (AR) on Policy and Procedures Regarding Actual or Potential Conflicts of Interest³ to reflect its perspectives 20 years ago. This AR, which was initiated in 1988, has been revised as recently as April 2007 (see AR at www.aad.org). The AR states that "it is important that Academy decisions and actions not be unduly influenced by any special interests of individual members."

The language in the disclosure form that all individuals within the AAD governance structure must sign annually states, "I occupy a position of trust and that I am expected to act at all times in good

faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with whom I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.”

The AAD is committed to clarity and transparency in our conflict of interest policies, especially in the areas of governance, education, and scientific publication. All individuals in the Academy governance and educational structure are required to disclose their and their first-degree relatives’ relationships with industry, employers, other associations, or any other organization that could create a private interest in conflict with the Academy’s interest. Comprehensive disclosure forms are maintained in the Academy’s offices and on the Academy’s Web site. Disclosure statements are circulated prior to any meeting or educational activity for viewing by attendees or participants. The opportunity to review or update disclosure statements is provided at the beginning of each session.

As the current AR states, for determining whether actual, potential, or apparent conflict could prevent service to the Academy, council chairpersons review their constituent members’ disclosure statements. If any appear to have conflicts that could prevent them from serving, they are forwarded to the secretary-treasurer with any relevant observations or recommendations. The secretary-treasurer reviews the statements submitted and if further review is required, forwards the statements to the Ethics Committee. The Ethics Committee then initiates any request for further information and reports its findings to the secretary-treasurer and then to the Board of Directors.

As the AR currently states, “Because proper disclosure by each individual author, speaker or Academy leader is essential if the system is to function satisfactorily, it is important for everyone involved to approach with the proper perspective the question of what types of circumstances call for disclosure. The purpose of the procedures is not to discourage all involvement by Academy members in outside activities which might produce actual or potential conflicts with interests of the Academy. Neither is the objective to intrude into aspects of an individual’s professional or personal life which are, realistically, unlikely to have any significant bearing on Academy activities. Common sense should guide all decisions about what to disclose, and one

reasonable test is whether a particular circumstance, interest or relationship, if made known to the full membership of the Academy or to the general public, would be likely to cause embarrassment for the Academy and/or the individual involved or evoke suspicion about the motives behind any Academy action.”

The Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective, and free of commercial bias. The Academy AR also applies the same standards of disclosure and avoidance of actual, perceived, or potential conflicts of interest to authors of Academy publications and speakers at Academy educational meetings. Comprehensive disclosure, review by editors and oversight panels, and resolution of conflicts by directors and editors are essential steps in assuring the fair and balanced presentation of scientific information.

SUMMARY

Academy members in leadership positions should understand that they occupy a position of trust and are expected to act at all times in the best interests of the Academy, in good faith, and without bias or favor to outside interest. Whenever outside interests or other responsibilities potentially conflict with duty to the Academy, these must be declared. Members certify that they will act in such manner as to avoid even the appearance of using positions to advance any personal interest. If an actual, potential, or apparent conflict is detected, policies are in place to resolve such conflicts. All authors of Academy publications and speakers at Academy meetings adhere to the same principles of disclosure and avoidance of conflict of interest for the fair and balanced presentation of scientific information that guides practice. Any member who speaks at the annual business meeting or advisory board meeting must verbally disclose any potential conflicts of interest before speaking. The Academy is committed to transparency and objective decision-making at all organizational levels.

RESOURCES ON CONFLICT OF INTEREST

1. Accreditation Council for Continuing Medical Education (ACCME). The ACCME’s essential areas and their elements. Available from: URL: <http://www.accme.org>. Accessed April 16, 2008.
2. Advanced Medical Technology Association (AdvaMed). Code of ethics on interactions with health care professionals, 2003. Available from: URL: <http://www.advamed.org>. Accessed March 30, 2008.

3. American Academy of Dermatology. Administrative regulation on policy and procedures regarding actual or potential conflicts of interest, 2007. Available from: URL: <http://www.aad.org/Forms/Policies/ar.aspx>. Accessed June 1, 2008.
4. American Medical Association. AMA conflict of interest principles, 1999. Available from: URL: <http://www.ama-assn.org>. Accessed April 17, 2008.
5. Association of American Medical Colleges (AAMC). Report of the AAMC task force on industry funding of medical education to the AAMC executive council, April 2008. Available from: URL: <http://www.aamc.org/research/coi/industryfunding.pdf>. Accessed April 16, 2008.
6. Association of American Medical Colleges (AAMC) and Association of American Universities. Protecting patients, preserving integrity, advancing health: accelerating the implementation of COI policies in human subjects research. (Calls on all medical schools and major research universities to develop and implement institutional financial conflicts of interest [COI] policies within the next 2 years, and to refine standards for addressing individual financial COD), 2008. Available from: URL: <http://www.aamc.org>. Accessed June 1, 2008.
7. Institute of Medicine of the National Academies (IOM). Conflict of interest in medical research, education, and practice. Available from: URL: <http://www.iom.edu>. Accessed June 1, 2008.

The IOM has undertaken the task of coordinating a variety of associations involved in health care and education and will conduct 6 meetings throughout 2008 to hear testimony. The IOM will prepare a consensus report that will:

- Examine and describe conflicts of interest involving health care professionals and industry in different contexts, including, for example, the conduct of research, the education of health professionals, the development of practice guidelines, the provision of patient care, and the management of academic and other institutions;
 - Propose principles to inform the design of policies, guidelines, and other tools to identify and manage conflicts of interest in these contexts without damaging constructive collaboration with industry; and
 - Consider methods to disseminate, promote, implement, and evaluate these principles and policies.
8. International Committee of Medical Journal Editors (ICJME). Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publications, October 2007. Available from: URL: <http://www.icmje.org>. Accessed April 20, 2008.
 9. The Josiah Macy Foundation. Chairman's report on continuing education in the health professions: improving healthcare through lifelong learning. Available from: URL: http://www.josiahmacyfoundation.org/documents/Macy_ConEd_1_7_08.pdf. Accessed April 16, 2008.
 10. Office of the Inspector General, National Institutes of Health. Conflicts of interest in extramural research. Available from: URL: <http://www.oig.hhs.gov>. Accessed April 16, 2008.
 11. Pharmaceutical Research and Manufacturers of America (PhRMA). Code on interactions with healthcare professionals, 2008. Available from: URL: <http://www.phrma.org>. Accessed July 1, 2008.

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Andrew P. Lazar MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
DUSA graceway	"F" - Founder "C" - Consultant	"ST" - Stock "H" - Honoraria

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

None

5. Editor or Author of Non-Scientific Publications.

Assistant Editor of Skin Med

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice Professor of Clinincal Dermatology Northwestern University School of Medicine

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/11/2009 9:40:55 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Brett M. Coldiron MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

Board AAD, secretary American College of Mohs surgery

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

AAD board of director, secretary American College of Mohs Surgery

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private practice

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

2/13/2009 11:03:07 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Brian Berman MD, PhD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
3M	Speaker	"H" - Honoraria
Astellas	Advisory Board	"H" - Honoraria
Centocor	"SP" - Speaker	"H" - Honoraria
Collagenex	"A"- Advisory Board	"H" - Honoraria
Collagenex	Speaker	"H" - Honoraria
Doak	"A"- Advisory Board	"H" - Honoraria
Galderma	"SP" - Speaker	"H" - Honoraria
Galderma	"C" - Consultant	"H" - Honoraria
Galderma	"A"- Advisory Board	"H" - Honoraria
Graceway	Speaker	"H" - Honoraria
Halscion	"A"- Advisory Board	"H" - Honoraria
Medicis	"A"- Advisory Board	"H" - Honoraria
Medicis	"SP" - Speaker	"H" - Honoraria
Novartis	Speaker	"H" - Honoraria
Peplin	"C" - Consultant	"H" - Honoraria
Peplin	"A"- Advisory Board	"H" - Honoraria
Pharmaderm	"A"- Advisory Board	"H" - Honoraria
Red Rock	Speaker	"H" - Honoraria
Shionogi	Advisory Board	"H" - Honoraria
Stiefel	Speaker	"H" - Honoraria
Stiefel	"A"- Advisory Board	"H" - Honoraria
UCB	"SP" - Speaker	"H" - Honoraria
UCB (Sanofi-Aventis)	"A"- Advisory Board	"H" - Honoraria
UCB (Sanofi-Aventis)	"SP" - Speaker	"H" - Honoraria
Werner-Chilcott	Speaker	"H" - Honoraria

1. Special Circumstances.

Collagenex- Investigator - Department compensated
 Collagenex - Consultant - Department compensated
 3M - Consultant - Department compensated
 3M - Investigator - Department compensated
 Corgentech -Investigator - Department compensated
 Graceway - Consultant - Department compensated
 EOS - Investigator - Department compensated
 Orthologic - Consultant - Department compensated
 Novartis - Department compensated
 Obagi Medical - Consultant - Department compensated
 Shire - Consultant - Department compensated
 UCB - Consultant - Department compensated
 Promedior - Consultant - Department compensated

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

Advisory Panel FDA

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Women's Dermatologic Society- Member, Academic Interest Group

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Academic Practice, Professor of Dermatology and Internal Medicine, Miller School of Medicine

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

6/9/2009 9:15:46 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, C. William Hanke MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Allergan	Stockholder	"NC" - No compensation Received
Avance	"SH" - Stockholder	"NC" - No Compensation Received
Dermik DUSA	Investigator Stockholder	"G" - Grants "NC" - No compensation Received
Galderma	"I" - Investigator	"G" - Grants
Graceway	"I" - Investigator	"G" - Grants
Graceway	"C" - Consultant	"H" - Honoraria
Medicis	Investigator	"G" - Grants
Medicis	Stockholder	"NC" - No compensation Received
Merz	"I" - Investigator	"G" - Grants
Peplin	"I" - Investigator	"G" - Grants

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

Senior Vice-President, Skin Cancer Foundation
Senior Editor, Drugs in Dermatology

3. Government Affiliation.

NA

4. Dermatology Society Membership (officer, director, member or chair of a committee).

NA

5. Editor or Author of Non-Scientific Publications.

NA

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice, Indianapolis, IN

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/11/2009 10:27:00 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Clarence William Brown Jr. MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

AAD Young Physician Board Observer
Medical Malpractice Committee - Illinois State Medical Society

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

American College of Mohs Surgery Bylaws Committee

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

11/19/2009 7:29:30 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Daniel M. Siegel MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
DermFirst	"SH" - Stockholder	"NC" - No Compensation Received
Dermik Aventis	"SP" - Speaker	"H" - Honoraria
DermTech	"I" - Investigator	"G" - Grants
Dusa	"C" - Consultant	"H" - Honoraria
Elsevier	"O" - Other	"R" - Royalty
Encite	"C" - Consultant	"NC" - No Compensation Received
EOS	"C" - Consultant	"H" - Honoraria
Leerink Swann	"C" - Consultant	"H" - Honoraria
Logical images	"C" - Consultant	"SO" - Stock Options
MedaCorp	"C" - Consultant	"H" - Honoraria
Michelson Diagnostics	"I" - Investigator	"NC" - No Compensation Received
Photomedex	Advisory Board	"SO" - Stock Options
Quinnova	Advisory Board	"SO" - Stock Options
Telederm Solutions	Consultant	"SO" - Stock Options
Vivacare	"A" - Advisory Board	"NC" - No Compensation Received

1. Special Circumstances.

None I am aware of

2. Boards/Officer of Public or Academic Organizations.

Trustee, DebRA of America; BOD of Mohs College, Womens Derm Society, Noah Worcester Derm Society. Board member for DebRA International,

3. Government Affiliation.

One day a week at the Brooklyn VA as a staff physician.

Faculty at a New York State medical school.

AAD appointed representative to AMA RUC committee, a congressionally mandated, AMA run entity.

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Mohs College BOD from April 2007. WDS BOD from Feb 2008. Board of Trustees Noah Worcester;
Board of trustees DebRA of America
1972-present New York Academy of Sciences, Member
1977-present American Medical Association, Member
1984-present Dermatological Photographic Society, Member
1992- present Dermatology Foundation Leaders Society
1985-present American Society for Dermatologic Surgery, Fellow
1986 -present International Society for Dermatologic Surgery, Fellow
1991-present Long Island Dermatological Society, member.
1991-present Suffolk County Dermatology Society, Member
1991-present Association of Academic Dermatologic Surgeons, Member
1993-present New York State Society of Dermatology and Dermatologic Surgery, Member
1995-present American College of Physician Executives, Member
1997-present New York Facial Plastic Surgery Society, Member
1999-present American Telemedicine Association, Member
2001-present Skin Cancer Foundation, Medical Council
2002-present Noah Worcester Dermatological Society, member
2002-present International Society for Dermatology, member
2005-present Association for the Advancement of Wound Care, member
2006-present Suffolk County Medical Society, member
2006-present American Dermatological Association, member

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

M, Th, F: Private practice as partner in three physicians group
Tu- Brooklyn Va
Weds - SUNY Downstate
I run the procedural dermatology/Mohs surgery fellowship at SUNY Downstate

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/3/2009 9:01:33 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, David J. Goldberg MD, JD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Aesthetic Technologies	"I" - Investigator	"G" - Grants
Allergan	Advisory Board	"H" - Honoraria
Alma	Investigator	"G" - Grants
Bioform	Investigator	"G" - Grants
Bioform	"SP" - Speaker	"H" - Honoraria
Coapt	"I" - Investigator	"G" - Grants
Cutera	Investigator	"G" - Grants
Cynosure	"I" - Investigator	"G" - Grants
Cynosure	"SP" - Speaker	"H" - Honoraria
Hoya ConBio	"SP" - Speaker	"H" - Honoraria
Hoya ConBio	"I" - Investigator	"G" - Grants
J&J	Investigator	"G" - Grants
L'oreal	Investigator	"G" - Grants
Lumenis	Investigator	"G" - Grants
Lumenis	"SP" - Speaker	"H" - Honoraria
Medicis	Investigator	"G" - Grants
MedSurge	"I" - Investigator	"G" - Grants
Mentor	"SP" - Speaker	"H" - Honoraria
Mentor	Investigator	"G" - Grants
Neocutis	Investigator	"G" - Grants
Palomar	Investigator	"G" - Grants
Palomar	"SP" - Speaker	"H" - Honoraria
PhotoTherapeutics	"SP" - Speaker	"H" - Honoraria
PhotoTherapeutics	"C" - Consultant	"H" - Honoraria
Primeava	"I" - Investigator	"G" - Grants
Reliant	"I" - Investigator	"G" - Grants
Sanofi	"A"- Advisory Board	"H" - Honoraria
Sciton	Investigator	"G" - Grants
Skinovations	"I" - Investigator	"G" - Grants
Zeltiq	"I" - Investigator	"G" - Grants

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

None

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

None

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

11/18/2009 8:06:47 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, David Michael Pariser MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Abbott Labs	Investigator	"G" - Grants
Amgen/Wyeth	None Chosen	"H" - Honoraria
Basilea	"I" - Investigator	"G" - Grants
Centocor	Investigator	"G" - Grants
Centocor	Consultant	"H" - Honoraria
Dow Pharmaceuticals	"I" - Investigator	"G" - Grants
Eli Lilly	"I" - Investigator	"G" - Grants
Galderma	Investigator	"G" - Grants
Genentech	Investigator	"G" - Grants
Graceway	"I" - Investigator	"G" - Grants
Incyte	"I" - Investigator	"G" - Grants
Intendis	"I" - Investigator	"G" - Grants
Johnson and Hohnson	"I" - Investigator	"G" - Grants
Novo Nordisk	"I" - Investigator	"G" - Grants
Nucryst	Investigator	"G" - Grants
Ortho- Neutrogena	Other	"RF" - Residency or Fellowship Funding
Peplin	"I" - Investigator	"G" - Grants
Pfizer	"I" - Investigator	"H" - Honoraria
Photocure	Investigator	"G" - Grants
Photocure	Consultant	"H" - Honoraria
Shionogi	"I" - Investigator	"G" - Grants
Stiefel	"I" - Investigator	"G" - Grants
Tolman	"I" - Investigator	"G" - Grants

1. Special Circumstances.

I am a volunteer un-paid community faculty member of the department of dermatology at Eastern Virginia Medical School which has recieved grants for partial funding of residency salaries as indicated above. The grants are accepted as a general grant to the department, not to fund any specific resident (s) I recieve no personal compensation from these grants or from the Department of Dermatology. I would also like to disclose that I am a beneficiary of a trust set up from the estate of my father which holds stock in 3 pharmaceutical companies. Also, my wife has an investment portfolio which holds one pharmaceutical company stock and over which I have no control. Neither the stock in my wife's portfolio nor any of the individual stocks from my father's trust exceeds 1% of my net worth. Neither I nor any member of my immediate family nor any entity in which I am a principal (trust, partnership, etc) owns any stock options in either pharmaceutical or laser companies.

2. Boards/Officer of Public or Academic Organizations.

Board of Directors, Sentara Optima Health Plan, Virigina Beach, Va
 Medical Advisory Board and Chariman of Advocacy Committee, National Psoriasis Foundation
 President, International Hyperhidrosis Society
 President, Eastern Virginia Dermatology Foundation
 Secretary- Treasurer (2006-2011), American Dermatological Association

3. Government Affiliation.

NONE

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Secretary- Treasurer (2006-2011), American Dermatological Association

5. Editor or Author of Non-Scientific Publications.

NONE

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice , Norfolk Virginia

Clinical Research

Professor, Department of Dermatology, Eastern Virginia Medical School (Voluntary unpaid position)

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/14/2009 7:50:00 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Dirk Michael Elston MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Intedis	"I" - Investigator	"NC" - No Compensation Received

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Chair MOC Committee, American Society of Dermatopathology

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Director, Dept of Dermatology, Geisinger

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/11/2009 9:55:30 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Elise Olsen MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Allergan	"O" - Other	"R" - Royalty
Biocryst	"SP" - Speaker	"H" - Honoraria
Biocryst	Investigator	"G" - Grants
Eisai	"I" - Investigator	"G" - Grants
Genentech	Investigator	"G" - Grants
GenMab	Investigator	"G" - Grants
J&J	"C" - Consultant	"H" - Honoraria
J&J	"I" - Investigator	"G" - Grants
J&J	"O" - Other	"RF" - Residency or Fellowship Funding
Merck	Consultant	"H" - Honoraria
Merck	"SP" - Speaker	"H" - Honoraria
NA Hair Research Society	Investigator	"G" - Grants
Yaupon	Investigator	"G" - Grants

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

Committee on Misconduct in Research, Duke University
Assistant Editor, Dermatologic Therapy
Board, International Society for Cutaneous Lymphomas
President, United States Cutaneous Lymphoma Consortium
Board, Leaders Society, Dermatology Foundation
Scientific Advisory Board, National Alopecia Areata Foundation (NAAF)
Chairman, Steering Committee, Southeastern Consortium

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

International Society for Cutaneous Lymphomas
Leaders Society, Dermatology Foundation
Southeastern Consortium for Dermatology
NAAF
North American Hair Research Society
United States Cutaneous Lymphoma Consortium

5. Editor or Author of Non-Scientific Publications.

Hair section co-editor of Faculty of 1000 online journal

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Professor of Dermatology and Oncology, Duke University Medical Center

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/11/2009 9:50:47 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Evan Ragland Farmer MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Bostwick Laboratories	"E" - Employee	"S"- Salary

1. Special Circumstances.

Employment with Bostwick Laboratories was from March 2008- October 2009

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

AAD Committees/Council/Vice President (2009-10)
Wife is Executive Director of the American Board of Dermatology
Member- ASDP
Member- ADA
Member- AMA
Member- Richmond Dermatological Society
Member- ISD

5. Editor or Author of Non-Scientific Publications.

Editorial Boards-
Int J Dermatol
Am J Clin Dermatol

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Part-time Faculty-Medical College of Virginia

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/16/2009 3:18:25 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Frank C. Powell MD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

President-Elect of the European Academy of Dermatology and Venerology (EADV)

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Member Executive Committee EADV

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

None

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

6/16/2009 1:41:40 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Jennifer Lucas MD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

Secretary, House Staff Association, Cleveland Clinic

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Chairman, Residents and Fellows Committee, American Academy of Dermatology
American Society of Dermatologic Surgery
Ohio Society for Dermatologic Surgery
Skin Pac
Member Council on Member Services
Member Young Physicians Committee
American Academy of Dermatology, Resident Observer

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

MOHS fellow, Cleveland Clinic

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

6/22/2009 9:49:25 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Kenneth J. Tomecki MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Abbott Labts	"SH" - Stockholder	"NC" - No Compensation Received
Medtronics	"SH" - Stockholder	"NC" - No Compensation Received

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

Vice chairman, Dept Dermatology, Cleveland Clinic

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Board of Trustees, Ohio Dermatological Association
Chair, Audit Committee, AAD
Board of Directors, AAD

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Cleveland Clinic, Cleveland, OH

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

1/30/2009 11:48:53 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Lisa A. Garner MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Mary Kay Inc	Consultant	"S"- Salary
Shire Inc	Consultant	"S"- Salary

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

Child Abuse Prevention Center of Dallas- BOD- no compensation
Garland Summer Musicals-BOD-no compensation

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Past Womens Dermatologic Society-BOD , Past Chair Editorial Committee
Dermatology Foundation-BOD
President Elect - Women's Dermatologic Society

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private practice in Garland TX
Clinical Professor, Dept of Dermatology, University of TX Southwestern Med. School

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

6/1/2009 10:39:56 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Luis A. Diaz MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

AAD Board of Directors
International Society of Dermatology, newly elected Board of Directors

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Autoimmune Society of America (Scientific Advisory Board)
AAD Board of Directors, Director
International Society of Dermatology, Board of Directors

5. Editor or Author of Non-Scientific Publications.

Journal of Autoimmunity, Associate Editor

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Professor and Chair, Department of Dermatology, UNC School of Medicine

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/11/2009 10:08:32 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Margaret E. Parsons MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

Immediate Past-President: Sierra Sacramento Valley Medical Society (term ends 12/31/09)
Board Member, Exec Comm: BloodSource, Sacramento, California (blood-bank non-profit organization)
Board Member, Exec Comm: Am Acad Derm

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Womens Dermatology Society - Member and Audit Committee member
California Society of Dermatology and Dermatologic Surgery - member
Sacramento Valley Dermatology Society - member
Am Society Derm Surgery - member
American Dermatologic Association - member

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice, Dermatology Consultants of Sacramento, Sacramento, California
Asst Clinical Professor, UC Davis Dept Derm, Sacramento, California (lead journal club for residents)

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/11/2009 10:06:05 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Mary E. Maloney MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

Div receives only unrestricted educational grants

2. Boards/Officer of Public or Academic Organizations.

Div Chief of Dermatology, U Mass Memorial Health Center
Treasure of the ILDS

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Women's Derm Society, ILDS Treasurer, Member ASDS, Am College of Mohs Surgery Chain Ethics Committee, New England Derm Society,

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Div Chief, Div of Derm, U of Mass Medical School/ U Mass Memorial Hospital Worcester MA

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

7/20/2009 5:17:30 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Robert David Greenberg MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

AAD/A Assistant Secretary-Treasurer; Reviewer Dermatology World; Member - Priorities Committee, Strategy Committee, Investments Committee.

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private practice, Vernon, CT; Adjunct Assistant Clinical Professor of Dermatology, University of Connecticut Medical Center, Farmington, CT.

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/12/2009 2:30:16 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Ronald L. Moy MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
CLRS Technology Inamed	"I" - Investigator "I" - Investigator	"SH" - Stockholder "NC" - No Compensation Received
Medicis Suneva	"SP" - Speaker "I" - Investigator	"H" - Honoraria "G" - Grants

1. Special Circumstances.

Rhytec now bankrupt.

Inamed - This study became the product Dysport. No relationship with Medicis.

Discount on Cynosure Affirm laser and Ultrapulse laser from Lumenis - 8/1/09 and loan of Smart Lipo for research

Sell a skin care line called DNA EGF Renewal in our office and on website

2. Boards/Officer of Public or Academic Organizations.

Board of Trustees of the American Board of Cosmetic Surgery

3. Government Affiliation.

Past Member of the Medical Board of California

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Past President of the Pacific Dermatologic Association

5. Editor or Author of Non-Scientific Publications.

Editorial Boards of the Archives of Facial Plastic Surgery and Archives of Dermatology

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

9/13/2009 8:52:18 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Ronald Stephen Davis MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

I have no personal involvement and receive no personal compensation but my department may receive compensation from industry for speakers at meetings, clinical trials and educational grants.

2. Boards/Officer of Public or Academic Organizations.

Medical Advisory Board, National Vitiligo Foundation. Member, Board of Directors, American Academy of Dermatology

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Fellow, American Academy of Dermatology. Member: Louisiana Dermatological Society, Women's Dermatologic Society, American Society for Dermatologic Surgery, SkinPAC, Dermatology Foundation.

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Professor of Medicine, Section of Dermatology, Tulane School of Medicine, New Orleans, LA

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

6/15/2009 11:00:17 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Sandra I. Read MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Galderma	Speaker	"H" - Honoraria

1. Special Circumstances.

ProAssurance-Liability Carrier & Stock, Underwriting Risk Management Committee

2. Boards/Officer of Public or Academic Organizations.

American Academy of Dermatology - Board of Directors
Health Volunteer Overseas - Board of Directors
Citizens for Skin Cancer Prevention,- Medical Director: Compensation - salary
Glen Echo Partnership - Board of Directors - No compensation
American Academy of Dermatology - Co-Chair Skin PAC

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Washington DC Dermatologic Society: Chair of Scholarship Grants Committee
Women's Dermatologic Society - Chair of Ethics Committee
Women's Dermatologic Society - Co-Chair of Audit Committee

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice, Washington, DC

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

11/18/2009 8:12:02 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Susan C. Taylor MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Academy of Physicians Assistants	"SP" - Speaker	"H" - Honoraria
Allergan	"A"- Advisory Board	"H" - Honoraria
Allergan	"I" - Investigator	"G" - Grants
Allergan	Speaker	"H" - Honoraria
ASIM	"SP" - Speaker	"H" - Honoraria
Baldwin School	"O" - Other	"NC" - No Compensation Received
Beiersdorf	Advisory Board	"H" - Honoraria
Beiersdorf	"I" - Investigator	"G" - Grants
Colbar Lifescience Ltd.	"I" - Investigator	"G" - Grants
Johnson and Johnson	Investigator	"G" - Grants
Johnson and Johnson	Speaker	"H" - Honoraria
Johnson and Johnson	Advisory Board	"H" - Honoraria
Lluminari	"SP" - Speaker	"H" - Honoraria
Medicis	Investigator	"G" - Grants
Medicis	Speaker	"H" - Honoraria
Medicis	Advisory Board	"H" - Honoraria
Merz	"I" - Investigator	"G" - Grants
Philadelphia Life Sciences Institute	"O" - Other	"NC" - No Compensation Received
Promius Pharma	"I" - Investigator	"G" - Grants
Quinnova	"I" - Investigator	"G" - Grants
Stiefel	Investigator	"G" - Grants
Stiefel	Advisory Board	"H" - Honoraria
Stiefel	"C" - Consultant	"G" - Grants
T2 Skincare	"F" - Founder	"OB" - Other Financial Benefit
T2 Skincare	"O" - Other	"OB" - Other Financial Benefit
University of Pennsylvania	"O" - Other	"NC" - No Compensation Received

1. Special Circumstances.

T2 Skincare, other- CEO Dr. Susan Taylor's Rx for brown skin products sold at Home Shopping Network, Sephora and JCPenny, Dillards, Macys

2. Boards/Officer of Public or Academic Organizations.

Trustee, The Baldwin School
Trustee, University of Pennsylvania
Trustee, Philadelphia Life Sciences Institute

3. Government Affiliation.

Member, Council of Communications

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Chair, Skininnovations Committee

5. Editor or Author of Non-Scientific Publications.

Assistant Editor, Practical Dermatology Assistant Editor, Cutis

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice, Philadelphia, PA
Skin of Color Center, NY

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/16/2009 4:22:13 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a faculty member for Scientific Session(s) and will disclose all relevant financial relationship(s) with industry in any amount occurring within the past 12 months as outlined in the ACCME guidelines. (By disclosing all relevant financial relationships with industry in any amount you also satisfy the disclosure requirements for a Committee, Council and/or Task Force position.)

I, Theodore Rosen MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias. The Board of Directors requires that all scientific session faculty comply with all applicable laws and regulations governing disclosure. This comprehensive disclosure form provided will be abbreviated and printed in the faculty disclosure index of the Program Book and Program-at-a-Glance. All scientific session faculty are expected to disclose to their audiences all financial or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services regardless of whether it may be discussed in their presentation(s). Scientific session faculty are also required to know and disclose to their audiences the FDA approval status of all medical devices and pharmaceuticals for the uses discussed, described or demonstrated in their educational presentations. If no relationships exist, the speaker must state that no financial relationships exist with commercial interests. Speakers must disclose regardless of whether an actual conflict exists.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Abbott	"SP" - Speaker	"H" - Honoraria
Amgen (Discontinued 2009)	"SP" - Speaker	"H" - Honoraria
Centocor	Speaker	"H" - Honoraria
Galderma	"SP" - Speaker	"H" - Honoraria
Genentech (Discontinued 2009)	"SP" - Speaker	"H" - Honoraria
GlaxoSmithKline	Speaker	"H" - Honoraria
Graceway	"SP" - Speaker	"H" - Honoraria
Stiefel (Now a GlaxoSmithKline company)	"C" - Consultant	"H" - Honoraria

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

Board of Directors, Zola-Cooper Clinicopathologic Seminar (unpaid)

3. Government Affiliation.

Part-time dermatology staff
Houston Veterans Affairs Medical Center

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Member: Texas and Houston Dermatology Societies

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Professor of Dermatology, Baylor College of Medicine

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/11/2009 7:55:37 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Victor J. Marks MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

Board of Directors, AAD/AADA
Board of Trustees, Noah Worcester Dermatological Society

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Vice-president, PA Academy of Dermatology

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Associate, Department of Dermatology, Geisinger Health System

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/11/2009 9:40:27 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Vincent A. Muscarella MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Chair, New Mexico Medicare Carrier Advisory Committee, 6/2008- present
Professional Review and Advocacy Committee , Chair - 6/2008 - present
Fellow, American Academy of Dermatology 11/1969 - present
Fellow, Pacific Dermatological Association 6/1969 - present
Diplomate, American Board Dermatology 11/1969 - present
Diplomate, National Board of Medical Examiners 7/1962- present
Fellow, American Society of Dermatopathology 11/1981 - present
Fellow, American Academy of Cosmetic Surgery 6/1984 - present
Fellow, American Society of Lipo-Suction Surgery 6/1984 - present
Fellow, Oculoplastic Fellowship Society 9/1984
American Society of Dermatology 9/1992-12/1995
American Society for Dermatologic Surgery 6/1974 - present
American Society of Clinical Oncology 1-12/1995
New Mexico Dermatological Society 1/1971 - present
New Mexico Medical Society 6/1968 - present
Society of Investigative Dermatology 7/1968 – 12/1995
Southwestern Dermatological Society 1/1968-12/1992
International Society for Dermatological Surgery 6/1984 - present
International Society of Dermatopathology 6/1981 - present
American Medical Association 6/1968 - present
Greater Albuquerque Medical Association 6/1968 - present
American Academy of Facial Plastic and Reconstructive Surgery 6/1984 - present
American Society for MOHS Surgery 6/1991 - present

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Private Practice, Albuquerque, NM: Clinical Professor, Department of Dermatology, University of New Mexico

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

8/31/2009 7:53:32 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, William D. James MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
American College of Physicians	Other	"H" - Honoraria
Elsevier	Other	"R" - Royalty
	Other	"H" - Honoraria

1. Special Circumstances.

For Elsevier other = author/editor
For the American College of Physicians = author
For webmd = author

2. Boards/Officer of Public or Academic Organizations.

Vice-Chair, Department of Dermatology, University of Pennsylvania

3. Government Affiliation.

Consultant, Smithsonian Institution

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Atlantic Dermatological Conference, Permanent Secretary
Women's Dermatological Society Chair, Medical Student Awareness Task Force
American Society of Contact Dermatitis, member
Association Military Dermatologists, member
Association of Professors of Dermatology, member
Dermatologic Teachers Education Group, member
American Dermatological Association, member
Medical Dermatology Society, member
Alpha Omega Alpha Medical Honor Society, member
Dermatology Foundation, leader's society
Society of Investigative Dermatology, member
American Medical Association, member

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Full-time faculty, Clinical Educator and Clinical Practice. Paul Gross Professor of Dermatology, University of Pennsylvania

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

11/20/2009 12:55:58 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Ronald A. Henrichs, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

None

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

None

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

7/6/2009 11:35:27 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Karen Collishaw, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
Avon Products	"SH" - Stockholder	"SH" - Stockholder

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

None

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

None

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

12/18/2009 1:07:10 PM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, Eileen Murray MD, MM, CFRE, CAE, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
--------------	--------------	--------------

1. Special Circumstances.

None

2. Boards/Officer of Public or Academic Organizations.

None

3. Government Affiliation.

None

4. Dermatology Society Membership (officer, director, member or chair of a committee).

None

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

None

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

1/9/2009 11:38:43 AM

Disclosure Statement of Potential Conflict of Interest

I attest that I am completing the Academy electronic disclosure form as a Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology or Senior Staff and will disclose all relationship(s) with industry with a value of over \$500 within the past 12 months.

I, William D. James MD, FAAD, hereby acknowledge that, I am currently serving as a Faculty Member for Scientific Sessions and / or Chair or Member of a Council, Committee or Task Force; candidate for Office or am a member of the Board of Directors; an Editor of the Journal of the American Academy of Dermatology or Dialogues in Dermatology; or Senior Staff, or I expect to serve in such role at some point in the near future, and hereby disclose any potential conflicts of interest as they may pertain to my role in the Academy and dermatology.

I occupy a position of trust and that I am expected to act at all times in good faith and without bias or favor to outside interests. Whenever my outside interests or other responsibilities potentially conflict with my duty to the Academy, I will declare these potential conflicts and will act in such a manner as to avoid even the appearance of using my position to advance any personal interest or the interest of any individual or entity with which I have a significant relationship. In particular, I will not act in a way inconsistent with the purposes and interest of the Academy.

I hereby certify that, to the best of my knowledge, no aspect of my current personal or professional circumstances places me in the position of having private interest which is in conflict with any interest of the Academy or with my obligations to the Academy, except perhaps the following: Describe any exceptions. Use additional page(s) if space below is insufficient.

Industry Relationships

For you and your first degree relatives, please indicate on the grid below the type of relationship and the nature of any industry relationships in any amount occurring within the past 12 months and that raise a potential conflict of interest.

Also, for any private company or private nonprofit organization in which you or any first degree relative has a controlling financial or operational interest, please indicate on the grid below the type of relationship and the nature of any industry relationships with a company or organization that has had with industry within the past 12 months. Use the appropriate abbreviation and one line for each type of relationship; thus, for example, if you were a consultant "C" and an investigator "I" for Company Q, these relationships would be placed on two separate lines. Use additional charts as necessary. You must update your disclosures verbally at the time you speak or vote on a relevant matter and update them annually in writing. If you have no such relationships, please write in "none."

Company Name	Relationship	Compensation
American College of Physicians	Other	"H" - Honoraria
Elsevier	Other	"R" - Royalty
Elsevier	Other	"H" - Honoraria

1. Special Circumstances.

For Elsevier other = author/editor
For the American College of Physicians = author
For webmd = author

2. Boards/Officer of Public or Academic Organizations.

Vice-Chair, Department of Dermatology, University of Pennsylvania

3. Government Affiliation.

Consultant, Smithsonian Institution

4. Dermatology Society Membership (officer, director, member or chair of a committee).

Atlantic Dermatological Conference, Permanent Secretary
Women's Dermatological Society Chair, Medical Student Awareness Task Force
American Society of Contact Dermatitis, member
Association Military Dermatologists, member
Association of Professors of Dermatology, member
Dermatologic Teachers Education Group, member
American Dermatological Association, member
Medical Dermatology Society, member
Alpha Omega Alpha Medical Honor Society, member
Dermatology Foundation, leader's society
Society of Investigative Dermatology, member
American Medical Association, member

5. Editor or Author of Non-Scientific Publications.

None

6. My principal professional activities relating to dermatology are conducted in the following setting(s):

Full-time faculty, Clinical Educator and Clinical Practice. Paul Gross Professor of Dermatology, University of Pennsylvania

Acknowledgement

I acknowledge my continuing obligation to report to the Secretary-Treasurer of the Academy, promptly and in writing, any change in the nature or setting of my professional activities or any possible conflict of interest, i.e., conflict between, on the one hand, the interests of the Academy and, on the other, my personal interests or those of a related party, which comes to my attention in the future. I will also verbally acknowledge any changes to this written disclosure at the time of my participation in an Academy meeting or event. I attest that to the best of my knowledge this is a complete and true disclosure and, that if found to be otherwise, would be grounds for discipline.

11/20/2009 12:55:03 PM